



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Board Meeting

August 12, 2015

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Table of Contents

1 – A.	Table of Contents	002
1 – B.	Agenda	003
1 – C.	Meeting Notice & Arrangements	004
1 – D.	Acronyms	005
2.	Invocation & Pledge of Allegiance	
3.	Quorum Call	
4.	Call for Additional Agenda Items & Adoption of Agenda	
5.	Consideration of Minutes from Previous Meetings ~ May 27, 2015	009
6.	Report on Action Items	
7.	Confirmation of Acts	
8.	Opportunity for Public Comment	
**	Special Order of the Day – Presentation of Pharmacist Gold Certificates	
9.	Committee Reports	
A.	Finance – Mr. Pitre	027
	• Consideration of <i>Final Report for Fiscal Year 2014-2015</i>	028
	• Consideration of <i>Proposed Budget Amendment #1 for Fiscal Year 15-16</i>	045
B.	Application Review – Mr. Soileau	051
C.	Reciprocity – Ms. Hall	052
	• Consideration of Committee Recommendations re Applications	
D.	Violations – Mr. Bond	054
	• Consideration of Proposed Voluntary Consent Agreements	055
E.	Impairment – Mr. Rabb	064
	• Consideration of Committee Recommendations re Applications	
F.	Reinstatement – Ms. Melancon	066
	• Consideration of Committee Recommendations re Applications	
G.	Tripartite – Mr. Burch	071
H.	Regulation Revision – Mr. McKay	072
I.	Executive Committee – Mr. Aron	073
	• Review of <i>Final Legislative Brief</i> from 2015 Legislature	074
	• Consideration of Committee Recommendations	078
10.	Staff Reports	
J.	Assistant Executive Director – Mr. Fontenot	099
	• Consideration of Requests for Waivers from PMP Reporting Rule	115
K.	General Counsel – Mr. Finalet	135
	• Consideration of Proposed Voluntary Consent Agreements	136
L.	Executive Director – Mr. Broussard	149
	• Census Reports	153
	• Productivity Reports	159
	• Exceptions Report	161
	• Annual Reports	165
	• Examination Reports	181
	• Final Legislative Report	232
11.	Request for Interpretation of LAC 46:LIII.2745.C.2 & 2747.B.4.b – Fred's Pharmacies	246
12.	Announcements	249
13.	Recess	

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Board has been ordered and called for 10:00 a.m. on Wednesday, August 12, 2015 at the Board office, for the purpose to wit:

AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 08-10-2015

1. Call to Order
2. Invocation & Pledge of Allegiance
3. Quorum Call
4. Call for Additional Agenda Items & Adoption of Agenda
5. Consideration of Minutes from Previous Meeting – May 27, 2015
6. Report on Action Items
7. Confirmation of Acts
8. Opportunity for Public Comment
- ** Special Order of the Day – Presentation of Pharmacist Gold Certificate
 - PST.008994 – Edward Miller, Jr.
 - PST.008995 – Charles Lewis Morvant
 - PST.009017 – Earl Lawrence Wattigny
9. Committee Reports
 - A. Finance – Mr. Pitre
 - Consideration of Final Report for Fiscal Year 2014-2015
 - Consideration of Proposed Budget Amendment for Fiscal Year 2015-2016
 - B. Application Review – Mr. Soileau
 - C. Reciprocity – Ms. Hall
 - Consideration of Committee Recommendations re Applications
 - D. Violations – Mr. Bond
 - Consideration of Proposed Voluntary Consent Agreements
 - E. Impairment – Mr. Rabb
 - Consideration of Committee Recommendations re Applications
 - F. Reinstatement – Ms. Melancon
 - Consideration of Committee Recommendations re Applications
 - G. Tripartite – Mr. Burch
 - H. Regulation Revision – Mr. McKay
 - I. Executive – Mr. Aron
 - Consideration of Final Legislative Brief from 2015 Legislature
 - Consideration of Committee Recommendations
10. Staff Reports
 - J. Assistant Executive Director – Mr. Fontenot
 - Consideration of Requests for Waivers from PMP Reporting Requirement
 - K. General Counsel – Mr. Finalet
 - Consideration of Proposed Voluntary Consent Agreements
 - L. Executive Director – Mr. Broussard
 - Consideration of 2015 Annual Report
11. Request for Interpretation of LAC 46:LIII.2745.C.2 and 2747.B.4.b – Fred's Pharmacies
12. Announcements
13. Recess

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

Acronyms

AACP	American Association of Colleges of Pharmacy
AAPS	American Association of Pharmaceutical Scientists
AAPT	American Association of Pharmacy Technicians
ACA	American College of Apothecaries
ACCME	Accreditation Council for Continuing Medical Education
ACCP	American College of Clinical Pharmacy
ACE	Advisory Committee on Examinations (NABP)
ACPE	Accreditation Council for Pharmacy Education
ADA	American Dental Association
ADC	automated dispensing cabinet
ADS	automated dispensing system
AFDO	Association of Food & Drug Officials
AFPE	American Foundation for Pharmaceutical Education
AIHP	American Institute of the History of Pharmacy
AMA	American Medical Association
AMCP	Academy of Managed Care Pharmacy
AMS	automated medication system
APEC	Australian Pharmacy Examining Council
APhA	American Pharmacists Association
APPE	advanced pharmacy practice experience
ASAE	American Society of Association Executives
ASAP	American Society for Automation in Pharmacy
ASCP	American Society of Consultant Pharmacists
ASHP	American Society of Health-System Pharmacists
ASPL	American Society for Pharmacy Law
AVMA	American Veterinary Medical Association
AWARxE	NABP consumer protection program
BNDD	Bureau of Narcotics and Dangerous Drugs
BPS	Board of Pharmacy Specialties
CAC	Citizen Advocacy Center
CCAPP	Canadian Council for Accreditation of Pharmacy Programs
CCGP	Commission for Certification in Geriatric Pharmacy
CDC	Centers for Disease Control and Prevention
CDER	Center for Drug Evaluation and Research
CDTM	collaborative drug therapy management
CDS	controlled dangerous substances
CE	continuing education
CFR	Code of Federal Regulations
CHPA	Consumer Healthcare Products Association
CLEAR	Council on Licensure, Enforcement and Regulation
CMI	consumer medication information
CMS	Centers for Medicare and Medicaid Services
CPD	continuing professional development
CPhA	Canadian Pharmacists Association
CPPA	Center for Pharmacy Practice Accreditation
CPSC	Consumer Product Safety Commission
DEA	Drug Enforcement Administration
DEQ	La. Department of Environmental Quality
DHH	La. Department of Health and Hospitals

DME	durable medical equipment
DMEPOS	durable medical equipment, prosthetics, orthotics, and supplies
DNV	Det Norske Veritas (Norwegian accreditation organization)
DSM	disease state management
EDK	emergency drug kit
ELTP	Electronic Licensure Transfer Program (NABP)
EPA	Federal Environmental Protection Agency
EPCS	Electronic Prescribing of Controlled Substances (DEA)
ETS	Educational Testing Service
EU	European Union
ExCPT	Examination for the Certification of Pharmacy Technicians
FARB	Federation of Associations of Regulatory Boards
FBI	Federal Bureau of Investigation
FD&C	Federal Food, Drug & Cosmetic Act
FDA	Federal Food & Drug Administration
FIP	Federation Internationale Pharmaceutique
FMI	Food Marketing Institute
FPGEC	Foreign Pharmacy Graduate Examination Committee (NABP)
FPGEE	Foreign Pharmacy Graduate Equivalency Examination (NABP)
FSBPT	Federation of State Boards of Physical Therapy
FSMB	Federation of State Medical Boards
FRC	Foreign Pharmacy Graduate Equivalency Examination Review Committee (NABP)
FTC	Federal Trade Commission
GPhA	Generic Pharmaceutical Association
GPO	US Government Printing Office
gTLD	generic top level domain (Internet addresses)
HCFA	Health Care Financing Administration
HDMA	Healthcare Distribution Management Association
HIPAA	Health Insurance Portability and Accountability Act (of 1996)
HIPDB	Healthcare Integrity and Protection Data Bank
HMO	health maintenance organization
IACP	International Academy of Compounding Pharmacists
ICANN	Internet Corporation for Assigned Numbers and Names
ICPT	Institute for the Certification of Pharmacy Technicians
IDOI	Internet Drug Outlet Identification (NABP)
INEOA	International Narcotic Enforcement Officers Association
IOM	Institute of Medicine
IPPE	introductory pharmacy practice experience
ISMP	Institute for Safe Medication Practices
JCPP	Joint Commission of Pharmacy Practitioners
LAMP	Louisiana Academy of Medical Psychologists
LANP	Louisiana Association of Nurse Practitioners
LAPA	Louisiana Academy of Physician Assistants
LBP	Louisiana Board of Pharmacy
LDA	Louisiana Dental Association
LIPA	Louisiana Independent Pharmacies Association
LPA	Louisiana Pharmacists Association
LPTA	Louisiana Physical Therapy Association
LPTB	Louisiana Physical Therapy Board
LSBD	Louisiana State Board of Dentistry
LSBME	Louisiana State Board of Medical Examiners

LSBN	Louisiana State Board of Nursing
LSBOE	Louisiana State Board of Optometry Examiners
LSBPNE	Louisiana State Board of Practical Nurse Examiners
LSBVM	Louisiana State Board of Veterinary Medicine
LSBWDD	Louisiana State Board of Wholesale Drug Distributors
LSHP	Louisiana Society of Health-System Pharmacists
LSMS	Louisiana State Medical Society
LSNA	Louisiana State Nurses Association
LTC	long term care
LTCF	long term care facility
LVMA	Louisiana Veterinary Medical Association
MPJE	Multistate Pharmacy Jurisprudence Examination (NABP)
MRC	MPJE Review Committee (NABP)
NABP	National Association of Boards of Pharmacy
NABP-F	National Association of Boards of Pharmacy Foundation
NABPLAW	National Association of Boards of Pharmacy – Law Database
NACDS	National Association of Chain Drug Stores
NAMSDL	National Alliance for Model State Drug Laws
NAPLEX	North American Pharmacist Licensure Examination (NABP)
NAPRA	National Association of Pharmacy Regulatory Authorities (Canada)
NASCSA	National Association of State Controlled Substance Authorities
NASPA	National Alliance of State Pharmacy Associations
NASPER	National All Schedules Prescription Electronic Reporting Act
NCC MERP	National Coordinating Council for Medication Error Reporting and Prevention
NCPA	National Community Pharmacists Association
NCPDP	National Council for Prescription Drug Programs
NCPIE	National Council on Patient Information and Education
NCPO	National Conference of Pharmaceutical Organizations
NCSBN	National Council of State Boards of Nursing
NCVHS	National Committee on Vital and Health Statistics
NDC	National Drug Code
NDMA	Nonprescription Drug Manufacturing Association
NIPCO	National Institute for Pharmacist Care Outcomes
NISPC	National Institute for Standards in Pharmacist Credentialing
NOCA	National Organization for Competency Assurance
NPA	National Pharmacy Association
NPC	National Pharmaceutical Council
NPDB	National Practitioner Data Bank
NPTA	National Pharmacy Technician Association
NRC	NAPLEX Review Committee (NABP) Federal Nuclear Regulatory Commission
OAL	Optometry Association of Louisiana
OBRA	Omnibus Budget Reconciliation Act
OIG	Office of Inspector General
ONDCP	Office of National Drug Control Policy
ONDD	Office of Narcotics and Dangerous Drugs
OSHA	Occupational Safety and Health Administration
PARE	Pharmacy Assessment, Remediation and Evaluation (NABP)
PBM	pharmacy benefit management
PCAB	Pharmacy Compounding Accreditation Board
PCCA	Professional Compounding Centers of America

PCMA	Pharmaceutical Care Management Association
PCOA	Pharmacy Curriculum Outcomes Assessment (NABP)
PDMA	Prescription Drug Marketing Act
PEBC	Pharmacy Examining Board of Canada
PhRMA	Pharmaceutical Research and Manufacturers of America
PMP	Prescription Monitoring Program
PMP-i	Prescription Monitoring Program Interconnect (NABP)
PTCB	Pharmacy Technician Certification Board
PTCE	Pharmacy Technician Certification Examination
PTEC	Pharmacy Technician Educators Council
RFID/EPC	Radio Frequency Identification / Electronic Product Code
SAMSHA	Federal Substance Abuse & Mental Health Services Administration
TJC	The Joint Commission
TOEFL	Test of English as a Foreign Language
TOEFL iBT	Test of English as a Foreign Language Internet-based Test
TSE	Test of Spoken English
URAC	Utilization Review Accreditation Commission
USP	United States Pharmacopeia / United States Pharmacopeial Convention
USP DI	US Pharmacopeia Dispensing Information
USP-NF	US Pharmacopeia – National Formulary
VAWD	Verified-Accredited Wholesale Distributors (NABP)
Vet-VIPPS	Veterinary-Verified Internet Pharmacy Practice Sites (NABP)
VIPPS	Verified Internet Pharmacy Practice Sites (NABP)
VPP	Verified Pharmacy Practice (NABP)
WHO	World Health Organization
WHPA	World Health Professions Alliance



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Minutes

Regular Meeting

Wednesday, May 27, 2015 at 10:00 a.m.

Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700

Table of Contents

<u>Agenda Item No.</u>	<u>Description</u>	<u>Page No.</u>
1.	Call to Order	03
2.	Invocation & Pledge of Allegiance	03
3.	Quorum Call	03
4.	Call for Additional Agenda Items & Adoption of Agenda	04
5.	Consideration of Minutes from Previous Meeting	04
6.	Report on Action Items	04
7.	Confirmation of Acts	04
8.	Opportunity for Public Comment	04
*	Statement of Purpose	04
9.	Committee Reports	
	A. Finance	05
	B. Application Review	05
	C. Reciprocity	06
	D. Violations	06
	E. Impairment	07
	F. Reinstatement	08
	G. Tripartite	10
	H. Regulation Revision	12
	I. Executive	14
10.	Staff Reports	
	J. Assistant Executive Director	17
	K. General Counsel	10
	L. Executive Director	16
11.	Changing Pharmacy Technician Certificates to Site-Specific Credentials	18
12.	New Orleans Pharmacy Museum	05
13.	Announcements	18
14.	Adjourn	18

A regular meeting of the Louisiana Board of Pharmacy was held on Wednesday, May 27, 2015 in the Boardroom of the Board's office, located at 3388 Brentwood Drive in Baton Rouge, Louisiana. The meeting was held pursuant to public notice, each member received notice, and notice was properly posted.

1. Call to Order

Mr. Carl Aron, President, called the meeting to order at 10:10 a.m.

2. Invocation & Pledge

Mr. Aron called upon Mr. Brian Bond, and he delivered the invocation. Mr. Richard Indovina then led the group in the recitation of the Pledge of Allegiance.

3. Quorum Call

Mr. Aron called upon the Secretary, Mr. Bond, to call the roll to establish a quorum.

Members Present:

Mr. Carl W. Aron
Mr. Brian A. Bond
Mr. Clovis S. Burch (early departure)
Mr. Ryan M. Dartez
Ms. Jacqueline L. Hall
Mr. Richard M. Indovina
Mr. Marty R. McKay
Ms. Diane G. Milano
Mr. Ronald E. Moore
Mr. Blake P. Pitre
Mr. T. Morris Rabb
Ms. Pamela G. Reed
Mr. Don L. Resweber
Dr. Deborah H. Simonson
Mr. Richard A. Soileau
Mr. Rhonny K. Valentine

Member Absent:

Ms. Chris B. Melancon

Staff Present:

Mr. Malcolm J. Broussard, Executive Director (late arrival)
Mr. Carlos M. Finalet, III, General Counsel
Mr. M. Joseph Fontenot, Assistant Executive Director
Ms. Kelley L. Villeneuve, Office Manager

Guests:

Mr. David Ruckman – Target Pharmacies
Mr. Michael Weber – Roadrunner Pharmacy
Mr. Ben J. Sims – Brookshire Grocery Co.
Ms. Mary Staples – NACDS

Mr. Eric Bopp – New Orleans Pharmacy Museum
Ms. Paula Belle – Walgreens Pharmacies
Ms. Barbara Jones – Walgreens Pharmacies

Mr. Bond certified 16 of the 17 members were present, constituting a quorum for the conduct of official business.

4. Call for Additional Agenda Items & Adoption of Agenda

Mr. Aron asked if there were any additional agenda items, but none were offered. With no objection, the Board adopted the posted agenda dated May 25, 2015. Mr. Aron then requested authority from the Board to reorder the agenda as necessary for the purpose of accommodating certain guests. There were no objections to that request.

5. Consideration of Minutes

Mr. Aron reminded the members they had received the draft minutes from the Regular Board Meeting on February 25, 2015 and the Administrative Hearing on November 26, 2015, both of which were held in Baton Rouge, Louisiana. With no objections, he waived the reading thereof. Hearing no requests for amendment or any objection to their approval, Mr. Aron declared the minutes were approved as presented. Mr. Bond reminded the members to sign the Minute Book.

6. Report on Action Items

In Mr. Broussard's absence, Mr. Aron presented the report. He reminded the members of their rulemaking decisions at their previous meeting and reviewed the subsequent activities for those regulatory and legislative projects.

7. Confirmation of Acts

Pursuant to Mr. Aron's declaration that the officers, committees, and executive director had attended to the business of the Board since the last meeting in accordance with policies and procedures previously approved by the Board, Mr. Moore moved,

Resolved, that the actions taken and decisions made by the Board officers, Board committees, and Executive Director in the general conduct and transactions of Board business since February 26, 2015 are approved, adopted, and ratified by the entire Board.

The motion was adopted after a unanimous vote in the affirmative.

8. Opportunity for Public Comment

Mr. Aron reminded the members and guests the Open Meetings Law requires all public bodies to provide an opportunity for public comment at all meetings and for each agenda item upon which a vote is to be taken. He solicited general comments on non-agenda items from the guests present, but none were offered.

Statement of Purpose

Mr. Aron reminded the members of the purpose and mission of the Board of Pharmacy by reciting the relevant portion of the Louisiana Pharmacy Practice Act. He urged the members to keep their mission in mind as they considered all the matters before them.

12. *New Orleans Pharmacy Museum*

Mr. Aron recognized Mr. Eric Bopp, an attorney from New Orleans who also serves on the Board of Directors of the museum. Mr. Aron invited Mr. Bopp to acquaint the Board's members with the museum and its activities. Mr. Bopp began by extending apologies from Ms. Liz Sherman, Curator of the museum, for her absence from the meeting. Mr. Bopp indicated the museum's board had embarked on a project to improve the number of pharmacists with membership in the museum, currently numbering around 150. He presented information on the museum's current activities and solicited suggestions from the board's members as to how to improve the pharmacist membership as well as to increase the visibility of the museum as a destination for professional social events. Mr. Aron authorized a waiver of the Board's usual fee for the production of a list of pharmacists as well as a list of pharmacy interns for the museum's use. The board members provided several suggestions, for which Mr. Bopp expressed his appreciation.

9. *Committee Reports*

A. *Finance Committee*

Mr. Aron called upon Mr. Pitre for the committee report. Mr. Pitre reviewed the interim report for the first three quarters of the current fiscal year. The members had no questions. Mr. Pitre tendered the report for information only, requiring no formal action by the Board.

Finally, Mr. Pitre expressed his appreciation to the other members of the committee for their ongoing work.

B. *Application Review Committee*

Mr. Aron called upon Mr. Soileau for the committee report. Mr. Soileau reported the committee met on April 30 to consider five referrals from the staff: four applications for a PTC registration and one application for a PHY permit. After interviews and deliberations, the Committee approved one of the applications for a PTC registration. One of the applicants for a PTC registration of their intent to appeal the committee's proposed denial, and that case will be heard during the August administrative hearing. The committee offered a proposed consent agreement to the applicant for a PHY permit, and that matter is still pending. Mr. Soileau then presented the following remaining applications to the Board for its consideration.

Chandra Demetria Norman (Applicant for PTC Registration) Mr. Soileau moved to deny the application and refuse to issue the registration. The motion was adopted after a unanimous vote in the affirmative. The Board denied the application and refused to issue the registration.

John Wesley Hill, III (Applicant for PTC Registration) Mr. Soileau moved to deny the application and refuse to issue the registration. The motion was adopted after a unanimous vote in the affirmative. The Board denied the application and refused to issue the registration.

Finally, Mr. Soileau expressed his appreciation to the other members of

the committee for their ongoing efforts.

C. Reciprocity Committee

Mr. Aron called upon Ms. Hall for the committee report. She reported the staff had evaluated 59 applications for pharmacist licensure by reciprocity and that none of them contained information that warranted a committee-level review. In conformance with policies and procedures previously approved by the Board, the staff approved the applications and issued the credentials.

Ms. Hall reported staff had referred one applicant to the committee, and the committee interviewed the applicant earlier that day.

Trenia Yielding (Applicant for Pharmacist Licensure) Ms. Hall moved to approve the application and issue the license. The motion was adopted after a unanimous vote in the affirmative. The Board approved the application and authorized the issuance of the license.

Finally, she closed her report with appreciation to the other committee members for their work earlier that day.

D. Violations Committee

Mr. Aron called upon Mr. Bond for the committee report. Mr. Bond reported the committee held an informal conference on March 4 to consider their posted agenda which included 13 cases: 2 pharmacists, 3 pharmacy technicians, and 7 pharmacy permits. After interviews and deliberations, the committee took no action against one of the respondents and issued informal warning letters to 4 respondents. The committee offered proposed voluntary consent agreements for the remaining 8 cases; of that number, 7 respondents had accepted the proposed agreements but one respondent will face an administrative hearing in August. Mr. Bond then presented the following proposed consent agreements for the Board's consideration.

Wal-Mart Louisiana, LLC d/b/a Wal-Mart Pharmacy No. 10-1109 (PHY,004768) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed the permit owner administrative and investigative costs.

Riche-Gebbie, Inc. d/b/a Bradley's Pharmacy (PHY.000093) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed the permit owner a fine of \$30,000 plus administrative and investigative costs.

Loye's Pharmacy, Inc. d/b/a Loye's Pharmacy (PHY.000683) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed

the permit owner a fine of \$15,000 plus administrative and investigative costs.

Megan Nichole Beech (CPT.010807) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a majority vote in the affirmative; Ms. Milano objected. The Board suspended the certificate for five years and stayed the execution thereof, then placed the certificate on probation for five years, effective May 27, 2015, subject to certain terms enumerated in the consent agreement, and further, assessed administrative costs.

Brittaney Nicole Sanford (CPT.011833) Mr. Bond moved to accept the voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender, resulting in the active suspension of the certificate for an indefinite period of time, effective March 4, 2015.

Diamondback Drugs, LLC d/b/a Diamondback Drugs (PHY.006003) [Single consent agreement resolved two separate cases.] Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed the permit owner a fine of \$30,000 plus administrative and investigative costs.

Mr. Bond reported the committee will meet on June 17, 2015 to consider that docket of 14 cases, which includes 3 pharmacists, 5 pharmacy technicians, one pharmacy technician candidate, 4 pharmacy permits, and one applicant for a pharmacy permit.

Finally, Mr. Bond concluded his report with appreciation to the other committee members for their ongoing efforts.

E. Impairment Committee

Mr. Aron called upon Mr. Rabb for the committee report. Mr. Rabb reported the committee met the previous day to receive an educational presentation from the professional staff of Palmetto Addiction Recovery Center, to perform their annual review of the Board's list of approved addiction medicine specialists, and to consider four referrals from staff. Mr. Rabb reported the committee reviewed the credentials for two new addiction medicine specialists, Dr. Jay Pyland and Dr. David Hammond, both of whom are affiliated with Palmetto Addiction Recovery Center, and further, the committee voted to recommend their approval and enrollment on the Board's list of approved addictionists. On behalf of the committee, Mr. Rabb moved,

Resolved, that the Board approve the addition of Dr. Jay Pyland and Dr. David Hammond to the Board's List of Approved Addictionists.

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then reported the committee had reviewed the remainder of the list and

determined that no changes were necessary. On behalf of the committee, Mr. Rabb then moved,

Resolved, that the Board renew its approval of the revised List of Approved Addictionists for Fiscal Year 2015-2016.

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then presented the following files for Board action.

Doddi Vidrine Alexander (PST.016007) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board approved the respondent's application for reinstatement of the lapsed license, suspended the license for ten years and stayed the execution of the suspension, then placed the license on probation for ten years, effective May 27, 2015, subject to certain terms enumerated in the consent agreement, and further, assessed a fine of \$5,000 plus administrative costs.

Richard Jeffrey Gaude (PST.015640) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board approved the respondent's application for reinstatement of the suspended license, converted the duration of the suspensive period from an indefinite term to a term of five years and stayed the execution of the suspension, then placed the license on probation for five years, effective May 27, 2015, subject to certain terms enumerated in the consent agreement.

Alex Anthony Capace (PST.013422) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board approved the respondent's application for reinstatement of the suspended license, converted the duration of the suspensive period from an indefinite term to a term of five years and stayed the execution of the suspension, then placed the license on probation for five years, effective May 27, 2015, subject to certain terms enumerated in the consent agreement.

Edwin Paul Domingue, Jr. (PST.010459) Mr. Rabb moved to deny the respondent's request to terminate probation and remove all restrictions. The motion was adopted after a unanimous vote in the affirmative. The Board denied the respondent's request to terminate probation and continued the existing restrictions on the license.

Finally, Mr. Rabb closed his report with appreciation to his fellow committee members for their work the previous day and for the ongoing staff support.

F. Reinstatement Committee

Mr. Aron noted the absence of committee chair Ms. Chris Melancon, and then called upon Mr. Rabb for the committee report. He reported the

committee had met the previous day to consider eight referrals from the staff. He then presented the following files for Board action.

Misty Lynn Apple (CPT.003809) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously lapsed certificate, conditioned upon the satisfaction of certain requirements identified in the consent agreement.

Sherrie Lynn Washington (CPT.003787) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously lapsed certificate, conditioned upon the satisfaction of certain requirements identified in the consent agreement.

Jessica Vea Harmon (CPT.006868) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously lapsed certificate, conditioned upon the satisfaction of certain requirements identified in the consent agreement.

Giselle Natasha Munroe (PST.015886) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the lapsed license, conditioned upon the satisfaction of certain requirements identified in the consent agreement.

Karen Michelle Huffstickler (CPT.003181) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the lapsed certificate, conditioned upon the satisfaction of certain requirements identified in the consent agreement.

Robert Mark McGee (PST.015107) Mr. Rabb moved to grant the respondent's request for termination of probation. The motion was adopted after a unanimous vote in the affirmative. The Board terminated the probationary period and restored the license to active and unrestricted status.

James Robert Lang (PST.010884) Mr. Rabb moved to grant the respondent's request for termination of probation. The motion was adopted after a unanimous vote in the affirmative. The Board terminated the probationary period and restored the license to active and unrestricted status.

Colleen Joiner Hayes (PST.014983) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a

unanimous vote in the affirmative. The Board granted the respondent's request to return her inactive pharmacist license to active status, conditioned upon the satisfaction of certain requirements identified in the consent agreement.

Mr. Rabb closed the report with appreciation to the other committee members for their work the previous day.

G. Tripartite Committee

Mr. Aron noted the committee had not met since the last Board meeting.

At this point, Mr. Aron indicated he would re-order the agenda to take up the Report of the General Counsel. He promised a luncheon recess immediately thereafter.

10. Staff Reports

K. Report of General Counsel

Mr. Aron called upon Mr. Finalet for the report. Mr. Finalet then presented the following files to the Board for its consideration.

Isabelle Huey Robinson (CPT.003165) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board revoked the certificate, and further, permanently prohibited the acceptance of any future application for the reinstatement of the certificate or any application for any other credential issued by the Board.

Celeste Ann Trahan (CPT.006620) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board revoked the certificate, and further, permanently prohibited the acceptance of any future application for the reinstatement of the certificate or any application for any other credential issued by the Board.

Elizabeth Ann Marie Freeman (PTC.021790) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board revoked the registration, and further, permanently prohibited the acceptance of any future application for the reinstatement of the registration or any application for any other credential issued by the Board.

Kristian Raymond Hahn (PST.016625) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand, and further, assessed a fine of \$1,000 plus administrative costs.

The Medicine Store Pharmacy, Inc. d/b/a Rxxpress Pharmacy (PHY.007083) Mr. McKay moved to approve the proposed voluntary consent

agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Warning, and further, assessed a fine of \$5,000 plus administrative costs.

Specialty Veterinary Pharmacy, Inc. d/b/a Specialty Veterinary Pharmacy (PHY.006428) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand, and further, assessed a fine of \$5,000 plus administrative costs.

Walter Gerard Lloyd (PST.017098) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand, and further, assessed a fine of \$1,000 plus administrative costs.

Tamia Anjani Cornish (PTC.020491) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board revoked the registration, and further, permanently prohibited the acceptance of any future application for the reinstatement of the registration or any application for any other credential issued by the Board.

Amgad Hassaballah Girgis (PST.018119) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand, and further, assessed a fine of \$1,000 plus administrative costs.

CP's Drug Store, LLC d/b/a CP's Drug Store (CDS.039363-PHY) Mr. McKay moved to accept the voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender, resulting in the active suspension of the CDS license for an indefinite period of time, effective May 21, 2015.

Charles Callan Mary, III (CDS.026554-MD) Mr. McKay moved to suspend the CDS license for an indefinite period of time based on the suspension of his medical license by the La. Board of Medical Examiners. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time, effective January 23, 2015.

Wayne Joseph Thibodeaux (CDS.025760-MD) Mr. McKay moved to suspend the CDS license for an indefinite period of time based on the summary suspension of his medical license by the La. Board of Medical Examiners. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time, effective February 11, 2015.

Lisa Smith Hodges (CDS.033642-MD) Mr. McKay moved to suspend the CDS license for an indefinite period of time based on the suspension of her medical license by the La. Board of Medical Examiners. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time, effective February 9, 2015.

Esteban Alberto Martinez, Jr. (CDS.021069-MD) Mr. McKay moved to suspend the CDS license for an indefinite period of time based on the suspension of his medical license by the La. Board of Medical Examiners. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time, effective March 15, 2015.

Bruce Harlan Lobitz (CDS.020450-MD) Mr. McKay moved to suspend the CDS license for an indefinite period of time based on the summary suspension of his medical license by the La. Board of Medical Examiners. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time, effective April 1, 2015.

Kyle Kristen Runnels, Sr. (CDS.036168-MD) Mr. McKay moved to suspend the CDS license for an indefinite period of time based on the summary suspension of his medical license by the La. Board of Medical Examiners. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time, effective April 20, 2015.

Bruce Leonard Wilson (CDS.045878-MD) Mr. Moore moved to suspend the CDS license for an indefinite period of time based on his failure to resolve the payment of license renewal fee with a check returned for insufficient funds. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time, effective May 12, 2015.

At this point, Mr. Aron declared a luncheon recess. It was noted the Board recessed at 11:45 am and then re-convened in open session at 12:30 pm. Mr. Aron indicated he would resume the sequence of the posted agenda, beginning with the Report of the Regulation Revision Committee. It was noted Mr. Burch did not return to the meeting.

9. *Committee Reports*

H. Regulation Revision Committee

Mr. Aron called upon Mr. McKay for the committee report. Mr. McKay reported the committee had met four times since the last Board meeting, as recently as the previous afternoon. The committee voted to recommend the approval of several regulatory proposals and he directed the members to copies of all the proposals in their electronic meeting binders. Mr. McKay then moved,

Resolved, to approve Regulatory Proposal 2015-D ~ Compounding for Office Use for Veterinarians (Draft #3), and further, to authorize the Executive Director to promulgate the proposed rule amendments upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved

Resolved, to approve the Declaration of Emergency – Compounding for Office Use for Veterinarians, and further, to authorize the Executive Director to prepare and issue the required notices for emergency rules upon the instruction of the President, and further, to declare the effective date of the emergency rule to be June 1, 2015.

The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

Resolved, to approve Regulatory Proposal 2015-E ~ Electronic Signature on Facsimile Prescription (Draft #2), and further, to authorize the Executive Director to promulgate the proposed rule amendment upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

Resolved, to approve the Declaration of Emergency – Electronic Signature on Facsimile Prescription, and further, to authorize the Executive Director to prepare and issue the required notices for emergency rules upon the instruction of the President, and further, to declare the effective date of the emergency rule to be June 1, 2015.

The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

Resolved, to approve Regulatory Proposal 2015-F ~ Telepharmacy Services (Draft #3), and further, to authorize the Executive Director to promulgate the new rule upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

During the discussion on the motion, Dr. Simonson moved to amend the proposal by deleting Sub-paragraph B.6 within §2425. Ms. Hall, Mr. Indovina, Mr. Pitre, Mr. Resweber, Dr. Simonson, Mr. Soileau, and Mr. Valentine voted in the affirmative; Mr. Bond, Mr. Dartez, Mr. McKay, Ms. Milano, Mr. Moore, Mr. Rabb, and Ms. Reed objected. Mr. Aron broke the 7-7 tie vote by voting in the negative; therefore, the motion for the amendment failed. Mr. McKay then moved to amend Sub-paragraph B.6 within §2425 to provide an option for the telepharmacy to convert its permit to a regular community pharmacy permit in

lieu of closing permanently. The motion for the amendment was adopted after a unanimous vote in the affirmative. Mr. Aron directed staff to prepare a new draft incorporating the amendment. The motion for the approval of the amended proposal (Draft #4) was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

Resolved, to approve Regulatory Proposal 2015-G ~ Remote Processor Pharmacy (Draft #2), and further, to authorize the Executive Director to promulgate the new rule upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

Resolved, to approve Regulatory Proposal 2015-H ~ Remote Access to Medical Orders (Draft #1), and further, to authorize the Executive Director to promulgate the proposed rule amendment upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process, and further, to authorize the continuation of the pilot project by the current participants until such time as the final rule is effective.

The motion was adopted after a unanimous vote in the affirmative. McKay then reviewed the remaining topics on the committee's agenda.

Finally, Mr. McKay concluded his report with appreciation to the other committee members for their ongoing efforts as well as for the staff support.

I. Executive Committee

Mr. Aron informed the members the executive office had reviewed the Board's two policy manuals as well as the Board's list of approved pharmacy schools, and some other documents. The committee had met the previous day to consider the staff recommendations and voted to recommend their approval. He indicated Mr. Rabb would be making the motions on behalf of the committee. Mr. Rabb then moved,

Resolved, that the Board rescind *Policy No. PPM.II.E.5 ~ Travel Card & CBA Policy* in the Board's Policy & Procedure Manual.

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, that the Board approve the proposed revision of *Policy No. PPM.II.6 ~ Corporate Travel Card* in the Board's Policy & Procedure Manual.

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, that the Board approve the proposed revision of *Policy No. PPM.II.H.2 ~ Sexual Harassment* in the Board's Policy & Procedure Manual.

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, that the Board approve the proposed revision of *Policy No. PPM.II.1.3 ~ Smoking in the Board's Policy & Procedure Manual*.

The motion was adopted after a unanimous vote in the affirmative.

It was noted Mr. Broussard arrived at the meeting shortly before 1:30 pm.

Mr. Rabb then moved,

Resolved, that the Board renew its approval of the updated *Policy & Procedure Manual* for Fiscal Year 2015-2016.

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, that the Board approve the proposed revision of *Policy No. LPM.I.K ~ Bloodborne Pathogens in the Board's Loss Prevention Manual*.

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, that the Board approve the proposed revision of *Policy No. LPM.I.L ~ First Aid in the Board's Loss Prevention Manual*.

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, that the Board approve the proposed revision of *Policy No. LPM.II.A ~ Authorized Drivers in the Board's Loss Prevention Manual*.

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, that the Board approve the proposed revision of *Policy No. LPM.II.F ~ Accident Reporting in the Board's Loss Prevention Manual*.

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, that the Board approve the proposed revision of *Policy No. LPM.III.H ~ Key Control in the Board's Loss Prevention Manual*.

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, that the Board renew its approval of the updated *Loss Prevention Manual* for Fiscal Year 2015-2016.

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, that the Board renew its approval of the updated *Roster of Approved Colleges & Schools of Pharmacy* for Fiscal Year 2015-2016.

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, that the Board approve the *Louisiana Compliance Questionnaire for 2015*, and further, authorize the President and

Secretary to execute the document on behalf of the Board.

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, that the Board approve the proposal from Covalent Logic to upgrade the software for the Board's website to accommodate users of mobile devices, in an amount not to exceed \$15,000.

The motion was adopted after a unanimous vote in the affirmative.

Finally, Mr. Aron completed his report with appreciation to his fellow officers for their ongoing efforts.

At this point, Mr. Aron noted the completion of all the committee reports. As to the staff reports, he noted Mr. Fontenot's absence and the previous completion of Mr. Finalet's report. He then called on Mr. Broussard for his report.

10. Staff Reports

L. Report of Executive Director

Mr. Aron called upon Mr. Broussard for the report. Mr. Broussard directed the members to his report which was posted in the Boardroom Library prior to the meeting; it was also included in the meeting binder. He reviewed the following topics:

- Meeting Activity
- Reports
 - Census Reports – Credentials & Compliance Divisions
 - Production Reports – Credentials Division
 - Exceptions Report
- Examinations
 - MPJE
 - NAPLEX
 - PARE
 - PTCB
- Operations
 - Credentials Division
 - Compliance Division
 - Administrative Division
- State Activities
 - 2015 Regular Session of Louisiana Legislature
 - Naloxone Access
- National Activities
 - U.S. Drug Enforcement Administration (DEA)
 - Multistate Pharmacy Jurisprudence Examination (MPJE)
 - National Association of Boards of Pharmacy (NABP)
 - NABP-AACP District 6 Annual Meeting
 - MALTAGON
- International Activities
 - International Pharmaceutical Federation (FIP)

Finally, Mr. Broussard indicated the completion of his report.

J. Report of Assistant Executive Director

Mr. Aron noted Mr. Fontenot's absence but directed the members to his report in the electronic meeting binder. He invited the members to review the slide presentation at their leisure and then noted the two requests from different sets pharmacies for waivers from the duty to report prescription transactions to the PMP database. With respect to the first list from two pharmacies seeking a partial waiver, Mr. Moore moved,

Resolved, to authorize the issuance of partial PMP reporting waivers to:

- > PHY.006015-IR – Carmichael's LTC of Crowley (LA); and
 - > PHY.006051-IR – Carmichael's Pharmacy IHP (LA);
- once they have executed the standard consent agreement for that purpose.

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, to authorize the issuance of PMP reporting waivers to:

- > PHY.007002-NR – AHF Pharmacy (FL);
 - > PHY.001289-HOS – Allen Parish Hospital Pharmacy (LA);
 - > PHY.007069-NR – Ardon Health (OR);
 - > PHY.007023-NR – Biologic Tx (NJ);
 - > PHY.006852-NR – BriovaRx of Indiana (IN);
 - > PHY.006757-IR – BriovaRx of Louisiana (LA);
 - > PHY.005663-NR – BriovaRx of Maine (ME);
 - > PHY.006353-NR – BriovaRx of Tennessee (TN);
 - > PHY.006354-NR – BriovaRx of Texas (TX);
 - > PHY.006934-NR – Cardiac Infusion Specialists (TX);
 - > PHY.001258-HOS – Children's Hospital Pharmacy (LA);
 - > PHY.005596-HOS – Cornerstone Hospital of West Monroe (LA);
 - > PHY.006764-NR – Eiris Health Services (TN);
 - > PHY.007102-NR – Family Factor (AL);
 - > PHY.006943-NR – GenRx Pharmacy (AZ);
 - > PHY.006370-NR – JAT Pharmacy (WI);
 - > PHY.006871-NR – JCB Laboratories (KS);
 - > PHY.006725-HOS – Leonard Chabert Medical Center (LA);
 - > PHY.006165-HOS – Opelousas Gen. H.S. Pharmacy South (LA);
 - > PHY.000838-HOS – Opelousas General Hosp Pharmacy (LA)
 - > PHY.006826-NR – Paragon Infusion Care (TX)
 - > PHY.007011-NR – PerformSpecialty (FL);
 - > PHY.006807-NR – Stockman's Rx (MS);
 - > PHY.007047-NR – Twin Lakes Phmarcy (TX);
 - > PHY.007042-NR – Walgreens Pharmacy #1261-2 (FL);
 - > PHY.001196-HOS – West Calcasieu Cameron; and
 - > PHY.006835-NR – CVS Central Pharmacy
- once they have executed the standard consent agreement for that purpose.

The motion was adopted after a unanimous vote in the affirmative.

Finally, Mr. Aron indicated completion of that report.

11. Changing Pharmacy Technician Certificates to Site-Specific Credentials – Ms. Milano

Mr. Aron recognized Ms. Milano for her request. She requested the Board develop a rule requiring the Board to notify pharmacies in the event a technician is terminated by a previous pharmacy employer. Following substantial discussion on the topic without a motion, Mr. Pitre moved to table the discussion. The motion was adopted after a majority vote in the affirmative; Ms. Milano objected.

13. Announcements

Mr. Aron directed the members to the announcements in their meeting binder.

14. Adjourn

Having completed the tasks itemized on the posted agenda, with no further business pending before the Board, and without objection, Mr. Aron recessed the meeting at 2:35 p.m.

Respectfully submitted,

Brian A. Bond
Secretary



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Finance Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Finance Committee

Final Report for Fiscal Year 2014-2015

August 12, 2015

Blake P. Pitre
Chair

Louisiana Board of Pharmacy
Finance Committee

Final Report for Fiscal Year 2014-2015

Table of Contents

Statement of Assets, Liabilities, & Equity	03
Statement of Revenue, Expenses, & Budget Performance	05
Statement of Equity	07
Summary of Income & Fund Balance Changes	08
Budget Variance Report	09
Schedule A – Hurricane Katrina/Rita Pharmacy Relief Fund	11
Summary of Board Actions	12
Iberia Bank – General Reserve Fund Statement	14
Iberia Bank – OPEB Reserve Fund Statement	16
Cumulative Fund Balance Report	17

Louisiana Board of Pharmacy
 FY 2014-2015
 Statement of Assets, Liabilities and Equity

	FY 13-14 Q4 06/30/2014	FY 14-15 Q4 06/30/2015
ASSETS		
> Current Assets		
* Cash		
General Operations		
Whitney Bank	160,352	160,513
Iberia Bank	829,409	928,695
Hurricane Relief Fund - Whitney Bank	83,137	83,221
Reserve Funds		
General Account	1,504,183	1,920,602
OPEB Account	<u>985,716</u>	<u>1,047,038</u>
* Total Cash	3,562,797	4,140,069
* Prepaid Expenses	<u>0</u>	<u>3,000</u>
* Total Prepaid Expenses	0	3,000
<i>Total Current Assets</i>	<i>3,562,797</i>	<i>4,143,069</i>
> Fixed Assets		
Land: Lot 5-A, Towne Center Business Park	709,080	709,080
Land: Lot 1-A-2, Leonard Place Subdivision	295,860	295,860
Office Building - 3388 Brentwood Drive	1,052,255	1,057,861
Office Equipment	195,598	216,119
Furniture	152,750	154,198
Software: Licensure & Website	408,560	408,560
Accumulated Depreciation	<u>(675,066)</u>	<u>(762,358)</u>
<i>Total Fixed Assets</i>	<i>2,139,037</i>	<i>2,079,320</i>
TOTAL ASSETS	5,701,834	6,222,389
DEFERRED OUTFLOWS OF RESOURCES	<u>0</u>	<u>464,626</u>
<u>TOTAL ASSETS & DEFERRED OUTFLOWS</u>	5,701,834	6,687,015
 LIABILITIES		
> Current Liabilities		
Accrued salaries and benefits	72,047	82,372
Unemployment taxes payable	26	57
State taxes withheld	3,098	3,365
Accounts payable	3,536	2,225
Interest payable	5,338	2,469
Compensated absences (ST)	56,065	64,373
Building Loan @ Iberia Bank (ST)	<u>75,795</u>	<u>108,026</u>
<i>Total Current Liabilities</i>	<i>215,905</i>	<i>262,887</i>

(continued)

Louisiana Board of Pharmacy
 FY 2014-2015
 Statement of Assets, Liabilities and Equity

	FY 13-14 Q4 06/30/2014	FY 14-15 Q4 06/30/2015
> Long Term Liabilities		
Compensated absences (LT)	63,228	53,962
Building Loan @ Iberia Bank (LT)	885,109	366,108
Other Post Employment Benefits (OPEB) Payable	1,016,868	1,173,689
Net Pension Liability	<u>0</u>	<u>4,117,091</u>
<i>Total Long Term Liabilities</i>	<i>1,965,205</i>	<i>5,710,850</i>
TOTAL LIABILITIES	2,181,110	5,973,737
DEFERRED INFLOWS OF RESOURCES	0	594,213
EQUITY	3,520,724	119,065
<u>TOTAL LIABILITIES, DEFERRED INFLOWS, & EQUITY</u>	5,701,834	6,687,015

Louisiana Board of Pharmacy
FY 2014-2015
Statement of Revenue, Expenses, and Budget Performance

Revenue

	FY 13-14 Q4 06/30/2014	FY 14-15 Q4 06/30/2015	FY 14-15 Budget (A#1)	Notes
<i>Licenses & Permits</i>				
Pharmacist Renewals	755,775	782,525	755,000	1
New Pharmacist Licensing Fee	164,400	193,100	161,000	2
Technician Renewals	312,350	315,900	312,000	3
Technician Candidate Registrations	37,375	37,725	35,000	4
Lapsed Credential Fees	57,000	66,600	50,000	5
Student Registrations	3,070	3,050	3,000	6
Permits - Pharmacies	264,200	275,675	260,000	7
Permits - CDS	437,860	454,215	440,000	8
Permits - Emergency Drug Kits	12,525	13,400	12,500	9
Permits - Automated Medication Systems	17,700	23,250	18,000	10
Permits - Durable Medical Equipment	68,975	82,600	70,000	11
<i>Examinations</i>				
Reciprocity	47,700	54,600	45,000	12
Technicians	61,300	55,900	63,000	13
<i>Penalties</i>				
Licenses and Certificates	8,187	8,633	8,000	14
Permits	11,473	12,150	11,000	15
<i>Administrative Fees</i>				
Documents: Copies and Certification Fees	8,820	4,903	7,500	16
Duplicate Credentials	3,665	5,710	4,000	17
Silver Certificates	400	400	500	18
Original Certificates	9,750	8,700	10,000	19
NSF Fees	425	450	500	20
Handling & Mailing Fees	170	190	0	21
<i>Sale of Goods & Services</i>				
Law Books	5,095	5,125	6,000	22
Official Lists of Licensees	6,750	10,800	6,000	23
USCPSC Inspection Fee	1,650	4,800	2,000	24
<i>Enforcement Actions</i>				
Hearing Fees	22,000	21,000	24,000	25
Fines	215,000	631,500	250,000	26
Investigative Costs	39,198	30,320	40,000	27
<i>Prescription Monitoring Program</i>				
Assessments	462,825	482,225	465,000	28
<i>Miscellaneous</i>				
	820	940	1,000	29
TOTAL REVENUE	3,036,458	3,586,386	3,060,000	30

Louisiana Board of Pharmacy
FY 2014-2015
Statement of Revenue, Expenses, and Budget Performance
Expenses

		FY 13-14	FY 14-15	FY 14-15	
		Q4 06/30/2014	Q4 06/30/2015	Budget (A#1)	Notes
<i>Operations</i>	Rentals - Office & Equipment	2,952	14,535	18,000	31
	Equipment Maintenance	2,681	2,579	4,000	32
	Telephone	15,629	19,634	15,000	33
	Printing	56,235	22,443	25,000	34
	Postage	51,628	48,112	45,000	35
	Civil Service Assessment	4,236	6,074	6,100	36
	Office Insurance (ORM)	6,272	7,112	7,500	37
	Dues & Subscriptions	20,354	10,613	23,000	38
	Office Supply Expenses	17,630	21,175	20,000	39
	Financial Service Charges	52,466	47,541	50,000	40
	Depreciation of Fixed Assets	141,772	99,091	141,000	41
	Interest Payments on Building Loan	63,000	44,882	63,000	42
	Office Meeting Expenses	47	538	500	43
	Utilities	10,655	10,614	10,000	44
	Miscellaneous	0	0	0	
<i>Acquisitions</i>		345	3,662	52,500	45
<i>Personal Services</i>					
	Salaries	1,193,177	1,258,895	1,334,100	46
	Payroll Taxes (FICA + FUTA)	21,330	22,117	27,100	47
	Retirement Contributions	371,283	185,294	494,000	48
	Health Insurance (SEGBP)	119,974	119,813	160,200	49
	Other Post Employment Benefits (OPEB)	91,464	156,821	91,500	50
	Board Member Per Diem	27,900	29,400	31,000	51
<i>Professional Services</i>	Accounting	23,961	22,519	25,000	52
	Legal	35,908	8,189	30,000	53
	Information Systems	97,303	93,011	98,000	54
	Property Management	16,375	20,350	35,000	55
	Temp. Labor	20,354	15,507	20,000	56
	Prescription Monitoring Program	195,791	77,300	80,000	57
<i>Staff Expenses</i>	ED - Travel	1,178	4,264	10,000	58
	GC - Travel	12	10,212	10,000	59
	AED - Travel	1,964	1,956	10,000	60
	CO - Travel	3,912	3,774	7,000	61
	CO - Rental Cars & Fuel	15,522	15,886	17,500	62
	CO - Education	7,079	8,514	15,000	63
	House Staff - Travel	0	199	1,000	64
	Mileage	15,491	15,327	20,000	65
<i>Board Expenses</i>					
	Meeting Expenses	13,637	12,070	15,000	66
	Committee Expenses	6,460	5,315	8,000	67
	Conventions	14,829	22,668	15,000	68
	Mileage	12,268	12,483	15,000	69
	President's Expenses	<u>10,946</u>	<u>10,192</u>	<u>10,000</u>	70
TOTAL EXPENSES		2,764,020	2,490,681	3,060,000	71

Louisiana Board of Pharmacy
 FY 2014-2015
 Statement of Equity

	FY 13-14 Q4-06/30/2014	FY 14-15 Q4-06/30/2015
Fund Balance at End of Prior Fiscal Year	1,872,264	
Fund Balance - designated	174,954	
Invested in Fixed Assets	1,178,132	
Net Income/Loss	<u>295,374</u>	
<i>TOTAL EQUITY</i>	<i>3,520,724</i>	
Balance of Equity at Beginning of FY 14-15	3,520,724	
Restatement caused by the implementation of <u>GASB Statement 68 - Accounting & Financial Reporting for Pensions</u>		(4,526,010)
Restated Balance at Beginning of FY 14-15		(1,005,286)
Fund Balance at End of Prior Fiscal Year		(2,793,425)
Fund Balance - designated		182,952
Invested in Fixed Assets		1,605,186
Net Income/Loss		<u>1,124,352</u>
Balance of Equity at End of FY 14-15		119,065

Louisiana Board of Pharmacy
 FY 2014-2015
 Summary of Income Fund Balance Changes

Summary

	FY 13-14 Q4 06/30/2014	FY 14-15 Q4 06/30/2015	FY 14-15 Budget (A#1)	<u>Notes</u>
Income Statement				
Total Revenue	3,036,458	3,586,386	3,060,000	72
Total Expenses	2,764,020	2,490,681	3,060,000	73
Net Ordinary Income	272,438	1,095,705	0	
Other Income & Expenses				
Investment	22,936	28,347	0	74
Disposal of Assets	0	300	0	
Net Income	295,374	1,124,352	0	75

	FY 13-14 Q4 06/30/2014	FY 14-15 Q4 06/30/2015	FY 14-15 Budget (A#1)
Fund Balance			
Beginning Fund Balance	3,225,350	(1,005,286)	(1,005,286)
Total Income	3,059,394	3,615,033	3,060,000
Total Expenses	2,764,020	2,490,681	3,060,000
GASB-68 Restatement	(4,526,010)		
Ending Fund Balance	(1,005,286)	119,065	(1,005,286)
Reservations of Fund Balance	2,162,000	1,272,000	1,272,000
Unreserved Fund Balance	(3,167,286)	(1,152,935)	(2,277,286)

Notes on Reservation of Fund Balance

FY 13-14	Other Post-Employment Benefits Payable	929,700
	Debt Service Payable	1,032,300
	Continuing Payroll Obligations	150,000
	Homeland Maintenance	<u>50,000</u>
	<i>TOTAL</i>	2,162,000

FY 14-15	Other Post Employment Benefits Payable	572,000
	Debt Service Payable	450,000
	Continuing Payroll Obligations	150,000
	Homeland Maintenance	<u>100,000</u>
	<i>TOTAL</i>	1,272,000

Louisiana Board of Pharmacy
 FY 2014-2015
 Budget Variance Report

<u>Notes</u>	<u>Acct. No.</u>	<u>Account Name</u>	<u>% Variance</u>	<u>Comment</u>
Revenue				
1	4201	Pharmacist Renewals	3.65	Underestimated by 275 pharmacists
2	4206	New Pharmacist Licensing Fee	19.9	Underestimated by 107 applicants
3	4204	Technician Renewals	1.25	Underestimated by 78 technicians
4	4208	Tech Candidate Registrations	7.79	Underestimated by 109 applicants
5	4205	Lapsed Credential Fees	33.2	Underestimated reinstatements
6	4350	Student Registrations	1.67	Underestimated by 5 applicants
7	4301	Permits - Pharmacies	6.03	Underestimated by 125 permits
8	4302	Permits - CDS	3.23	Underestimated growth and renewals
9	4303	Permits - EDK	7.2	Underestimated by 36 permits
10	4304	Permits - AMS	29.17	Underestimated by 35 permits
11	4306	Permits - DME	18	Underestimated by 100 permits
12	4153	Exams - Reciprocity	19.25	Underestimated by 64 applicants.
13	4152	Exams - Technicians	-11.27	Overestimated by 71 applicants
14	4252	Penalties - Licenses	7.91	Underestimated reinstatements
15	4251	Penalties - Permits	10.45	Underestimated reinstatements
16	4460+62	Documents: Copies + Certified	34.63	Overestimated demand
17	4452	Duplicate credentials	42.75	Underestimated demand
18	4453	Pharmacist Silver Certificates	-20	Overestimated demand by 1 certificate
19	4459	Pharmacist Original Certificates	-13	Overestimated demand by 17 certificates
20	4454	NSF Fees	-10	Overestimated incidence
21	4463	Handling & Mailing Fees	*	Underestimated demand
22	4402	Law Books	-14.59	Overestimated demand for supplements
23	4461	Lists of Licensees	80	Underestimated demand by 32 requests
24	4458	Inspection Fees	140	Increased demand from US CPSC
25	4102	Administrative Hearing Fees	-12.5	Overestimated caseload by 12 cases
26	4501	Fines	152.6	Underestimated amount of sanctions
27	4502	Investigative Costs	-24.2	Overestimated cost recoveries
28	4660	PMP Assessments	3.7	Underestimated by 689 accounts
29	4455	Miscellaneous	-6	Close estimate
30		Total Revenue	17.2	Exceeded FY 14 revenue by 18%

Louisiana Board of Pharmacy
FY 2014-2015
Budget Variance Report

<u>Notes</u>	<u>Acct. No.</u>	<u>Account Name</u>	<u>% Variance</u>	<u>Comment</u>
Expenses				
31	5321	Rentals - Office & Equipment	-19.25	Timing issue on office equipment leases
32	5330	Equipment Maintenance	-35.53	Overestimated need for some + timing issue
33	5370	Telephone	30.88	Underestimated demand
34	5305	Printing	-10.23	Overestimated demand + e-newsletter
35	5300	Postage	6.92	Underestimated demand
36	5125	Civil Service Assessment	0.43	Annual fee, based in part on size of staff
37	5230	Office Insurance (ORM)	-5.17	Annual fee, based in part on size of staff
38	5190	Dues & Subscriptions	-53.86	Terminated WestLaw service
39	5280	Office Supply Expenses	5.88	Underestimated demand
40	5381	Financial Service Charges	-4.92	Overestimated use of online renewal
41	5180	Depreciation	-29.72	Overestimated depreciation schedule
42	5385	Interest Payments on Bldg Loan	-28.76	Less interest due after extra payments
43	5260	Office Meetings	7.6	Close estimate
44	5390	Utilities	6.14	Close estimate
45	5115	Acquisitions	-93.02	Deliberate deferrals + timing issue
46	5350	Salaries	-5.64	Close estimate
47	5290	Payroll Taxes (FICA + FUTA)	-18.4	Paid less temp salaries than expected
48	5340	Retirement Contributions	-62.5	GASB-68 Implementation
49	5220	Health Insurance (SEGBP)	-25.21	ACA-related plan changes
50	2400	OPEB	71.39	Premium increased by state
51	5152	Board Member Per Diem	-5.16	Overestimated meeting activity
52	5110	Accounting Services	-9.92	Overestimated need for services
53	5250	Legal Services	-72.7	Overestimated demand for services
54	5295	Information Systems	-5.09	Contracted amount
55	5297	Property Management	-41.86	Deferred roof and A/C replacement
56	5296	Temporary Labor	-22.47	Less robust labor pool in high school
57	5600	Prescription Monitoring Program	-8.99	Contracted amount
58	5361	Staff Travel - Executive Director	-57.36	NABP-AM + MPJE x 2 + TALKOM
59	5365	Staff Travel - General Counsel	2.12	NABP-D6 + FARB + TALKOM
60	5373	Staff Travel - Asst Exec Dir	-80.44	MPJE x 2 + TALKOM
61	5363	Staff Travel - Compliance Offcra	-46.09	Improved travel management
62	5371-72	Staff Travel - Rental Cars & Fuel	-9.22	Overestimated demand
63	5368	Staff Educ - Compliance Officers	-43.24	Limited to USP-797 inspection training
64		Staff - Office staff travel	-80.1	House staff educational seminars
65	62+64+67	Mileage - entire staff	-23.37	Overestimated travel demands
66	5153	Board - Meeting Expenses	-19.53	Overestimated meeting travel
67	5155	Board - Committee Expenses	-33.56	Overestimated meeting travel
68	5154	Board - Convention Expenses	51.12	Underestimated demand for N.O. conference
69	5151	Board - Mileage	-16.78	Overestimated meeting travel
70	86+87+88	Board - President's Expenses	1.92	Underestimated meeting travel
71		Total Expenses	-18.65	Reduced FY 14 expenses by 10%
Summary				
72		Total Revenue	17.2	18.1% increase over FY 14 revenue
73		Total Expenses	-18.65	9.9% decrease from FY 14 expenses
74	6003	Investments	*	84% from dividends; 16% market value
75		Net Income/Loss	*	280% increase over FY 14 net income

Louisiana Board of Pharmacy
 FY 2014-2015
 Schedule A - Hurricane Katrina/Rita Pharmacy Relief Fund

Statement of Assets, Liabilities & Equity	FY 13-14 Q4 06/30/2014	FY 14-15 Q4 06/30/2015
ASSETS		
Current Assets		
Whitney Bank - Checking Account	<u>83,137</u>	<u>83,221</u>
<u>TOTAL ASSETS</u>	<u>83,137</u>	<u>83,221</u>
LIABILITIES		
Current Liabilities	0	0
EQUITY		
Retained Earnings	83,054	83,137
Net Income	<u>83</u>	<u>84</u>
<u>TOTAL LIABILITIES & EQUITY</u>	<u>83,137</u>	<u>83,221</u>
Statement of Revenues & Expenses		
	FY 13-14 Q4 06/30/2014	FY 14-15 Q4 06/30/2015
Revenues		
FEMA - Funds for payment of claims	8,920,812	8,920,812
FEMA - Administrative allowance	81,103	81,103
Pharmacies - reversal of claims	430,138	430,138
Interest income	<u>22,062</u>	<u>22,146</u>
<u>Total Revenues</u>	<u>9,454,115</u>	<u>9,454,199</u>
Expenses		
Claims paid to pharmacies	8,920,812	8,920,812
Reversed claim funds returned	430,138	430,138
Reversed administrative allowance returned	7,338	7,338
Interest earned on reversed admin. allowance returned	<u>12,690</u>	<u>12,690</u>
<u>Total Expenses</u>	<u>9,370,978</u>	<u>9,370,978</u>
FUND BALANCE	<u>83,137</u>	<u>83,221</u>

Note: These funds are held in an account separate and apart from the Board's operating funds. Further, all recordkeeping is kept separate from the Board's general fund records. At the conclusion of the audit exposure period, any funds remaining will be transferred to the Board's operating account.

Louisiana Board of Pharmacy
FY 2014-2015
Summary of Board Actions

Date	Action
11/6/2013	Original Budget - Finance Committee Approval
11/7/2013	Original Budget - Board Approval
8/5/2014	Budget Amendment #1 - Finance Committee Approval
8/6/2014	Budget Amendment #1 - Board Approval
	Budget Amendment #2 - Finance Committee Approval
	Budget Amendment #2 - Board Approval
8/12/2015	Acceptance of Final Report



Securities and advisory services are offered through Essex National Securities, LLC, member FINRA/SIPC, an independent broker/dealer and Registered Investment Advisor. Insurance products are offered through Essex National Insurance Agency, Inc. Neither are affiliated with IBERIABANK. Not Guaranteed by IBERIABANK. Not FDIC Insured. Not a Bank Deposit. Not Insured by Any Federal Government Agency. May Lose Value Including Loss of Principal.

Portfolio Snapshot
Louisiana Board of Pharmacy Portfolio
April 01, 2015 through June 30, 2015


Prepared By

JOSEPH BARRECA, JR.
Iberia Financial Services, LLC
Ridgelake
2900 Ridgelake Drive
Metairie, LA 70002
Work/Business Phone: (504) 310-7346
E-Mail: jbarreca@iberiabank.com

Accounts and Holdings

Portfolio by Holding Type

	Shares/Units	NAV/Price	Value	% of Portfolio
Non-Qualified Accounts				
H5E049797, Pershing Louisiana Board of Pharmacy Nonprofit Organization		General Reserve Fund	\$1,919,630.46	100.00 %
BMO HARRIS BK NATL ASSN CHICAGO ILL CTF DEP ACT/365 ANNUAL Fixed Income - CDs (05573JVN1)	250,000.000	\$98.50	\$246,250.00	12.83 %
PACIFIC WESTN BK LOS ANGELES CALIF CTF DEP ACT/365 Fixed Income - CDs (69506YBD0)	243,000.000	\$100.03	\$243,072.90	12.66 %
PEOPLES UTD BK BRIDGEPORT CT CTF DEP ACT/365 Fixed Income - CDs (71270QA3)	243,000.000	\$100.03	\$243,072.90	12.66 %
HSBC BK USA N A MC LEAN VA CTF DEP ACT/365 INCOME OPPTY Fixed Income - CDs (40434AHV4)	250,000.000	\$95.60	\$239,000.00	12.45 %
BANK OF CHINA NEW YORK CITY BRH CTF DEP ACT/365 Fixed Income - CDs (06426THE2)	170,000.000	\$100.01	\$170,013.60	8.86 %
ALLY BK MIDVALE UTAH CTF DEP ACT/365 0.650% 12/12/16 B/E Fixed Income - CDs (02006LRH8)	170,000.000	\$99.88	\$169,802.80	8.85 %
CAPITAL ONE BK USA NATL ASSN GLEN ALLEN VA CTF DEP ACT/365 Fixed Income - CDs (140420RU6)	170,000.000	\$99.88	\$169,802.80	8.85 %
JPMORGAN CHASE BK NA COLUMBUS OH CTF DEP CTF DEP LKD J P Fixed Income - CDs (48125TDG7)	125,000.000	\$97.49	\$121,862.50	6.35 %
UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 Fixed Income - CDs (90521AHP6)	88,000.000	\$124.37	\$109,445.60	5.70 %
BANK OF THE WEST INSTL CTF DEP PROGRAM BOOK ENTRY Fixed Income - CDs (06426XCL2)	89,000.000	\$97.96	\$87,186.18	4.54 %
UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 Fixed Income - CDs (90521AQG6)	74,000.000	\$100.15	\$74,111.00	3.86 %
UNITED STATES TREAS NTS INFLATION INDEXED NOTES TIPS Fixed Income - Govt (912828NM8)	25,000.000	\$107.00	\$29,018.94	1.51 %
IBERIABANK LAFAYETTE LA CTF DEP ACT/365 0.000% 05/31/16 B/E Fixed Income - CDs (45083AAV4)	10,000.000	\$102.18	\$10,217.70	0.53 %



	Value	Value
Fixed Income - CDs	\$1,889,116.48	98.41 %
Fixed Income - Govt	\$29,018.94	1.51 %
Money Market	\$1,495.04	0.08 %


Accounts and Holdings

	Shares/Units	NAV/Price	Value	% of Portfolio
Non-Qualified Accounts				
H5E049797, Pershing Louisiana Board of Pharmacy Nonprofit Organization		General Reserve Fund	\$1,919,630.46	100.00 %
BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 ANNUALLY Fixed Income - CDs (06740AA41)	5,000.000	\$105.57	\$5,278.50	0.27 %
Pershing General Money Market Fund cl B Money Market (GMMB)	1,495.040	\$1.00	\$1,495.04	0.08 %
			\$1,919,630.46	100.00 %
Total Portfolio Value			\$1,919,630.46	100.00 %

Accounts and Holdings

Portfolio by Holding Type

	Shares/Units	NAV/Price	Value	% of Portfolio
Non-Qualified Accounts				
H5E077160, Pershing Louisiana Board of Pharmacy Nonprofit Organization		OPEB Account	\$1,046,595.12	100.00 %
CARDINAL BK MCLEAN VA CTF DEP ACT/365 0.300% 11/12/15 B/E Fixed Income - CDs (14147VEE2)	173,000.000	\$100.00	\$172,991.35	16.53 %
BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 Fixed Income - CDs (06740AYS2)	160,000.000	\$94.17	\$150,672.00	14.40 %
BANK OF THE WEST INSTL CTF DEP PROGRAM BOOK ENTRY Fixed Income - CDs (06426XGL8)	155,000.000	\$96.79	\$150,030.70	14.34 %
BANK BARODA NEW YORK BRH CTF DEP ACT/365 Fixed Income - CDs (06062A3P2)	127,000.000	\$100.01	\$127,011.43	12.14 %
JPMORGAN CHASE BK NA COLUMBUS OHIO CTF DEP DTD 07/31/2013 Fixed Income - CDs (48124JS41)	125,000.000	\$98.64	\$123,300.00	11.78 %
GOLDMAN SACHS BK USA NEW YORK CTF DEP ACT/365 Fixed Income - CDs (38143ASV8)	120,000.000	\$101.59	\$121,902.00	11.65 %
DISCOVER BK GREENWOOD DEL CTF DEP ACT/365 Fixed Income - CDs (254671BG4)	120,000.000	\$100.84	\$121,004.40	11.56 %
BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 ZERO CPN LKD Fixed Income - CDs (06740ATS8)	83,000.000	\$95.65	\$79,389.50	7.59 %
FCR Money Market (FCR)	293.740	\$1.00	\$293.74	0.03 %
			\$1,046,595.12	100.00 %
Total Portfolio Value			\$1,046,595.12	100.00 %



	Value	Value
Fixed Income - CDs	\$1,046,301.38	99.97 %
Money Market	\$293.74	0.03 %

Louisiana Board of Pharmacy

Cumulative Fund Balance Reports

	FY 98-99 <u>Actual</u>	FY 99-00 <u>Actual</u>	FY 00-01 <u>Actual</u>	FY 01-02 <u>Actual</u>	FY 02-03 <u>Actual</u>	FY 03-04 <u>Actual</u>	FY 04-05 <u>Actual</u>	FY 05-06 <u>Actual</u>	FY 06-07 <u>Actual</u>	FY 07-08 <u>Actual</u>
Beginning Fund Balance	910,394	1,127,239	1,267,076	1,351,191	1,521,807	1,588,141	1,478,412	1,587,349	1,677,669	2,077,236
Total Income	984,414	1,030,423	1,168,798	1,200,575	1,223,872	1,274,804	1,524,411	1,627,306	2,228,918	2,657,168
Total Expenses	767,569	890,586	1,084,683	1,029,959	1,170,252	1,384,533	1,415,474	1,536,986	1,829,351	2,184,076
Ending Fund Balance	1,127,239	1,267,076	1,351,191	1,521,807	1,588,141	1,478,412	1,587,349	1,677,669	2,077,236	2,550,328
Reservations of Fund Balance	48,884	102,368	476,000	524,000	1,210,000	1,245,000	1,300,000	1,300,000	1,400,000	2,050,000
Unreserved Fund Balance	1,078,355	1,164,708	763,515	997,807	378,141	233,412	287,349	377,669	677,236	500,328



	FY 08-09 <u>Actual</u>	FY 09-10 <u>Actual</u>	FY 10-11 <u>Actual</u>	FY 11-12 <u>Actual</u>	FY 12-13 <u>Actual</u>	FY 13-14 <u>Actual</u>	FY 14-15 <u>Actual</u>	FY 15-16 <u>Actual</u>	FY 16-17 <u>Actual</u>	FY 17-18 <u>Actual</u>
Beginning Fund Balance	2,550,328	2,607,575	2,715,185	2,810,463	2,936,874	3,225,350	(1,005,286)			
Total Income	2,570,282	2,706,829	2,808,468	2,775,418	2,849,249	3,059,394	3,615,033			
Total Expenses	2,513,035	2,599,219	2,713,190	2,649,007	2,560,773	2,764,020	2,490,681			
GASB-68 Restatement						(4,526,010)				
Ending Fund Balance	2,607,575	2,715,185	2,810,463	2,936,874	3,225,350	(1,005,286)	119,065			
Reservations of Fund Balance	1,900,000	1,650,000	1,650,000	500,000	750,000	2,162,000	1,272,000			
Unreserved Fund Balance	707,575	1,065,185	1,160,463	2,436,874	2,475,350	(3,167,286)	(1,152,935)			



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Finance Committee

Proposed Budget Amendment No. 1 Fiscal Year 2015-2016

(Draft #2)

August 12, 2015

Blake P. Pitre
Chair

Louisiana Board of Pharmacy
FY 2015-2016 Budget

		Revenue		
<u>Acct. No.</u>		<u>FY 15-16 Original</u>	<u>FY 15-16 Amend. #1</u>	<u>Notes</u>
Licenses & Permits				
4201	Pharmacist Renewals	755,000	770,000	1
4206	New Pharmacist Licensing Fee	161,000	190,500	2
4204	Technician Renewals	312,000	316,000	3
4208	Tech Candidate Registrations	35,000	25,000	4
4205	Lapsed Credential Fees	55,000	55,000	
4350	Student Registrations	3,000	3,000	
4301	Permits - Pharmacies	260,000	270,000	5
4302	Permits - CDS	440,000	450,000	6
4303	Permits - Emergency Drug Kits	12,500	12,500	
4304	Permits - Automated Medication Systems	18,000	20,000	7
4306	Permits - Durable Medical Equipment	70,000	80,000	8
Examinations				
4153	Reciprocity	45,000	50,000	9
4152	Technicians	50,000	50,000	
Penalties				
4252	Licenses and Certificates	8,000	8,000	
4251	Permits	11,000	11,000	
Administrative Fees				
4460+4462	Documents: Copies and Certification Fees	7,500	5,000	10
4452	Duplicate Credentials	4,000	5,000	11
4453	Pharmacist Silver Certificates	500	400	12
4459	Pharmacist Original Certificates	10,000	7,500	13
4454	NSF Fees	500	500	
4463	Handling & Mailing Fees	0	100	14
Sale of Goods & Services				
4402	Law Books	6,000	6,000	
4461	Official Lists of Licensees	6,000	7,500	15
4458	USCPSC Inspection Fee	2,000	2,000	
Enforcement Actions				
4102	Hearing Fees	22,000	22,000	
4501	Fines	215,000	200,000	16
4502	Investigative Cost Recoveries	35,000	30,000	17
Prescription Monitoring Program				
4660	Assessments	465,000	475,000	18
4455	Miscellaneous	1,000	1,000	
TOTAL REVENUE		3,010,000	3,073,000	19

Louisiana Board of Pharmacy
FY 2015-2016 Budget

		Expenses		
<u>Acct. No.</u>		FY 15-16 <u>Original</u>	FY 15-16 <u>Amend. #1</u>	<u>Notes</u>
5321	<i>Operations</i> Rentals - Equipment	15,000	17,000	20
5330	Equipment Maintenance	3,000	3,000	
5370	Telephone	18,000	20,000	21
5305	Printing	17,000	25,000	22
5300	Postage	52,000	52,000	
5125	Civil Service Assessment	6,100	6,400	23
5230	Office Insurance (ORM)	7,500	8,400	24
5190	Dues & Subscriptions	10,000	20,000	25
5280	Office Supply Expenses	20,000	21,000	26
5381	Financial Service Charges	53,000	50,000	27
5180	Depreciation of Fixed Assets	142,000	64,000	28
5385	Interest Payments on Building Loan	60,000	15,000	29
5260	Office Meeting Expenses	500	500	
5390	Utilities	11,000	11,000	
5105	<i>Acquisitions</i>	12,500	75,000	30
5350	<i>Personal Services</i>			
5350	Salaries	1,334,100	1,357,400	31
5290	Payroll Taxes (FICA + FUTA)	27,100	28,000	32
5340	Retirement Contributions	494,000	505,000	33
5220	Health Insurance (SEGBP)	160,200	135,800	34
5400	Other Post Employment Benefits (OPEB)	91,500	156,000	35
5152	Board Member Per Diem	31,000	31,000	
	<i>Professional Services</i>			
5110	Accounting	25,000	25,000	
5250	Legal	30,000	30,000	
5295	Information Systems	108,000	128,000	36
5297	Property Management	35,000	42,000	37
5296	Temp. Labor	20,000	20,000	
5600	Prescription Monitoring Program	80,000	80,000	
	<i>Staff Expenses</i>			
5361	Travel - Executive Director	10,000	10,000	
5365	Travel - General Counsel	10,000	10,000	
5373	Travel - Assistant Executive Director	10,000	10,000	
5363	Travel - Compliance Officers	5,000	5,000	
5371+72	Travel - Compliance Officers - Rental & Fuel	17,500	17,500	
5368	Education - Compliance Officers	10,000	10,000	
5366	Travel & Education - Office Staff	1,000	1,000	
5362+64+67+74	Mileage - entire staff	20,000	20,000	
5153	<i>Board Expenses</i> Meeting Expenses	15,000	15,000	
5155	Committee Expenses	8,000	8,000	
5154	Conventions	15,000	15,000	
5151	Mileage	15,000	15,000	
5286+87+88	President's Expenses	10,000	10,000	
	TOTAL EXPENSES	3,010,000	3,073,000	38

Louisiana Board of Pharmacy
FY 2015-2016 Budget

Summary

<u>Acct. No.</u>	FY 15-16 <u>Original</u>	FY 15-16 <u>Amend. #1</u>
Income Statement		
Total Revenue	3,010,000	3,073,000
Total Expenses	3,010,000	3,073,000
Net Ordinary Income	0	0
Other Income & Expenses		
6003 Investments	0	0
Disposal of Assets	0	0
Net Income	0	0

	FY 14-15 <u>Actual</u>	FY 15-16 <u>Budget</u>	FY 15-16 <u>Amend #1</u>
Fund Balance			
Beginning Fund Balance	(1,005,286)	119,065	119,065
Total Income	3,615,033	3,010,000	3,073,000
Total Expenses	2,490,681	3,010,000	3,073,000
Ending Fund Balance	119,065	119,065	119,065
Reservations of Fund Balance	1,272,000	2,100,000	1,237,000
Unreserved Fund Balance	(1,152,935)	(1,980,935)	(1,117,935)

Notes on Reservation of Fund Balance

Other Post Employment Benefits Payable	572,000	1,150,000	572,000
Debt Service Payable	450,000	750,000	465,000
Continuing Payroll Obligations	150,000	150,000	150,000
Land & Building Maintenance	<u>100,000</u>	<u>50,000</u>	<u>50,000</u>
<i>Total</i>	1,272,000	2,100,000	1,237,000

Louisiana Board of Pharmacy
FY 2015-2016 Budget

Notes

Revenue

- 1 Using historical data, estimate 7,700 pharmacists renewing @ \$100 each
- 2 Using historical data, estimate 635 new pharmacists @ \$300 each
- 3 Using historical data, estimate 6,320 technicians renewing @ \$50 each
- 4 Using historical data, estimate 1,000 new candidates @ \$25 each
- 5 Using historical data, estimate 1,900 permits renewing @ \$125 each + 215 new @ \$150 ea
- 6 Using historical data, with 2% growth in CDS credentials across all classifications
- 7 Using historical data, estimate 133 permits renewing @ \$150 each
- 8 Using historical data, estimate 640 permits renewing @ \$125 each
- 9 Using historical data, estimate 333 applicants @ \$150 each
- 10 Using historical data
- 11 Using historical data
- 12 Using historical data, estimate 4 requests @ \$100 each
- 13 Using historical data, estimate 100 requests @ \$75 each
- 14 Using historical data
- 15 Using historical data, estimate 50 requests @ \$150 each
- 16 Significant reduction from prior year; reflects 6.5% of revenue budget
- 17 Using historical data.
- 18 Using historical data, estimate 19,000 clients @ \$25 each
- 19 Reflects 2.1% increase from original budget and 14.3% decrease from FY 14-15 revenue

Expenses

- 20 Renewal of copier contracts w/ color capacity
- 21 Using historical data, w/ increased feature capacity
- 22 Using historical data, with board nomination election printing added
- 23 Premium assigned by state; already paid for FY 15-16.
- 24 Premium assigned by state; already paid for FY 15-16.
- 25 Using historical data, with MelissaData added (\$9,500 for 3 yr term)
- 26 Using historical data
- 27 Using historical data
- 28 Depreciation of eLicense software is complete.
- 29 Final loan payment due December 2015
- 30 Includes equipment purchases deferred from FY 14-15 + new bookshelf units
- 31 Includes performance adjustments + 2 replacements + 3 promotions
- 32 Calculated value: 2% of salaries + temp labor
- 33 Calculated value: 37.2% of salaries
- 34 Calculated value: 10% of salaries
- 35 Using historical data
- 36 Using historical data + website upgrade for mobile devices
- 37 Planned facelift for Board office building
- 37 Reflects 2.1% increase from original budget and 23.3% increase from FY 14-15 expenses

Louisiana Board of Pharmacy
FY 2015-2016 Budget

Board Action Summary

Date	Action
11/12/2014	Original Budget - Finance Committee Approval
11/13/2014	Original Budget - Board Approval
8/11/2015	Budget Amendment #1 - Finance Committee Approval
8/12/2015	Budget Amendment #1 - Board Approval
	Budget Amendment #2 - Finance Committee Approval
	Budget Amendment #2 - Board Approval
8/__/2016	Acceptance of Final Report



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Application Review Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Reciprocity Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Reciprocity Committee has been ordered and called for 8:00 a.m. on Wednesday, August 12, 2015 at the Board office, for the purpose to wit:

AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 07-28-2015

- A. Call to Order
- B. Quorum Call
- C. Call for Additional Agenda Items & Adoption of Agenda
- D. Opportunity for Public Comment
- E. Consideration of Applications
 - 1. Case No. 15-0212 ~ PST.A Cydney Lee Estes (AL)
- F. Adjourn

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Violations Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Impairment Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Impairment Committee has been ordered and called for 1:00 p.m. on Tuesday, August 11, 2015 at the Board office, for the purpose to wit:

AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 07-24-2015

1. Call to Order
2. Quorum Call
3. Call for Additional Agenda Items & Adoption of Agenda
4. Opportunity for Public Comment
5. Review of Docket
 - A. *For Acceptance of Voluntary Surrenders of Credentials*
 - i. Case No. 15-0181 ~ PST.016606 – Ginger Allen Teekell
 - ii. Case No. 15-0182 ~ PST.010643 – William Coleman Honeycutt
 - B. *Petitions For Reinstatement of Suspended Credentials*
 - i. Case No. 15-0200 ~ PST.015475 – Kim Cox Vines
 - C. *Petitions for Modification of Previous Orders*
 - i. Case No. 15-0203 ~ PST.020284 – Elizabeth Farrell Heard
 - D. *Applications for a Credential*
 - E. *Appearances for Informal Conference*
 - i. Case No. 15-0160 ~ CPT.006935 – Jamie Lyne Wheeler
 - ii. Case No. 15-0196 ~ PST.015778 – John Sherwood Bannister
 - F. *Appearances for Guidance*
6. Adjourn

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17..



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Reinstatement Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ Email: info@pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Reinstatement Committee has been ordered and called for 8:30 a.m. on Tuesday, August 11, 2015 in the Board office, for the purpose to wit:

AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 07-30-2015

1. Call to Order
 2. Quorum Call
 3. Call for Additional Agenda Items & Adoption of Agenda
 4. Opportunity for Public Comment
 5. Consideration of Applications
 - A. *Petitions for Reinstatement (suspended + lapsed > 5 years + chair's discretion)*
 - i. Case No. 15-0210 ~ PST.016824 – John Alan Smith
 - ii. Case No. 15-0211 ~ PST.011262 – Taddese Tewelde
 - iii. Case No. 15-0214 ~ PST.010983 – Aaron Wayne Nash
 - B. *Petitions for Modification of Previous Orders*
 - C. *Petitions for Return of Inactive Licenses to Active Status*
- [Note: Appearances are not required for the remaining applicants.]**
- D. *Applications for Reinstatement (Lapsed > 5 years + chair's discretion)*
 - i. PST.015326 – Cecil David Matthews
 - ii. CPT.005080 – Jennifer Dawn Tucker
 - E. *Applications for Reinstatement of CDS Licenses Lapsed > 5 years*
 - i. CDS.032375.MD – Stephen Wayne Houseworth
 - ii. CDS.035131.MD – James Harold Price
 - iii. CDS.010009.MD – Jack A. Hurst
 - iv. CDS.031506.MD – Shawn Jason Stafford
 - v. CDS.032664.MD – Mohammed Moizuddin
 - vi. CDS.032573.RES – Walter Cotton
 - F. *Applications for Reinstatement of CDS Licenses Previously Suspended Secondary to Action by Another Agency*
 - i. CDS.021832-MD – Kenneth Lemoyne Wiley, Sr.

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

ii. CDS.016907.MD – Linda Camille Bunch

G. Discretionary Approvals by Committee Chair (lapsed > 1 year but < 5 years)

- i. CDS.037673.MD – J. Foster Chapman
- ii. CDS.042377.DDS – Charles Zachary Staples
- iii. PST.019200 – Ajay Babu Cherukuri
- iv. CDS.023106.MD – Jose Nelson Dorta
- v. CDS.035725.MD – Ravi Tandon
- vi. CDS.035546.MD - Vineeta A. Estes
- vii. CDS.012955.MD - Kennan J. Buechter
- viii. CDS.042022.MD – Harlan Weiss
- ix. CPT.008064 – Sarah Jean Thompson
- x. CPT.010257 – Heather Rae Richard
- xi. CDS.031323.MD – Louise-Ann F. Gombako-Amos
- xii. CDS037085.DVM – Jeffrey David Schumacher
- xiii. CDS.036971.MD – Nathan Nielsen
- xiv. CDS.037277.MD – Althea Theresa Conley
- xv. CDS.033898.APN – Daphne J. Dureau
- xvi. CPT.009184 – Kara Taylor Sibley
- xvii. CDS.037640-RES – Deborah E. Sullivan
- xviii. CDS.021207.MD – Frederick Robert Martin
- xix. CPT.011256 – Shelby Elizabeth Pritchard
- xx. CPT.005427 – Krysti Reed Fontenet
- xxi. CPT.009036 – Keisha Williams Cannady
- xxii. CPT.011954 – Smarie Aunrie Aliska Brown
- xxiii. CPT.005712 – Amanda Harrington Vernon
- xxiv. PST.018915 – Sandra Vucinovich III
- xxv. CDS.038323.PA – Jennifer Menard Piker
- xxvi. CPT.008089 – Kimberly Lynn Blalock
- xxvii. CDS.042445.APN – Mary Alice Moron
- xxviii. CDS.005967.MD – Christopher Robert Brooks Merritt
- xxix. CDS.026775.MD – Mark H. Davis
- xxx. CDS.037541.MD – Marna Joy Eissa
- xxxi. CPT.007201 – Lucretia Marie Naquin
- xxxii. CPT.001887 – Jennifer Truxillo Lasseigne

H. Staff Approvals by Board Policy (lapsed < 1 year)

- i. CDS.037509.PA – Jamie Nicole Smith
- ii. CDS.036477.MD – Angelle Marie Cresswell
- iii. CDS.040171.APN – Sandra Lynn Coleman
- iv. CDS.043787.MD – John Patrick Guste
- v. CDS.020272.MD – Suman Dewan Gupta
- vi. CDS.030982.MD - Martha McDonald Whyte
- vii. CDS.044271.MD – Chyi Chyo Chong
- viii. CDS.027531.MD – Casey Clark McVea
- ix. CDS.009670.MD - Norman Eugene Anseman Jr
- x. PST.020622 – Brandon Hendrickson
- xi. CDS.042863.DVM - David Hunter Kergosien
- xii. CDS.033345.MD - William Alexander Gabbard
- xiii. CDS.044358.DIS - Diamondback Drugs
- xiv. CDS.000819.MD - Andrew J. Sanchez, Jr.

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

- xv. CDS.016236.MD - Linda Gage-White
- xvi. CDS.034079.APN - John L. Lenfant V
- xvii. CDS.032243.MD - Corey Robertson
- xviii. CDS.040983.MD – Bryan Scott Waits
- xix. CDS.035488.MD - Jacob M. Estes
- xx. CDS.033403.MD – Brian Lange Porche
- xxi. CDS.040357.ASC – Southlake Surgery Center
- xxii. CDS.042753.MD – Liam Anthony Morris
- xxiii. CDS.044518.MD – Clinton Young McCready
- xxiv. CDS.036542.MD – Isolde Fionna Butler
- xxv. CDS.044449.MD – Jay E. Dujon
- xxvi. CDS.036538.OD – Jason P. Allemond
- xxvii. CDS.036449.MD – Kosi J. Avotri
- xxviii. CDS.041314.MD – Keitha Renee Smith
- xxix. CDS.020977.MD – Nancy Lynn Rogers
- xxx. PST.018332 – Robert Gerard Passavanti
- xxxi. CDS.042779.MD - Stephen Douglas Baker Jr
- xxxii. CDS.043055.MD - Michael Kevin Seep
- xxxiii. CDS.027692.DPM – John Gibson Fasick
- xxxiv. CDS.005093.MD – Rise Delmar Ochsner
- xxxv. CDS.021662.MD – Roberta G. Lottinger
- xxxvi. CDS.040103.MD – Andrew Michael Brown
- xxxvii. CDS.041473.MD – Ryan Wesley Johnson
- xxxviii. PST.020201 – Chioma Cynthia Obih
- xxxix. CPT.008610 – Melissa Michelle Thornton
 - xl. CDS.019085.MD – Anna Lee Woeckener
 - xli. CDS.042633.APN – Rachel Waller
 - xlii. CDS.042905.APN – Maureen K. Gomez
 - xliii. CDS.029368.DVM – Reynaldo R. Gonzalez
 - xliv. CDS.033327.OD – Michael Nicholas Kleamenakis
 - xlv. CDS.041553.DVM – Lindsay Willis Seffens
 - xlvi. CDS.037754.MD – Seth Billiodeaux
 - xlvii. CDS.044422.PA – Holly Gaines Scurlock
 - xlviii. CDS.010058.MD – Fernando Jesus Martinez
 - xliv. CDS.041600.MD – Maneesh Kumar Gupta
 - I. CPT.007591 – Renata La'Avery Bradberry
 - li. CDS.027879.MD – Stephanie Mills
 - lii. CDS.042783.RES – Matthew D. Woolard
 - liii. CDS.043125.APN – Jean Erickson Cefalu
 - liv. CDS.027813.MD – Charles U. Gbadouwey
 - lv. CDS.043187.DDS – Claire Joyce Raphael
 - lvi. CDS.002067.MD – Andre Keith Perron
 - lvii. CDS.021098.DDS – Jon Damon Celino
 - lviii. EDK.008386 – Edgefield Recovery Center / Omnicare of Alexandria
 - lix. CDS.018023.DDS – Russell Wayne Cranford
 - lx. CDS.022624.MD – Ernest Kelly, Jr.
 - lxi. CDS.032360.MD - Lori Ann McBride
 - lxii. CDS.043957.MD – Arthur Rafael Menezes
 - lxiii. CDS.020869.MD – John Paul Areno
 - lxiv. CDS.037806.DVM – Elizabeth M. Brown
 - lxv. CDS.000921.MD - Julian Hallman Sims

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

- lxvi. CDS.030845.MD – David Spence Texada
- lxvii. CDS.037847.RHC – Butler-Anshire Medical Clinic, APMC
- lxviii. CDS.031412.MD – Cuthbert Simpkins
- lix. CDS.031339.MD – Usha P. Mandhare
- lxx. CDS.026958.DVM – Mark Lewis Gray
- lxxi. CDS.002896.MD – William C. Coney
- lxxii. PHY.006259 – Healthwarehouse
- lxxiii. CDS.021525.MD – James F. Cardwell
- lxxiv. CDS.028925.MD – Michael Benjamin Defatta
- lxxv. CDS.034345.DVM – Susan St. Pierre
- lxxvi. CDS.036656.MD – Sailendra Kumar Upendram
- lxxvii. CDS.009320.MD – William V. Spires, Jr.
- lxxviii. CDS.040458.DDS – Bernard Matt Hollis
- lxxix. CDS.024476.DVM – Chris C. Casten
- lxxx. CDS.033515.DDS – Kayla P. Soirez
- lxxxi. CDS.036249.MD – Samir Abdou Tomajian
- lxxxii. CDS.041617.MD – Timur Anum Baruti
- lxxxiii. CDS.031474.DVM – Christine D. McHughes
- lxxxiv. CDS.042385.MD – Carol Olivia Carrillo
- lxxxv. CDS.036659.MD – Mahija Mungara
- lxxxvi. CDS.025394.DVM – Lori Schega
- lxxxvii. CDS.043299.APN – Jayme LaBauve Boudreaux
- lxxxviii. CDS.017877.DDS – Roscoe Gerard Harris

6. Adjourn

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Tripartite Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Regulation Revision Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Executive Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Final Legislative Brief

2015-0611 @ 1800

Regular Session of the 2015 Louisiana Legislature
Convened 2015-0413 @ 1200 – Adjourned 2015-0611 @ 1800

Last Items Reviewed						
HB 847	HR 229	HCR 232	HSR 5	HCSR 1		
SB 285	SR 229	SCR 140	SSR 1	SCSR 3	Acts 473	
Total = 1,972					Items on Watch List = 42	

House of Representatives

Bills

HB 72 Mack Administration of Criminal Justice
Adds additional substances to Schedule I of the Uniform Controlled Dangerous Substances Law.
07-01-2015 Signed by Governor; **Act 373 effective 07-01-2015.**

This measure added additional substances to the hallucinogenic, stimulant, and synthetic cannabinoids sections within Schedule I. This will require an update of the law book.

HB 149 Badon Administration of Criminal Justice
Amends certain criminal penalties for possession of marijuana and prohibits the applicability of the Habitual Offender Law relative to possession of marijuana.
06-29-2015 Signed by Governor; **Act 295 effective 06-29-2015.**

This measure reduced the criminal penalties for possession of marijuana. This will require an update of the law book.

HB 159 Hoffman Health & Welfare
Adds a fee at license renewal for pharmacists and pharmacies and dedicates proceeds to certain pharmacy education programs.
06-29-2015 Signed by Governor; **Act 298 effective 08-01-2015.**

This measure amended the fee section of the Pharmacy Practice Act to require the Board to assess each pharmacist license and pharmacy permit a \$100 pharmacy education support fee, in addition to the regular renewal fee, at the time of license renewal, and further, to remit those proceeds to ULM College of Pharmacy on or before April 1 of each year. The law also requires the Board to provide an option for each pharmacist and pharmacy to elect not to pay the pharmacy education support fee.

HB 174 LeBas Administration of Criminal Justice
Provides for the scheduling of controlled dangerous substances.
06-23-2015 Signed by Governor; **Act 189 effective 06-23-2015.**

This measure, which was sponsored by the Board, amended the state list of controlled substances to re-schedule hydrocodone combination products from Schedule III to Schedule II, and to place tramadol and suvorexant in Schedule IV. The bill was amended in the Senate to revise legislation adopted the previous year which placed limitations on the dispensing of opioid derivatives prescribed by practitioners not licensed in Louisiana. The revision did not change the existing limitations but instead provides they are not applicable if the prescription monitoring information for the state where the prescriber is licensed is available (through the Louisiana PMP) to the dispensing pharmacist.

HB 210 Moreno Health & Welfare
Authorizes the prescribing and dispensing of naloxone to third parties.
06-23-2015 Signed by Governor; **Act 192 effective 08-01-2015.**

This measure authorizes a medical practitioner to prescribe naloxone (intra-nasal route only) or another opioid antagonist to a third party without a prior examination of the patient when deemed appropriate for treatment of opioid-related drug overdose. Further, the law requires the pharmacist to dispense such prescriptions.

HB 304 Hall Health & Welfare
Provides relative to sharing of prescription monitoring program information with equivalent programs of other states.
05-29-2015 Signed by Governor; **Act 22 effective 08-01-2015.**

This measure, which was sponsored by the Board, amended the PMP Law to update the protection from civil discovery clause in a manner that will allow the Board to share PMP information with more states than previously permitted.

HB 319 Simon Health & Welfare
Provides relative to the dispensing of interchangeable biological products.
07-01-2015 Signed by Governor; **Act 391 effective 08-01-2015.**

This measure amended the Pharmacy Practice Act, more specifically the provision relative to generic interchange, to insert an additional provision relative to biological product interchange. The additional provision requires the dispensing pharmacist to notify the prescriber when dispensing an interchangeable biological product.

HB 568 Thierry Health & Welfare
Provides relative to the licensing and regulation of pharmacists.
07-01-2015 Signed by Governor; **Act 409 effective 08-01-2015.**

This measure amended the Pharmacy Practice Act, more specifically the section on discipline, to establish additional activities for which the board may sanction a licensee, including the use of an independent contractor to market any practitioner where the compensation of the contractor is based on the volume or value of prescriptions generated by the practitioner, as well as the dispensing of prescriptions generated by a practitioner where the practitioner has a direct or indirect financial relationship with the pharmacy, with the exception of those transaction meeting certain federal rules.

HB 638 Ivey Appropriations
Provides for the collection of fees associated with payments to state agencies by credit cards, debit cards, or other forms of electronic payment.
07-01-2015 Signed by Governor; **Act 414 effective 08-01-2015.**

This measure amended an existing law that permits certain state departments to receive payments by credit cards, debit cards, or other forms of electronic payments and requires those departments to levy a convenience fee calculated in a certain manner.

Resolutions

HR 185 Thibault
Requests state-approved non-public schools to consider keeping epinephrine on the school premises for emergency situations.
06-11-2015 Enrolled; signed by House Speaker; delivered to Secretary of State

This resolution urges and requests state-approved non-public schools to consider keeping epinephrine on the school premises for emergency situations.

Concurrent Resolutions

HCR 44 Foil House & Governmental Affairs
Requests all state agencies in the executive branch of state government to provide for a crisis leave pool and requests the Dept. of State Civil Service to report progress to the state legislature.
05-21-2015 Signed by Senate President; delivered to Secretary of State.

This measure urges and requests all state agencies in the executive branch to develop a policy for a crisis leave pool, where employees may donate a portion of their previously-earned leave to a crisis pool which may be utilized by a fellow employee in a time of need where they have exhausted their own leave balance. The Board of Pharmacy has already adopted such a policy for its employees.

HCR 84 Simon Health & Welfare
Directs the La. Law Institute to reorganize and recodify the Miscellaneous Health Provisions chapter of Title 40 of the Louisiana Revised Statutes.
06-04-2015 Delivered to Secretary of State.

This measure will reorganize a very disorganized section of health-related law. When completed, this project will require an update of the pharmacy law book.

Senate

Bills

SB 39 Mills Health & Welfare
Provides for the Louisiana Board of Drug and Device Distributors.
07-01-2015 Signed by Governor; **Act 443 effective 07-01-2015.**

This measure amended the law relative to drug and device distribution. Among other changes, the name of the current Board of Wholesale Drug Distributors was changed to the Board of Drug and Device Distributors. It also makes significant changes to that law in order to harmonize the state law with the recently-enacted federal Drug Supply Chain Security Act.

SB 83 White Commerce, Consumer Protection, International Affairs
Provides relative to the exception from the issuance of provisional licenses to ex-offenders to work in certain fields.
06-23-2015 Signed by Governor; **Act 157 effective 08-01-2015.**

This measure added the Real Estate Commission to the list of licensing agencies which are exempted from the law requiring the issuance of provisional licenses to certain ex-offenders.

SB 115 Mills Health & Welfare
Provides with respect to the practice of physician assistants.
07-01-2015 Signed by Governor; **Act 453 effective 07-01-2015.**

This measure amended the medical practice act to primarily address the supervisory relationship requirements between physicians and physician assistants. The bill also revised the scope of practice for physician assistants, including a revision of their prescriptive authority that adds Schedule II to the list of controlled substances they may prescribe. The bill was amended to add Schedule II authority for optometrists.

SB 143 Mills Health & Welfare
Provides relative to prescribed marijuana for therapeutic uses and the development of rules and regulations by the Louisiana Board of Pharmacy and the Louisiana State Board of Medical Examiners.
06-29-2015 Signed by Governor; **Act 261 effective 06-29-2015.**

This measure amended the controlled substances law to authorize the cultivation, production, distribution, and dispensing of marijuana for medical conditions previously adopted by the legislature in 1991. The law directs the Board of Pharmacy to develop rules relative to the dispensing of marijuana.

Resolutions

SR 177 Mills
Creates a task force to study and recommend revisions of regulations related to the distribution of medical devices in Louisiana.
06-04-2015 Passed Senate without objection.

This resolution seeks to reduce any duplicative regulatory oversight relative to the distribution of medical devices.

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII: Pharmacists

Chapter 7. Pharmacy Interns

...

§705. Practical Experience

- A. All applicants for licensure by examination shall earn practical experience in the practice of pharmacy concurrent with attending or after graduation from a board-approved college of pharmacy.
- B. The practical experience shall be predominantly related to the provision of pharmacy primary care and the dispensing of drugs and medical supplies, the compounding of prescriptions, and the keeping of records and making of reports as required under federal and state law.
 1. The practical experience earned shall have been under the supervision of a pharmacist.
 2. A pharmacy intern shall not practice in a permitted pharmacy site that is on probation with the board. A pharmacy intern shall not practice under the supervision of a pharmacist whose license is on probation with the board.
- C. Practical Experience Hours. To qualify for pharmacist licensure, an intern shall supply evidence of the acquisition of at least 1,500 hours of practical experience.
 1. The board shall award 1,000 hours credit to an intern for his successful completion of a professional experience curriculum at a board-approved college of pharmacy. The dean of the board-approved college of pharmacy shall certify the completion of this requirement in the manner prescribed by the board office.
 2. The intern shall earn at least 500 hours of practical experience in a permitted pharmacy site under the supervision of a pharmacist with no less than two years of experience as a licensed pharmacist. Further, neither the pharmacist's license nor the pharmacy's permit may be on probation with the board at the time the practical experience is earned.
 3. Practical experience hours that are submitted to the board for credit consideration shall be listed on an affidavit form supplied by the board office, and signed by the pharmacist and pharmacy intern.
 - a. A pharmacy intern may receive credit for a maximum of 50 hours per week.
 - b. A separate affidavit shall be required from each permitted pharmacy site.
 - c. No credit shall be awarded for hours earned within the professional experience curriculum of a board-approved college of pharmacy, nor for hours earned outside the professional experience curriculum but at the same time and location as hours earned for that professional experience curriculum.
 4. Certification of Hours To and From Another Jurisdiction.
 - a. Interns enrolled in a board-approved college of pharmacy in Louisiana who earn hours of practical experience in another jurisdiction, as well as interns enrolled in a board-approved college of pharmacy in another jurisdiction who earn hours of practical experience in another jurisdiction, may transfer those hours to Louisiana under the following conditions:
 - i. The hours of practical experience shall be listed on an affidavit form supplied by the Louisiana Board of Pharmacy, signed by the preceptor pharmacist and the intern, and submitted to the Louisiana Board of Pharmacy for consideration of credit; and
 - ii. The board of pharmacy in the jurisdiction where the hours were earned shall certify those hours to the Louisiana Board of Pharmacy.
 - iii. The Louisiana Board of Pharmacy may grant credit for all hours that comply with the Louisiana Board of Pharmacy's requirements as delineated in this section.
 - b. Upon written request by the pharmacy intern, the Louisiana Board of Pharmacy may certify practical experience hours earned in Louisiana to a board of pharmacy in another jurisdiction.

5. Credited hours of practical experience shall expire on the expiration date of the Intern Registration.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1211.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 14:708 (October 1988), effective January 1, 1989, amended LR 26:2285 (October 2000), amended LR 29:2086 (October 2003), effective January 1, 2004, LR 32:636 (April 2006), amended LR 33:1130 (June 2007), amended LR 34:1409 (July 2008).

NATIONAL ASSOCIATION OF
BOARDS OF PHARMACY

2015

ORGANIZATIONAL LAW

LICENSING LAW

DRUG LAW

CENSUS DATA



Survey of Pharmacy Law

Including all 50 states, DC, Guam, and Puerto Rico

4. Pharmacy Practice Experience Hour Requirements

Table 4 responds to the following questions:

1. Number of hours of practical experience required by the board?
2. Number of hours of practical experience required post-graduation?
3. In which academic year does board recognition of pharmacy internship/externship credit begin?
4. Number of hours of college-supervised experience recognized by the board?

State	1.	2.	3.	4.
Alabama	1,500 B	—	First professional year	1,500 hours internship may be obtained through a college-structured or nonstructured program, all under the supervision of a registered preceptor. 400 hours of the minimum total requirement must be obtained after completing the requirements of the second professional year. The 400 hours must be completed in a traditional setting, so emphasis is on distribution of medicines, prescriptions, and medical supplies.
Alaska	1,500 B	None	After third year of a five- or six-year program	1,500 hours internship required by Board. Maximum of 1,000 hours completed in conjunction with educational requirement of the college of pharmacy.
Arizona	1,500 B	None	First professional year	1,500 hours.
Arkansas	1,500	None	First professional year	Actual hours accepted for internship in conjunction with year of academic credit, 1,500 hours for PharmD program. After presenting satisfactory proof of graduation and receipt of the first professional undergraduate degree from an ACPE-accredited college of pharmacy approved by the Board, the intern may be designated as a candidate suitable for full licensure if other conditions have been met. The Board allows consideration of graduation from a nationally accredited college of pharmacy as fully meeting the experiential requirements to apply for pharmacist licensure in Arkansas. (Also see Section 6 Foreign Pharmacist Licensure.)
California	1,500 C	None	First professional year	Minimum of 900 hours internship time in a pharmacy under a pharmacist's supervision; 600 hours granted at Board's discretion, which may include 600 hours clinical clerkship.
Colorado	1,500	None	First professional year	1,500 hours.
Connecticut	1,500	None	After the completion of the second professional year	1,500 internship hours while enrolled in ACPE-accredited college of pharmacy. Maximum of 40 hours per week. While enrolled not more than 400 hours can be obtained from non-college of pharmacy traditional experience.
Delaware	1,500	None	First professional year	Full credit for college-supervised programs.
District of Columbia	1,500/1,000 B	—	First professional year	The applicant must successfully complete a pharmacy Internship consisting of one of the following: 1,000 hours of pre-licensure professional practice in a program administered by a college of pharmacy accredited by ACPE at the time the applicant does the internship; or 1,500 hours of independent pre-licensure professional practice under the supervision of a licensed pharmacist who uses the standards for pre-licensure professional practice described in the regulations; or two rotations totaling 660 hours of pre-licensure professional practice administered by a college of pharmacy accredited by ACPE at the time the applicant does the internship and 510 hours of independent pre-licensure professional practice under the supervision of a licensed pharmacist who uses the standards for pre-licensure professional practice described in §6502.2. Starting with the graduating class of 2014, in addition to the requirements above, each applicant for a pharmacist license shall submit proof of having completed an additional 400 hours of independent pre-licensure practice in a pharmacy setting with the emphasis on the distribution of medicines and prescriptions.

— Indicates information is not available.

4. Pharmacy Practice Experience Hour Requirements (cont.)

Table 4 responds to the following questions:

1. Number of hours of practical experience required by the board?
2. Number of hours of practical experience required post-graduation?
3. In which academic year does board recognition of pharmacy internship/externship credit begin?
4. Number of hours of college-supervised experience recognized by the board?

State	1.	2.	3.	4.
Florida	2,080 (varies) D	None	First professional year	Varies.
Georgia	1,500 B	—	First professional year	1,000 hours for PharmD program.
Guam	1,500 C	None	After completion of third academic year	1,500 hours.
Hawaii	1,500 C	None	After successful completion of first professional year	1,500 hours.
Idaho	0 F	None	Enrolled in a college of pharmacy	0 hours.
Illinois	400 B	None	First professional year	400 hours internship in conjunction with academic credit.
Indiana	1,500	None	First professional year	The number of hours required by an ACPE- or CCAPP-accredited college of pharmacy or other Board-approved experiential program. For those who have not graduated from such a program, 1,500 hours.
Iowa	1,500 B	None	Upon commencement of first professional year †	1,500 hours †
Kansas	1,500 B	None	First professional year †	1,500 hours required by Board.
Kentucky	1,500	None	Admission to a college of pharmacy	Credit shall be awarded for each hour of successful completion of an academic experience program at a college or school of pharmacy approved by the Board.
Louisiana	1 yr C 1,500 B	None	First professional year	Maximum credit of 1,000 hours for structured program.
Maine	1,500	None	First professional year	1,500 hours. At least 500 hours must be completed in the United States.
Maryland	1,560/1,000	None	First professional year	Graduates of a school of pharmacy approved by the Board or accredited by ACPE up to 1,000 hours; college of pharmacy students from foreign pharmacy schools up to 1,560 hours.
Massachusetts	1,500 G	None	After completion of second year	1,500 hours required by Board of which at least 1,000 hours has been acquired in a pharmacy or pharmacy-related setting approved by the Board.
Michigan	1,600	None	First professional year	40 hours a week while enrolled but not in classes; 16 hours a week while attending classes. Board-approved practical experience within college program varies by college. 1,600 hours required.
Minnesota	1,600	None	After first professional year	400 hours while attending classes; 1,600 hours allowed by Board. 800 hours must be actual dispensing hours.
Mississippi	1,600	None	First professional year	1,600 hours.
Missouri	1,500 B	None	First professional year	1,500 hours.
Montana	1,500 B	None	After 30 days enrollment in professional program	1,500 hours in conjunction with academic credit.

Colored text denotes change from 2014 edition.

† Other comments noted in 2014 edition no longer apply.

— Indicates information is not available.

4. Pharmacy Practice Experience Hour Requirements (cont.)

Table 4 responds to the following questions:

1. Number of hours of practical experience required by the board?
2. Number of hours of practical experience required post-graduation?
3. In which academic year does board recognition of pharmacy internship/externship credit begin?
4. Number of hours of college-supervised experience recognized by the board?

State	1.	2.	3.	4.
Nebraska	E	None	First professional year	E
Nevada	1,740 C	None	Enrollment in professional program	1,740 hours required by Board.
New Hampshire	1,500 B, C	None	Summer preceding first professional year	Full credit for college-supervised programs.
New Jersey	1,440 B	Varies	First professional year	1,440 hours.
New Mexico	1,500 B	None	After 15 semester hrs of college of pharmacy credit	1,500 hours.
New York	6 mos B (1,040 hrs)	None	After first professional year	Graduates of registered or accredited programs leading to the doctor of pharmacy degree shall be considered to have completed the internship requirement.
North Carolina	1,500 D	None	After second academic year	Actual hours worked.
North Dakota	1,500	None	After first academic year	1,500 hours required by rule.
Ohio	1,500 B	None	After successful completion of 60 semester hrs or 90 quarter hrs of college and beginning professional classes	Board-approved hours. Graduates of registered or accredited programs leading to the doctor of pharmacy degree shall be considered to have completed the internship requirement.
Oklahoma	1,500	None	First professional year	Up to 1,500 hours.
Oregon	1,440	None	Enrolled in a course of study and in good academic standing at a school or college of pharmacy approved by the Board	1,440 hours required by the Board.
Pennsylvania	1,500	None	A	Up to 750 hours in conjunction with academic credit.
Puerto Rico	1,500	None	First professional year	1,500 hours. At least 500 of the hours must be in community pharmacy.
Rhode Island	1,500	None	First professional year	1,500 hours required by Board.
South Carolina	1,500 C	None	Three months prior to entering pharmacy school	Up to 1,000 hours in conjunction with academic credit.
South Dakota	2,000 B	None	First professional year	1,740 hours.
Tennessee	1,500 B	None	First professional year	All hours now valid through experiential programs through pharmacy school.

Colored text denotes change from 2014 edition.

4. Pharmacy Practice Experience Hour Requirements (cont.)

Table 4 responds to the following questions:

1. Number of hours of practical experience required by the board?
2. Number of hours of practical experience required post-graduation?
3. In which academic year does board recognition of pharmacy internship/externship credit begin?
4. Number of hours of college-supervised experience recognized by the board?

State	1.	2.	3.	4.
Texas	1,500 B	None	Upon enrollment in a Texas school or college of pharmacy whose professional degree program has been accredited by ACPE and approved by the Board, or after a student has successfully completed the first professional year with a minimum of 30 credit hours towards a professional degree in pharmacy	Pharmacist interns completing a Board-approved Texas-college-based structured internship will be awarded the number of hours actually obtained. No credit shall be awarded for didactic experience.
Utah	1,500 C	None	First professional year	ACPE standard of 1,740 hours from ACPE program.
Vermont	1,740	None	First professional year	1,240 hours in conjunction with academic credit.
Virginia	1,500	None	Upon enrollment in an ACPE-accredited school of pharmacy when practical experience conforms to current ACPE standards.	1,500 hours withIn an ACPE-accredited program that must be gained within the US.
Washington	1,500	None	Upon enrollment in a Washington school or college of pharmacy whose professional degree program has been accredited by ACPE and approved by the Commission, or after a student has successfully completed the first quarter/semester of the professional degree program. Intern may begin earning the required additional 300 experiential training hours above those earned through school or college of pharmacy.	1,200 hours in conjunction with academic credit.
West Virginia	1,500 B	None	Upon pharmacy school enrollment	Up to 1,500 pharmacy school hours for a PharmD program.
Wisconsin	1,500 B	None	Second year of pharmacy school curriculum	Up to 1,500 pharmacy school hours for a PharmD program.
Wyoming	1,200 B	None	PI year once academic studies have begun; P4 clinical clerkship fulfills 1,200 hour requirement	1,200 hours of college-supervised clinical clerkship.

Colored text denotes change from 2014 edition.



nabp

National Association of Boards of Pharmacy

1600 Feehanville Drive • Mount Prospect, IL 60056-6014
Tel: 847/391-4406 • Fax: 847/391-4502
Web Site: www.nabp.net

Amendment Three to the Memorandum of Understanding Between the National Association of Boards of Pharmacy and the State of Louisiana Relating to its Prescription Drug Monitoring Program

The National Association of Boards of Pharmacy® (NABP®) and the Louisiana Board of Pharmacy (State), collectively “Parties,” agree to amend the aforementioned Memorandum of Understanding (MOU) regarding the provision of Prescription Monitoring Program InterConnect System services, dated September 5, 2012.

On or about November 26, 2013 the Parties executed Amendment One to the MOU nunc pro tunc effective September 5, 2012 addressing various sections of the MOU;

On or about May 6, 2014 the Parties executed Amendment Two to the MOU nunc pro tunc effective September 5, 2012 amending the “NABP Responsibilities” section;

This third amendment (“Amendment Three”) is made effective August 1, 2015.

NOW THEREFORE, the Parties agree to amend the MOU as follows:

1. The “NABP Responsibilities” section, is amended as follows:
 - a. “To the extent that funds are available to and budgeted by NABP, “is inserted at the beginning of the sentence in paragraph 11 and “solely” is added between “PMPs” and “to”.
 - b. Replace “June 30, 2016” with “June 30, 2018” in the first sentence of paragraph 12.
2. The “State Responsibilities” section is amended as follows:
Add new paragraph 10. “Except as legally required pursuant to a valid subpoena or court order, State cannot provide or otherwise make available non-State PMP data obtained through PMP InterConnect to a state or another individual or entity unless State uses the PMP InterConnect to provide such PMP data.”

Except as provided in this Amendment Three, all other terms and conditions of the above referenced MOU, as amended, shall remain in full force and effect.

By their signatures, below, the undersigned warrant that they are authorized representatives of their respective entities and that they are authorized to execute this Amendment Three to the MOU and bind their respective entities as of the effective date stated above.

National Association of Board of Pharmacy

Louisiana Board of Pharmacy

By: _____

Name: Carmen A. Catizone, MS, RPh, DPh

Name: _____

Title: Executive Director/Secretary

Title: _____

Date: August 5, 2015

Date: _____



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, LA 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



August 12, 2015

Legislative Auditor
1600 North Third Street
P. O. Box 94397
Baton Rouge, LA 70804-9397

In connection with your audit of Louisiana Board of Pharmacy's financial statements as of June 30, 2015 and for the year then ended conducted for the purpose of expressing an opinion as to the fair presentation of our financial statements in accordance with accounting principles generally accepted in the United States, to review our system of internal control over financial reporting, and to review our compliance with applicable laws and regulations, we confirm, to the best of our knowledge and belief, the following representations. These representations are based on the information available to us as of August 12, 2015.

PART I. GENERAL

1. We have fulfilled our responsibilities, as set out in the terms of the audit engagement or entrance document, for the preparation and fair presentation of our financial statements in conformity with accounting principles generally accepted in the United States of America. The annual financial statements present fairly, in all material respects, our financial position as of June 30, 2015 and changes in financial position, (including cash flows, if applicable) for the year then ended in accordance with accounting principles generally accepted in the United States of America. We acknowledge that we have engaged you to advise us in fulfilling our responsibility, but that engagement does not reduce our responsibility in relation to our financial statements.

Yes No
2. We acknowledge our responsibility for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Yes No
3. We acknowledge our responsibility for the design, implementation, and maintenance of internal controls to prevent and detect fraud.

Yes No

4. Significant assumptions used by us in making accounting estimates, including those measured at fair value, are reasonable.
- Yes No
5. We have disclosed to you the identity of the entity's related parties and all the related party relationships and transactions of which we are aware.
- Yes No **There are none**
6. The substance of all related party relationships and transactions involving sales, purchases, receivables, payables, guarantees, transfers, equipment usage, amounts receivable or payable to related parties, etc., has been considered, and appropriate adjustments or disclosures are made in the financial statements.
- Yes No **There are none**
7. Events that have occurred subsequent to the balance sheet date and through the date of this letter have been evaluated and classified as recognized or nonrecognized.
- Yes No There are none
8. We acknowledge our responsibility to advise you of events occurring after the date of this representation.
- Yes No
9. The effects of all known actual or possible litigation and claims have been accounted for and have been disclosed to you in accordance with accounting principles generally accepted in the United States of America and whose effects should be considered when preparing the financial statements.
- Yes No **NA**
10. It is correct that there are no unasserted claims or assessments that our lawyer has advised us are probable of assertion and must be recorded and/or disclosed in accordance with GASB Codification C50, *Claims and Judgments*.
- Yes No
11. It is correct that there are no other liabilities or gain or loss contingencies that are required to be accrued or disclosed by GASB Codification C50, *Claims and Judgments*.
- Yes No
12. It is correct that all accounting estimates that could be material to the financial statements, including the key factors and significant assumptions underlying those estimates and measurements are included in the financial statements, are complete and accurate, and have been prepared in accordance with GASB Codification C50, *Claims and Judgments*.
- Yes No NA

13. It is correct that we are not aware of any pending or threatened litigation and claims whose effects should be considered when preparing the financial statements, and we have not consulted legal counsel concerning litigation or claims.
- Yes X** No NA
14. It is correct that all funds and activities under our control and oversight are properly classified in the financial statements in accordance with GASB 54.
- Yes X** No
15. It is correct that all transactions have been properly recorded in the accounting records and are reflected in the financial statements, and there are no undisclosed assets, liabilities, or other unrecorded transactions.
- Yes X** No
16. It is correct that we have disclosed to you the results of our assessment of the risk that the financial statements may be materially misstated as a result of fraud.
- Yes X** No
17. It is correct that there have been no communications from regulatory agencies concerning noncompliance with, or deficiencies in, financial reporting practices, or noncompliance with statutory provisions, that could have an effect on the financial statements.
- Yes X** No
18. We have complied with all aspects of state and federal laws and regulations, contractual agreements, debt agreements, tax propositions, and grant restrictions that would have a material effect on the financial statements or on the individual agreement, grant award, etc., in the event of noncompliance.
- Yes X** No
19. It is correct that there are no violations or possible violations of laws and regulations (including those pertaining to adopting, approving, and amending budgets), provisions of contracts and grant agreements, and any related debt covenants whose effects should be considered for disclosure in the financial statements or as a basis for recording a loss contingency or for reporting on noncompliance.
- Yes X** No
20. It is correct that we have identified and disclosed to you all instances that have occurred or are likely to have occurred, of fraud and noncompliance with provisions of laws and regulations that have a material effect on the financial statements or other financial data significant to the audit objectives, and any other instances that warrant the attention of those charged with governance.
- Yes X** No

21. It is correct that we have identified and disclosed to you all instances that have occurred or are likely to have occurred, of noncompliance with provisions of contracts and grant agreements that have a material effect on the determination of financial statement amounts or other financial data significant to the audit objectives.

Yes No

22. It is correct that we have identified and disclosed to you all instances that have occurred or are likely to have occurred, of abuse that could be quantitatively or qualitatively material to the financial statements or other financial data significant to the audit objectives.

Yes No NA

23. We have disclosed to the auditor all fraud, noncompliance with laws and regulations, or uncorrected misstatements that have occurred at service organizations and have been reported to us by the service organization(s) or of which we are aware and that affect our financial statements (AU-C §402.19).

Yes No NA

24. The accounting principles, and the practices and methods followed in applying them, are as disclosed in the financial statements.

Yes No

25. During the fiscal year under audit, there have been no changes of our accounting principles and practices.

Yes No

26. We have made available to you all, if and to the extent requested by you, of the following data relevant to the preparation and fair presentation of the financial statements - (exceptions should be listed)

a) Financial records and related data.

b) Minutes of the meetings of directors, board members, commission members, etc., and the committees thereof, or summaries of actions of recent meetings for which minutes have not yet been prepared.

c) Accurate names and addresses of board members, officials, or other interested parties, to include any audit committee or other committee exercising significant oversight of the finance function, who should receive the audit report.

d) Financial records, agreements, guidelines, and related data pertaining to federal and state grant awards. **(No grants – not applicable)**

e) Additional information that you have requested from us for the purpose of the audit.

f) Unrestricted access to persons within the entity from whom you determined it necessary to obtain audit evidence.

Yes No

27. It is correct that we have not knowingly withheld from you any financial records or related data that in our judgment would be relevant to your audit.

Yes No

28. We are responsible for adopting sound accounting policies, establishing and maintaining effective internal control over financial reporting, sufficient to record, process, summarize, and report financial data consistent with the assertions embodied in the financial statements; to safeguard public assets; and to comply with applicable laws and regulations.

Yes No

29. We have disclosed to the auditor any known matters within our internal controls, to include those components relating to compliance with laws and regulations that we consider to be significant deficiencies and/or material weaknesses in relation to our financial statements.

Yes No

30. It is correct that we have no knowledge of any fraud or suspected fraud affecting the entity involving:

a) Management,

b) Employees who have significant roles in internal control, or

c) Others when the fraud could have a material effect on the financial statements or, where applicable, state and/or federal grants, contracts, and awards.

Yes No

31. It is correct that we have no knowledge of any allegations of fraud or suspected fraud affecting the entity received in communications from employees, former employees, regulators, or others.

Yes No

32. We have taken timely and appropriate steps to remedy fraud, illegal acts, violations of or noncompliance with provisions of laws, regulations, contracts, and grant agreements, or abuse that you have reported to us.

Yes No NA

33. We have a process to track the status of audit findings and recommendations.

Yes No

34. It is correct that we are not aware of any employees who were employed by this entity during the above time period who have committed "dishonest acts" as defined in the Office of Risk Management (ORM) Insurance Information Notice No. 2002-2 (exceptions should be listed).

Yes No

35. It is correct that we are not aware of any current employees of this entity who have committed “dishonest acts,” as defined by ORM Insurance Notice No. 2002-2, who are in a position to cause a loss to this entity (exceptions should be listed).

Yes No

36. It is correct that the ORM has not refused to cover a loss by this entity because it was caused by an employee who had previously committed a “dishonest act” (exceptions should be listed).

Yes No

37. We have identified to you any previous financial audits, attestation engagements, performance audits, or other studies related to the objectives of the audit being undertaken and the corrective actions taken to address significant findings and whether related recommendations have been implemented.

Yes No **There are none**

38. It is correct that we have not adopted any plans, nor do we have present intentions, that could materially affect the carrying value or classification of assets, liabilities, or net position in the financial statements.

Yes No

39. It is correct that there are no guarantees, whether written or oral, under which the entity is contingently liable.

Yes No

40. We acknowledge our responsibility for compliance with laws, regulations, and provisions of contracts and grant agreements applicable to our entity.

Yes No

41. We have identified and disclosed to you all laws, regulations, and provisions of contracts and grant agreements that have a direct and material effect on the determination of financial statement amounts or other financial data significant to the audit objectives, including provisions for reporting specific activities in separate funds and legal matters that could have a material impact on our operations.

Yes No

42. Where applicable, all financial reports and claims for reimbursements, required under state grant awards, have been based on accurate financial data taken from our financial records and such reports and claims have been filed in a timely manner.

Yes No **NA**

43. It is correct that there are no reservations or designations of net position that were not properly authorized and approved.
- Yes No
44. We have satisfactory title to all owned assets, and there are no liens or encumbrances on such assets nor has any asset been pledged as collateral.
- Yes No
45. The financial statements include all component units as well as joint ventures with an equity interest, and properly disclose all joint ventures and other related organizations, if any.
- Yes No **There are none**
46. All funds that meet the quantitative criteria of GASB 34 and GASB 37 for presentation as major are identified and presented as such, and all other funds that are presented as major are particularly important to the financial statement users.
- Yes No NA
47. Components of net position (invested in capital assets, net of related debt; restricted; and unrestricted), and components of fund balance (nonspendable and restricted, committed, assigned, and unassigned) are properly classified and, if applicable, approved.
- Yes No NA
48. Provisions for uncollected receivables have been properly identified and recorded.
- Yes No **NA**
49. Expenses have been appropriately classified in or allocated to functions and programs in the statement or activities and/or schedules of the annual fiscal report, and allocations have been made on a reasonable basis (if applicable).
- Yes No
50. Revenues are appropriately classified in the statement of activities within program revenues, general revenues, contributions to term or permanent endowments, or contributions to permanent fund principal.
- Yes No
51. Interfund, internal, and intra-entity activity and balances have been appropriately classified and reported.
- Yes No NA
52. Special and extraordinary items are appropriately classified and reported.
- Yes No NA

53. Investments, derivative transactions, and land and other real estate held by endowments are properly valued.
- Yes No
54. Risk disclosures associated with deposit and investment securities and derivative transactions are presented in accordance with GASB requirements.
- Yes No
55. Capital assets held under capital leases are properly classified and disclosed.
- Yes No
56. Capital assets, including infrastructure assets, are properly classified, reported, and, if applicable, depreciated (modified approach not used).
- Yes No NA
57. If the modified approach is used to account for eligible infrastructure assets, the entity meets the GASB established requirements for doing so.
- Yes No NA
58. The entity's policy regarding whether to first apply restricted or unrestricted resources when an expense is incurred for purposes for which both restricted and unrestricted net position are available is appropriately disclosed, and net position is properly recognized under the policy.
- Yes No NA
59. It is correct that we are following either our established accounting policy regarding which resources (i.e., restricted, committed, assigned, or unassigned) are considered to be spent first for expenditures for which more than one resource classification is available, or we are following GASB 54, paragraph 18 to determine the fund balance classifications for financial reporting purposes.
- Yes No
60. We acknowledge that for required supplementary information (RSI):
- a) We are responsible for RSI.
 - b) RSI is measured and presented in accordance with prescribed guidelines.
 - c) The methods of measurement or presentation of the RSI have not changed from those used in the prior period. If the methods of measurement have changed, we provided the reasons for the changes.
 - d) We have communicated all significant assumptions or interpretations underlying the measurement and presentation of RSI.
- Yes No NA

61. We acknowledge that for supplementary information (SI):
- a) We are responsible for the presentation of the SI in accordance with applicable criteria.
 - b) We believe the SI, including its form and content, is fairly presented in accordance with the applicable criteria.
 - c) The methods of measurement or presentation of the SI have not changed from those used in the prior period. If the methods of measurement have changed, we provided the reasons for the changes.
 - d) We have communicated all significant assumptions or interpretations underlying the measurement and presentation of SI.
 - e) We will make the audited financial statements readily available to the intended users of the SI no later than the date of issuance by us of the SI and the auditor's report, thereon, when the SI is not presented with the audited financial statements.
- Yes No NA
62. We acknowledge as part of the audit, you prepared the draft financial statements, related notes, and/or other schedules. We have designated a competent management-level individual to oversee your services and have made all management decisions and performed all management functions. We have reviewed, approved, and accepted responsibility for those financial statements and related notes and/or schedules.
- Yes No NA
63. We acknowledge our responsibilities as it relates to nonaudit services performed by you, including a statement that we assume all management responsibilities; that we oversee the services by having designated an individual within senior management who possesses suitable skill, knowledge, or experience; that we have evaluated the adequacy and results of the services performed; and that we accept responsibility for the results of the services.
- Yes No NA
64. We agree with the findings of specialists in evaluating the [*describe the assertion*] and have adequately considered the qualifications of the specialists in determining the amounts and disclosures used in the financial statements and underlying accounting records. We did not give or cause any instructions to be given to specialists with respect to the values or amounts derived in an attempt to bias their work, and we are not otherwise aware of any matters that have had an impact on the independence or objectivity of the specialists.
- Yes No NA
65. We have evaluated our ability to continue as a going concern and have made appropriate disclosures in the financial statements as necessary under GASB requirements.
- Yes No

Legal Compliance

PART II. PUBLIC BID LAW

66. We have complied with the provisions of the public bid law, R.S. 38:2212, and the regulations of the Division of Administration - Office of State Purchasing.

Yes No

PART III. CODE OF ETHICS LAW FOR PUBLIC OFFICIALS AND PUBLIC EMPLOYEES

67. It is correct that no employees or officials have accepted anything of value, whether in the form of a service, loan, or promise, from anyone which would constitute a violation of R.S. 42:1101-1170.

Yes No

68. It is correct that no member of the immediate family of any member of the governing authority, or the chief executive of the governmental entity, has been employed by the governmental entity after April 1, 1980, under circumstances which would constitute a violation of R.S. 42:1119.

Yes No

PART IV. LAWS AFFECTING BUDGETING

69. We have complied with the state budget requirements of R.S. 39:21-87.5 and the provisions of the annual appropriation act.

Yes No NA

PART V. ACCOUNTING, AUDITING, AND FINANCIAL/OTHER REPORTING LAWS

70. We have maintained our accounting records in such a manner as to provide evidence of legal compliance and the preparation of annual financial statements to comply with R.S. 24:514.

Yes No

71. All non-exempt governmental records are available as a public record and have been retained for at least three years, as required by R.S. Title 44, Chapter 1.

Yes No

72. We have submitted a document retention schedule to State Archives in accordance with R.S. 44:411(A)(1).

Yes No

73. We have filed our annual financial statements in accordance with R.S. 24:514.

Yes No NA

74. We have had our financial statements audited in accordance with R.S. 24:513.
Yes No NA
75. We have complied with the distribution requirements for entity reports submitted to the Louisiana Legislature as established in R.S. 24:772.
Yes No NA
76. We have reported (in writing) any known misappropriations to the Legislative Auditor and the appropriate parish district attorney as required by R.S. 24:523.
Yes No **There are none**

PART VI. ASSET MANAGEMENT LAWS

77. We have maintained records of our fixed assets and movable property, as required by R.S. 24:515 and R.S. 39:321-332.
Yes No NA

PART VII. FISCAL ENTITY AND CASH MANAGEMENT LAWS

78. We have complied with the fiscal entity and cash management requirements of R.S. 49:301-330.
Yes No

PART VIII. DEBT RESTRICTION LAWS

79. It is correct that we have not incurred any indebtedness (including installment purchase agreements) without the approval of the State Bond Commission, as provided by Article VII, Section 8 of the 1974 Louisiana Constitution; Article VI, Section 33 of the 1974 Louisiana Constitution; R.S. 39:1402-1405; and A.G. Opinion 95-508.
Yes No NA

PART IX. REVENUE AND EXPENDITURE RESTRICTION LAWS

80. We have complied with the regulations of the Louisiana Department of State Civil Service in the employment, payment, and management of our personnel.
Yes No NA
81. We have complied with the policy and procedure memoranda (PPMs) and other regulations issued by the Division of Administration.
Yes No NA
82. We have restricted the collections and expenditures of revenues to those amounts authorized by Louisiana statutes, tax propositions, and the annual appropriation act.
Yes No NA

83. It is correct that we have not advanced wages or salaries to employees or paid bonuses, in violation of Article VII, Section 14 of the 1974 Louisiana Constitution; R.S. 14:138; and A.G. Opinion 79-729.

Yes No NA

84. It is correct that no property or things of value have been loaned, pledged, or granted to anyone in violation of Article VII, Section 14 of the 1974 Louisiana Constitution.

Yes No NA

The previous responses have been made to the best of our belief and knowledge.

Signature _____ Date 12 August 2015

Title Carl W. Aron, President

Signature _____ Date 12 August 2015

Title Malcolm J. Broussard, Executive Director

Update to the Financial and Compliance Questionnaire Representations

- A. We have reviewed the representations contained in this document, and to the best of our knowledge those representations continue to be accurate.
- B. We have reviewed the financial statements, to include any adjustments proposed by you our auditor, and find that we are in agreement with them, and we take full responsibility for them.
- C. We believe the effects of the uncorrected financial statement misstatements summarized in the attached schedule are immaterial, both individually and in the aggregate, to the financial statements as a whole for each opinion unit.

No uncorrected misstatements

- D. We have provided our views of reported findings, conclusions, and recommendations, as well as our planned corrective actions, for the report.

No findings communicated to management

- E. Furthermore, we acknowledge the additional representations made in the addendum to this statement.

No addendum of representations obtained

Signature _____ Date _____

Title _____

Signature _____ Date _____

Title _____



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Report of Assistant Executive Director

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Prescription Monitoring Program Annual Report

Fiscal Year 2014-2015

July 1, 2015

Introduction

Act 676 of the 2006 Louisiana Legislature authorized the development, implementation, operation, and evaluation of an electronic system for the monitoring of controlled substances and other drugs of concern that are dispensed within the state or dispensed by a licensed pharmacy outside the state to an address within the state. The goal of the program is to improve the state's ability to identify and inhibit the diversion of controlled substances and drugs of concern in an efficient and cost-effective manner and in a manner that shall not impede the appropriate utilization of these drugs for legitimate medical purposes.

The Prescription Monitoring Program (PMP) was implemented in August 2008. We notified pharmacies of their requirement to report all eligible prescription transactions to the program, and further, required them to report all historical data retroactive to June 1, 2008 no later than December 31, 2008. In December 2008, the Board notified all prescribers and dispensers wishing to acquire direct access privileges of the requirement to complete the web-based orientation program prior to receiving their access privileges. The web portal to the program database was opened to queries on January 1, 2009, and the program remains fully functional.

Advisory Council

The enabling legislation created the PMP Advisory Council to assist the Board in the development and operation of the program. The Board shall seek, and the advisory council shall provide, information and advice regarding: (1) which controlled substances should be monitored, (2) which drugs of concern demonstrate a potential for abuse and should be monitored, (3) design and implementation of educational courses required by the PMP law, (4) methodology to be used for analysis and interpretation of prescription monitoring information, (5) design and implementation of a program evaluation component, and (6) identification of potential additional members to the advisory council. The original legislation specifically identified the 25 organizations named to the council and further, named the leader of the organization but permitted the leader to name a designee to function in the absence of the appointee. The organizations represented on the council include the licensing agencies for the prescribers and dispensers, the professional membership organizations for the prescribers and dispensers, organizations representing federal, state, and local law enforcement agencies, as well as representatives from the legislature. The advisory council has elected its own leadership, adopted policies and procedures for its operations, and meets on a quarterly basis.

Program Metrics

The data on the following page provides summary data for the operational aspects of the program – number of prescription transactions reported to the program database, number of prescribers and dispensers registered to access the program data, the number of queries performed by those authorized prescribers and dispensers as well as law enforcement agencies and regulatory agencies.

Louisiana Board of Pharmacy
Prescription Monitoring Program

Calendar Year:	<u>2008</u>	<u>2009</u>	<u>2010</u>	<u>2011</u>	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>6/30/2015</u>	<u>Total</u>
Prescription Database:									
Transactions Reported (in Millions)	6.015	11.144	12.117	12.775	12.990	13.032	13.020	6.093	87.186
Access to Program Data:									
New prescribers registered		1,526	721	548	574	640	1093	453	5,555
New prescriber-delegates registered							473	342	815
New pharmacists registered		728	483	361	494	509	466	170	3,211
New pharmacist-delegates registered							143	126	269
Searches Performed by Users:									
Solicited by prescribers		235,985	368,376	496,270	650,514	842,139	942,733	578,347	4,114,364
Solicited by prescriber-delegates							26,993	93,655	120,648
Solicited by pharmacists		74,277	111,075	153,783	212,754	382,204	456,568	470,536	1,861,197
Solicited by pharmacist-delegates							3,954	17,257	21,211
Solicited by law enforcement		680	889	1,230	845	1,150	1,224	556	6,574
Solicited by regulatory agencies		833	1,401	1,612	1,584	1,364	1,675	785	9,254
Average queries per day		854	1,319	1,788	2,372	3,361	3,926	6,362	2,585

Legislative Mandates

The 2014 Legislature adopted a number of measures which will serve to improve the program. Beginning August 1, 2014, pharmacies and other dispensers will be required to report their eligible prescription transactions to the program database no later than the next business day following the date of dispensing, instead of the previous seven day allowance. In addition, the Board has recently completed the rulemaking process authorized by the 2013 Legislature that will allow authorized prescribers and dispensers to appoint delegates for the purpose of retrieving data from the program's database.

The 2015 Legislature also adopted a measure that will require prescribers of certain controlled substances for the treatment of certain conditions to access the patient's history in the program database prior to initiating such treatment. The same measure will require pharmacists dispensing certain controlled substances to certain patients to access the patient's history in the program database prior to dispensing such medications.

Outlook for Next Fiscal Year

The program continues to enroll new authorized users, and the daily average number of queries continues to increase. With assistance from the licensing agencies encouraging use of the program by their licensees, we hope to improve on the current 30% registration rate, as well as the daily query rate of approximately 3,000.

Conclusion

The program has completed approximately seven years of operation. Based on feedback from authorized users, it appears to represent an efficient and cost-effective use of resources. Data from the program suggests we have made some early contributions to the reduction of diversion of controlled substances. Our interstate collaborations have yielded high marks for our program design and operation. We look forward to fully developing the potential of our program to identify and inhibit the diversion of controlled substances in Louisiana.

We acknowledge the contributions from Ms. Danielle Meadors, our Administrative Coordinator, and Mr. Joseph Fontenot, Program Manager, for their operation of the program and the development of this report.

Prepared by:
Malcolm J. Broussard
Executive Director



Prescription Monitoring Program


Board Meeting
August 12, 2015

Joe Fontenot, R.Ph. Assistant Executive Director
Danielle C. Meadors, Administrative Assistant

Number of Eligible Transactions Reported to the PMP

Total Reported as of
June 30, 2015


87,186,280




Prescriber & Pharmacist Access

(as of June 30, 2015)

Prescribers – Total
Authorized 6,370




Pharmacists – Total
Authorized 3,480



Combined totals – 9,850

Prescriber & Pharmacist Queries – 2015

Overall Query total = 1,159,795



Prescriber & Pharmacist Queries


(01/01/2009 through 06/30/2015)

Overall Query total = 6,117,420



Board and Regulatory Agencies

Profile Views by Boards & Regulatory Agencies Total = 9,254
(01/01/2009 through 06/30/2015)



Law Enforcement Access and Requests


Number of Law Enforcement
Requests Processed = **6,574**
(01/01/2009 through 06/30/2015)

2009	2010	2011	2012	2013	2014	2015
680	889	1,230	845	1,150	1,224	556

Individuals Requesting Their Own PMP Information


Patient Profiles Requested and Received as of June 30, 2015

Number of Requests



Hydrocodone Combination Products Rate Analysis

No of Rx Dispensed




No of Doses Dispensed




Tramadol Rate Analysis

No of Rx Dispensed




No of Doses Dispensed




Carisoprodol Rate Analysis

No of Rx Dispensed



No of Doses Dispensed



Requests for Partial Exemption from PMP Reporting

August 12, 2015

In accordance with LA.R.S:40.4.X-A.1006.C. The board may issue an exemption from the reporting requirement to a dispenser whose practice activities are inconsistent with the intent of the program. The board may rescind any previously issued exemption without the need for an informal or formal hearing.

Permit	Permit Type	Name	Scope of Practice	DEA	City	State
5087	IR	Community Pharmacy Service	Inpatient Hospital Pharmacy	Yes	Harahan	LA

Staff Recommendation

Approve the proposed waivers conditioned upon execution of the standard Consent Agreement:

PARTIAL EXEMPTION TO PRESCRIPTION MONITORING PROGRAM REPORTING REQUIREMENTS CONSENT AGREEMENT

WHEREAS, in order to facilitate the pharmacy's request for a PARTIAL EXEMPTION to the reporting requirements of the Louisiana Board of Pharmacy's Prescription Monitoring Program (PMP) as required by law, the Pharmacy indicated below agrees to the following terms:

- (1) The Pharmacy shall only be exempt from reporting eligible prescription transactions dispensed for **hospital in-patient administration**, but the pharmacy shall report all other eligible prescription transactions as required by law.
- (2) Upon the first instance of receipt of evidence by the Board indicating the Pharmacy failed to report non-exempt eligible prescription transactions, the Pharmacy agrees to the following sanction:
The Pharmacy agrees to pay a fine of \$5,000.00 and reimburse the Board \$250.00 in administrative hearing costs, with total payment due the Board of \$5,250.00, due by certified check or money order within 30 days of notice of this prohibited activity.
- (3) Upon the second instance of receipt of evidence indicating the Pharmacy failed to report non-exempt eligible prescription transactions, the Pharmacy agrees to pay the above sanction, the termination of this exemption and the resumption of its reporting to the PMP.
- (4) The Pharmacy shall post a copy of this agreement adjacent or attached to its pharmacy permit.

By signing this Consent Agreement, Respondent agrees that the Board has jurisdiction in this

matter and waives all rights to informal conference, to Notice of Hearing, to a formal Administrative Hearing, and to judicial review of this Consent Agreement.

Requests for Full Exemption from PMP Reporting

August 12, 2015

In accordance with LA.R.S:40.4.X-A.1006.C. The board may issue an exemption from the reporting requirement to a dispenser whose practice activities are inconsistent with the intent of the program. The board may rescind any previously issued exemption without the need for an informal or formal hearing.

Permit	Permit Type	Name	Scope of Practice	DEA	City	State
7140	NR	Alegria Pharmacy Services	Specialty Pharmacy	Yes	Manhasset	NY
3045	HOS	Baton Rouge General Health Center Pharmacy	Inpatient Hospital Pharmacy	Yes	Baton Rouge	LA
54	HOS	Baton Rouge General Medical Center Pharmacy	Inpatient Hospital Pharmacy	Yes	Baton Rouge	LA
469	HOS	Claiborne Memorial Medical Center	Inpatient Hospital Pharmacy	Yes	Homer	LA
7113	NR	Complete Medical Homecare	Mail Order Pharmacy	Yes	Kansas City	MO
7133	HOS	Cornerstone Hospital of Bossier City	Inpatient Hospital Pharmacy	Yes	Bossier City	LA
7131	NR	Cystic Fibrosis Services	Specialty Pharmacy	No	Bethesda	MD
7108	NR	Hemophilia Preferred Care of Memphis	Specialty Pharmacy	Yes	Memphis	TN
2953	CH	Lafayette Community Healthcare Clinic Pharmacy	Charitable Pharmacy	Yes	Lafayette	LA
7135	NR	NuFACTOR	Infusion Pharmacy	No	Kernersville	NC
6453	NR	Pegasus Express Pharmacy Services		Yes	Cookeville	TN
7139	NR	Pet360 Pharmacy	Mail Order Veterinary Pharmacy	Yes	Louisville	KY
6402	NR	Retail Pharmacy Customer Care Center		Yes	Cumberland	RI
7130	NR	Total Vein Pharmacy	Specialty Pharmacy	Yes	Houston	TX

Staff Recommendation

Approve the proposed waivers conditioned upon execution of the standard Consent Agreement:

EXEMPTION TO PRESCRIPTION MONITORING PROGRAM REPORTING REQUIREMENTS
CONSENT AGREEMENT

WHEREAS, in order to facilitate the pharmacy's request for an exemption to the reporting requirements to the Louisiana Board of Pharmacy's Prescription Monitoring Program (PMP) as required by law, the Pharmacy indicated below agrees to the following terms:

- (1) The Pharmacy shall not be authorized to dispense any controlled dangerous substances (CDS) or *drugs of concern*, with the exception of a hospital pharmacy permit's inpatient dispensing, as identified by the Louisiana Board of Pharmacy (Board) by regulation.
- (2) Upon the first instance of receipt of evidence by the Board indicating the Pharmacy dispensed CDS or drugs of concern, the Pharmacy agrees to the following sanction:
The Pharmacy agrees to pay a fine of \$5,000.00 and reimburse the Board \$250.00 in administrative hearing costs, with total payment due the Board of \$5,250.00, due by certified check or money order within 30 days of notice of this prohibited activity.
- (3) Upon the second instance of receipt of evidence indicating the Pharmacy dispensed CDS or drugs of concern, the Pharmacy agrees to pay the above sanction, the termination of this exemption and the resumption of its reporting to the PMP.
- (4) The Pharmacy shall post a copy of this agreement adjacent or attached to its pharmacy permit.

By signing this Consent Agreement, Respondent agrees that the Board has jurisdiction in this matter and waives all rights to informal conference, to Notice of Hearing, to a formal Administrative Hearing, and to judicial review of this Consent Agreement.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Report of General Counsel

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Report of Executive Director

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



August 12, 2015

Agenda Item 10-L: Report of Executive Director

1. Meeting Activity
2. Reports
3. Examinations
4. Operations
5. State Activities
6. National Activities
7. International Activities

1. **Meeting Activity**

In addition to Board and committee meetings, I have also participated in or attended the following meetings since the last Board meeting.

June 6-10 ASHP Summer Meeting – Denver, CO

2. **Reports** (all in the Boardroom Library)

- A. Census Reports
 1. Compliance Division – Practitioner Recovery Program & Discipline
 2. Credentials Division – CDS & Pharmacy Programs
- B. Credentials Division Production Reports
 1. Licensure Activity Report [new credentials in previous quarter]
 2. Application Activity Report [pending applications count]
- C. Exceptions Report
 1. PIC in Multiple Locations
 2. Resurrected Credentials / Special Work Permits
- D. Compliance Division Annual Summary
- E. Annual Report – July 1, 2015

3. **Examinations**

- A. MPJE – the results for the first trimester of 2015 are available.
- B. NAPLEX – the results for the first trimester of 2015 are available.
- C. PARE – our last administration of this test was in July 2014.
- D. PTCB – the results for the second half of 2014 are available.

4. **Operations**

A. Credentials Division

Shortly before the beginning of July, we sent renewal notices to 603 DME permit holders. As of this past weekend, 73.3% had already renewed, and of that number, 80% did so online. Their renewal cycle closes on August 31.

B. Compliance Division

Our 5 pharmacist compliance officers are responsible for inspecting all the pharmacies and other facilities holding controlled substances (CDS). The census reports available for this meeting reflect 1,470 pharmacies within the state, as well as approximately 605 various types of facilities for CDS visits, including hospitals, rural health clinics, animal control shelters, researchers, etc.

In addition to their routine site visits, the compliance officers are also responsible for investigating complaints filed with the Board. We began the fiscal year with 252 cases pending from the prior fiscal year. We entered 404 new cases and closed 442, leaving 214 cases currently open. Of the 442 cases closed last fiscal year, 58% were disposed of through staff activities and the balance through committee and Board action.

C. Administrative Division

As you authorized during your last meeting, we completed an upgrade that allows our website to be more responsive to visitors using mobile applications. The screen resizes based upon the available screen size of the mobile device. The extension of that responsive design to include online transactions will have additional costs; we have had very few requests for that service so we have deferred that project for now.

We are working with the medical and optometry boards to facilitate the implementation of Act 453 of the 2015 Legislature. That law expanded the controlled substance prescriptive authority for physician assistants and optometrists to include Schedule II medications. Those practitioners must obtain authority from their respective licensing agencies, and provide a copy of that authority to us with their application. The DEA has also been informed of the new law, and they will need time to update their registration information systems. We have already notified pharmacists and pharmacies via a bulletin of the new legal authority, and we have also cautioned them of the necessity for an updated federal registration before those new prescriptions can be dispensed.

Finally, we are currently working on our annual audit. This year, the Office of the Legislative Auditor elected not to contract out our audit, and they are using regular office staff. Since they typically have not audited boards and commissions in the past, their staff has received some general training prior to engaging our staff. We have already had an entrance conference, and we hope to complete the work before the end of this month.

5. **State Activities**

A. 2015 Regular Session of Louisiana Legislature

The session convened on April 13 and adjourned on June 11. I posted two items in the library for your review or reference: the *Final Report* is a comprehensive record of all the actions for all the bills we followed, and the *Final Brief* is a listing of only those bills that passed. Since this meeting is your first meeting since the legislature adjourned, you are required to take formal notice of all acts which affect the practice of pharmacy as well as those which may affect the Board's operations. You also need to determine whether any of those legislative mandates require any rulemaking, and if so, you should refer those items to the Board's Regulation Revision Committee for their consideration and development of regulatory proposals for your further consideration. The Executive Committee is scheduled to review the *Final Brief* during their meeting.

6. **National Activities**

A. National Association of Boards of Pharmacy (NABP)

For your planning purposes, the 2016 meeting will be held May 14-17 in San Diego, CA. This conference is one of the three meetings for which your travel expenses

are eligible for reimbursement, subject to the limitations itemized in the Board's travel policy as well as the state's travel policy in PPM-49.

B. NABP-AACP District 6 Annual Meeting

For your planning purposes, the 2015 meeting will be held Sep 14-17 in Lake Tahoe, NV. This conference is one of the three meetings for which your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board's travel policy as well as the state's travel policy in PPM-49.

C. MALTAGON

For your planning purposes, the 2015 meeting will be held Oct 25-28 in Louisville, KY. We have not yet received any lodging or conference registration materials; we will forward those items to you when they are available. This conference is one of the three meetings for which your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board's travel policy as well as the state's travel policy in PPM-49.

7. *International Activities*

A. International Pharmaceutical Federation (FIP)

The 75th World Congress of the International Pharmaceutical Federation will be held in Dusseldorf, Germany on Sep 28 – Oct 3. For your planning purposes, the next two hosting sites have also been identified: 2016 in Buenos Aires, Argentina and 2017 in Seoul, South Korea.

Respectfully submitted,
Malcolm J Broussard
Executive Director



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Compliance Division Census Report

August 12, 2015

Practitioner Recovery Program

- Probation Completion Report

[none since last Board meeting]

- Active Probation 49 pharmacist
 0 intern
 2 technician
 0 technician candidate
- Active Suspension 42 pharmacist
 3 intern
 15 technician
 4 technician candidate

Disciplinary Restrictions

- Probation Completion Report

06-01-2015 PST.014226 – Patrick Glen Andrus
 PST.010314 – David Wayne Spears

- Active Probation 23 pharmacist
 0 intern
 6 technician
 3 technician candidate
 11 pharmacy permit
 1 DME permit
 4 CDS license @ pharmacy
 1 CDS license @ distributor
- Active Suspension 43 pharmacist
 1 intern
 64 technician
 15 technician candidate
 13 pharmacy permit
 3 CDS license @ pharmacy
 55 CDS licenses for practitioners

Louisiana Board of Pharmacy
 Credentials Division
 Pharmacy Program

		06/30/06	06/30/07	06/30/08	06/30/09	06/30/10	06/30/11	06/30/12	06/30/13	06/30/14	06/30/15
PST-VI	LA	0	0	0	0	0	12	10	9	9	13
	NR	0	0	0	0	0	9	10	15	14	15
	Total	0	0	0	0	0	21	20	24	23	28
PST-GVI	LA	0	0	0	0	0	0	6	13	13	12
	NR	0	0	0	0	0	0	0	3	5	5
	Total	0	0	0	0	0	0	6	16	18	17
PST-M	LA	0	0	0	0	0	3	5	3	1	2
	NR	0	0	0	0	0	11	11	11	13	10
	Total	0	0	0	0	0	14	16	14	14	12
PST-G	LA	0	0	0	0	0	158	157	164	166	186
	NR	0	0	0	0	0	30	35	32	31	31
	Total	0	0	0	0	0	188	192	196	197	217
PST	LA	4,460	4,522	4,612	4,750	4,860	4,654	4,933	4,981	5,140	5,408
	NR	1,915	1,975	1,964	2,029	2,098	2,079	2,212	2,527	2,479	2,471
	Total	6,375	6,497	6,576	6,779	6,958	6,733	7,145	7,508	7,619	7,879
	PST	6,375	6,497	6,576	6,779	6,958	6,935	7,353	7,758	7,871	8,108
PNT	LA	980	1,079	1,074	1,035	965	907	938	942	948	952
	NR	109	117	67	84	153	137	128	128	127	143
	Total	1,089	1,196	1,141	1,119	1,118	1,044	1,066	1,070	1,075	1,095
PNT-FPG	Total	0	0	0	0	0	5	0	3	6	2
	PNT	1,089	1,196	1,141	1,119	1,118	1,049	1,066	1,073	1,081	1,097
CPT	LA	4,552	4,587	4,780	4,733	5,363	5,720	5,509	5,751	6,463	6,584
	NR	163	152	144	109	144	145	120	112	138	141
	Total	4,715	4,739	4,924	4,842	5,507	5,865	5,629	5,863	6,601	6,725
CPT-M	Total	0	0	0	0	0	1	0	1	2	1
	CPT	4,715	4,739	4,924	4,842	5,507	5,866	5,629	5,864	6,603	6,726
PTC	LA	1,081	1,389	1,446	1,510	1,679	1,574	1,665	1,658	1,870	1,929
	NR	32	32	23	32	35	35	39	37	37	52
	PTC	1,113	1,421	1,469	1,542	1,714	1,609	1,704	1,695	1,907	1,981
PHY	CH	12	12	11	12	14	12	12	12	12	12
	HOS	167	164	167	167	165	151	154	158	164	163
	HOX	0	0	0	0	0	19	18	14	11	8
	IN	35	36	37	37	27	14	10	12	12	11
	INX	0	0	0	0	0	11	14	13	11	10
	IR	681	620	588	592	587	570	568	558	583	588
	IRX	0	0	0	0	0	21	19	17	10	10
	NR	226	240	250	256	286	318	361	387	422	473
	NRN	0	0	0	0	0	0	0	0	9	9
	NRP	0	0	0	0	0	0	0	0	1	2
	NU	17	16	16	16	16	15	15	15	15	14
	PEN	0	0	0	0	0	0	0	0	0	0
	PEX	0	0	0	0	0	0	0	1	2	2
	SAT	0	0	0	0	0	0	0	0	1	3
RC	430	491	534	545	562	576	587	597	619	649	
PHY	1,568	1,579	1,603	1,625	1,657	1,707	1,758	1,784	1,872	1,954	
AMS	AMS	173	212	255	306	361	55	64	349	92	456
	AMS-X	0	0	0	0	0	301	302	289	359	356
	AMS	173	212	255	306	361	356	366	638	451	812
EDK	EDK	428	412	439	388	503	417	435	421	464	474
	EDK-X	0	0	0	0	0	13	13	10	10	10
	EDK	428	412	439	388	503	430	448	431	474	484
DME	LA							223	160	209	336
	NR								218	281	267
	DME								378	490	603
CDTM								41	41	52	
MAR								1,617	2,037	2,383	
SWP						58	78	126	38	54	
TOTAL									21,405	22,865	24,254

Louisiana Board of Pharmacy
 Credentials Division
 CDS Program

<i>Classification</i>	<u>06/30/08</u>	<u>06/30/09</u>	<u>06/30/10</u>	<u>06/30/11</u>	<u>06/30/12</u>	<u>06/30/13</u>	<u>06/30/14</u>	<u>06/30/15</u>
ACS Animal Control Shelter	0	0	1	1	1	1	1	1
AMS Automated Medication Sys	0	0	0	0	0	0	26	29
AMX Automated Medication Sys - Exempt	0	0	0	0	0	0	2	1
APN APRN	479	607	758	889	1,015	1,103	1,479	1,954
ASC Ambulatory Surgical Ctr	101	106	113	90	88	85	89	87
CRX Correctional Ctr - Exempt	0	0	0	7	6	5	6	4
DDS Dentist	2,177	2,267	2,363	2,027	2,048	1,902	2,123	2,133
DET Drug Detection / Canine	20	20	22	14	12	10	11	11
DEX Drug Detection / Canine - Exempt							1	1
DIS Distributor	322	363	400	279	288	273	324	319
DPM Podiatrist	153	161	165	139	136	118	133	142
DVM Veterinarian	936	1,000	1,065	922	901	852	1,002	1,045
DYS Dialysis Ctr	63	63	63	6	4	3	4	0
EMC Emergency Medical Ctr	17	17	18	14	16	17	22	26
EMS Emergency Medical Service	58	63	66	54	50	45	50	49
ETC Animal Euthanasia Tech - Cert	39	44	49	16	7	6	6	5
ETL Animal Euthanasia Tech - Lead	0	0	0	12	20	21	23	23
HOS Hospital	387	405	438	280	267	263	272	271
HOX Hospital - Exempt	0	0	0	12	14	5	6	6
LAB Laboratory	14	14	15	8	6	7	8	8
LAX Laboratory - Exempt	0	0	0	4	5	5	5	5
MD Physician	13,876	14,599	15,269	12,362	11,727	10,698	11,913	12,124
MDT Physician on Telemedicine	0	0	0	0	0	0	2	1
MED Medical Clinic	78	88	102	77	81	68	78	71
MEX Medical Clinic - Exempt	0	0	0	3	5	14	11	10
MFR Manufacturer	43	52	58	48	50	45	42	42
MIS Miscellaneous	73	58	59	11	10	9	11	9
MIX Miscellaneous - Exempt	0	0	0	9	4	3	2	2
MP Medical Psychologist	44	50	58	65	67	69	78	82
OD Optometrist	253	269	278	275	287	279	309	316
PA Physician Assistant	194	232	272	294	326	344	449	487
PHX Pharmacy - Exempt	0	0	0	50	47	41	30	24
PHY Pharmacy	0	0	0	1,307	1,318	1,329	1,357	1,379
REP Sales Representative	65	66	88	29	20	7	0	0
RES Researcher	110	119	156	109	110	98	113	113
RHC Rural Health Clinic	20	21	23	17	12	11	12	11
ROF Registered Outsourcing Facility	0	0	0	0	0	0	0	8
SAC Substance Abuse Clinic	14	14	17	7	9	9	9	9
SAX Subst. Abuse Clinic - Exempt	0	0	0	0	0	0	0	1
Total	19,536	20,698	21,916	19,437	18,957	17,745	20,009	20,809

Total Credentials Under Management

Pharmacy	16,407	16,601	17,818	18,260	18,625	21,405	22,865	24,254
CDS	<u>19,536</u>	<u>20,698</u>	<u>21,916</u>	<u>19,437</u>	<u>18,957</u>	<u>17,745</u>	<u>20,009</u>	<u>20,809</u>
Total	35,943	37,299	39,734	37,697	37,582	39,150	42,874	45,063

Louisiana Board of Pharmacy
Census Report

<i>Type of Credential</i>	<u>3/17/1995</u>	<u>6/30/1996</u>	<u>3/19/1997</u>	<u>6/30/1998</u>	<u>6/30/1999</u>	<u>6/30/2000</u>	<u>6/30/2001</u>	<u>6/30/2002</u>	<u>6/30/2003</u>	<u>6/30/2004</u>	<u>6/30/2005</u>
Pharmacists											
In-state	3,642	3,660	4,143	4,247	4,269	4,830	3,887	4,386	4,435	4,486	4,532
Out-of-state	377	446	1,339	1,435	1,421	944	1,901	1,453	1,455	1,484	1,686
TOTAL	4,019	4,106	5,482	5,682	5,690	5,774	5,788	5,839	5,890	5,970	6,218
Pharmacy Interns											
In-state											
Out-of-state											
TOTAL							957	976	929	995	1,154
Pharmacy Technicians											
In-state											
Out-of-state											
TOTAL							3,216	3,453	3,505	4,114	4,455
Pharmacy Technician Candidates											
In-state											
Out-of-state											
TOTAL							2,896	2,372	1,336	1,069	1,074
Pharmacy Permits											
IR	651	634	636	609	621	585	584	576	573	633	729
RC	464	473	471	493	505	520	528	535	541	555	473
H	177	174	171	175	172	171	171	174	179	181	181
IN	46	45	38	39	19		17	18	19	27	36
NU	9	10	10	9	10		12	14	13	13	13
CH	4	4	4	7	4		8	9	11	12	12
PEN											
OS	122	152	168	175	216	223	262	313	353	339	200
PE	78	104	102	120	102			95	94	0	
CO	13	12	12	12	12		12	13	13	0	
TOTAL	1,564	1,608	1,612	1,639	1,668	1,663	1,717	1,771	1,818	1,760	1,644
Equipment Permits											
AMS							0	109	136	158	174
EDK							468	461	474	444	471

Louisiana Board of Pharmacy
Census Report

<i>Type of Credential</i>	<u>6/30/2006</u>	<u>6/30/2007</u>	<u>6/30/2008</u>	<u>6/30/2009</u>	<u>6/30/2010</u>	<u>6/30/2011</u>	<u>6/30/2012</u>	<u>6/30/2013</u>	<u>6/30/2014</u>	<u>6/30/2015</u>
Pharmacists										
In-state	4,460	4,522	4,612	4,750	4,860	5,000	5,095	5,170	5,329	5,596
Out-of-state	1,915	1,975	1,964	2,029	2,098	2,179	2,258	2,588	2,542	2,512
TOTAL	6,375	6,497	6,576	6,779	6,958	7,179	7,353	7,758	7,871	8,108
Pharmacy Interns										
In-state	980	1,079	1,074	1,035	965	917	938	945	950	953
Out-of-state	109	117	67	84	153	137	128	128	131	144
TOTAL	1,089	1,196	1,141	1,119	1,118	1,054	1,066	1,073	1,081	1,097
Pharmacy Technicians										
In-state	4,552	4,587	4,780	4,733	5,363	5,722	5,509	5,752	6,463	6,585
Out-of-state	163	152	144	109	144	145	120	112	138	141
TOTAL	4,715	4,739	4,924	4,842	5,507	5,867	5,629	5,864	6,601	6,726
Pharmacy Technician Candidates										
In-state	1,081	1,389	1,446	1,510	1,679	1,574	1,665	1,658	1,870	1,929
Out-of-state	32	32	23	32	35	35	39	31	37	52
TOTAL	1,113	1,421	1,469	1,542	1,714	1,609	1,704	1,695	1,907	1,981
Pharmacy Permits										
IR	681	620	588	592	587	591	587	575	583	598
RC	430	491	534	545	562	576	587	597	619	649
H	167	164	167	167	165	170	172	172	175	174
IN	35	36	37	37	27	25	24	25	23	21
NU	17	16	16	16	16	15	15	15	15	14
CH	12	12	11	12	14	12	12	12	12	12
PEN								1	2	2
NR	226	240	250	256	286	318	361	387	432	484
TOTAL	1,568	1,579	1,603	1,625	1,657	1,707	1,758	1,784	1,861	1,954
Equipment Permits										
AMS	173	212	255	306	361	356	366	638	451	812
EDK	428	412	439	388	503	430	448	431	474	484
DME							223	378	490	603
Special Activity								41	41	52
CDTM										
MAR								1,617	2,037	2383
Special Work Permit						58	78	126	38	54

Louisiana Board of Pharmacy
CDS Program - Census Report

<i>Classification</i>	<u>6/30/2007</u>	<u>6/30/2008</u>	<u>6/30/2009</u>	<u>6/30/2010</u>	<u>6/30/2011</u>	<u>6/30/2012</u>	<u>6/30/2013</u>	<u>6/30/2014</u>	<u>06/30/15</u>
ACS Animal Control Shelter	0	0	0	1	1	1	1	1	1
AMS Automated Medication System	0	0	0	0	0	0	0	28	30
APN Advanced Practice Registered Nurse	346	479	607	758	889	1,015	1,103	1,479	1,954
ASC Ambulatory Surgical Center	94	101	106	113	90	88	85	89	87
CRX Correctional Center	0	0	0	0	7	6	5	6	4
DDS Dentist	2,090	2,177	2,267	2,363	2,027	2,048	1,902	2,123	2,133
DET Drug Detection Canine	20	20	20	22	14	12	10	11	12
DIS Distributor	285	322	363	400	279	288	273	324	319
DPM Podiatrist	147	153	161	165	139	136	118	133	142
DVM Veterinarian	870	936	1,000	1,065	922	901	852	1,002	1,045
DYS Dialysis Center	63	63	63	63	6	4	3	4	0
EMC Emergency Medical Center	17	17	17	18	14	16	17	22	26
EMS Emergency Medical Service	57	58	63	66	54	50	45	50	49
ETC Animal Euthanasia Tech - Cert	31	39	44	49	28	27	27	29	28
HOS Hospital	369	387	405	438	292	281	268	278	277
LAB Analytical Laboratory	13	14	14	15	12	11	12	13	13
MD Physician	13,195	13,876	14,599	15,269	12,362	11,727	10,698	11,913	12,124
MDT Physician on Telemedicine	0	0	0	0	0	0	0	2	1
MED Medical Clinic	73	78	88	102	80	86	82	89	81
MFR Manufacturer	36	43	52	58	48	50	45	42	42
MIS Other	74	73	58	59	20	14	12	13	11
MP Medical Psychologist	37	44	50	58	65	67	69	78	82
OD Optometrist	230	253	269	278	275	287	279	309	316
PA Physician's Assistant	170	194	232	272	294	326	344	449	487
PHY Pharmacy	0	0	0	0	1357	1,365	1,370	1,387	1,403
REP Sales Representative	57	65	66	88	29	20	7	0	0
RES Researcher	100	110	119	156	109	110	98	113	113
RHC Rural Health Clinic	19	20	21	23	17	12	11	12	11
ROF Registered Outsourcing Facility	0	0	0	0	0	0	0	0	8
SAC Substance Abuse Clinic	<u>14</u>	<u>14</u>	<u>14</u>	<u>17</u>	<u>7</u>	<u>9</u>	<u>9</u>	<u>9</u>	<u>10</u>
TOTAL	18,407	19,502	20,663	21,916	19,437	18,957	17,745	20,009	20,809

Total Credentials Under Board Management

Pharmacy Program	16,056	16,407	16,601	17,818	18,260	18,625	21,405	22,865	24,254
CDS Program	<u>18,407</u>	<u>19,536</u>	<u>20,698</u>	<u>21,916</u>	<u>19,437</u>	<u>18,957</u>	<u>17,745</u>	<u>20,009</u>	<u>20,809</u>
TOTAL	34,463	35,943	37,299	39,734	37,697	37,582	39,150	42,874	45,063

**New Credentials Issued
FYE 2015 ~ 4th Quarter
April 1, 2015 - June 30, 2015**

Prefix	Subcategory	CredentialType	Total
AMS		Automated Medication System	12
AMS	X	Automated Medication System - Exempt	4
Prefix Totals			16
CDS	AMS	CDS License - Automated Medication System	1
CDS	APN	CDS License - APRN	114
CDS	DDS	CDS License - Dentist	43
CDS	DIS	CDS License - Distributor	7
CDS	DPM	CDS License - Podiatrist	4
CDS	DVM	CDS License - Veterinarian	17
CDS	EMC	CDS License - Emergency Medical Center	1
CDS	EMS	CDS License - Emergency Medical Service	1
CDS	ETC	CDS License - Animal Euthanasia Technician, Certified (AET-C)	1
CDS	ETL	CDS License - Animal Euthanasia Technician, Lead (AET-L)	1
CDS	HOS	CDS License - Hospital	3
CDS	MD	CDS License - Physician	251
CDS	MFR	CDS License - Manufacturer	1
CDS	MP	CDS License - Medical Psychologist	2
CDS	PA	CDS License - Physician Assistant	8
CDS	PHY	CDS License - Pharmacy	13
CDS	RES	CDS License - Researcher	1
CDS	ROF	CDS License - Registered Outsourcing Facility	4
CDS	SAX	CDS License - Substance Abuse Clinic - Exempt	1
Prefix Totals			474
CPT		Certified Pharmacy Technician	96
Prefix Totals			96
DME		Durable Medical Equipment (DME) Provider	22
Prefix Totals			22
EDK		Emergency Drug Kit	20
Prefix Totals			20
MA		Medication Administration (V)	102
Prefix Totals			102
PHY	HOS	Pharmacy - Hospital Inpatient	2
PHY	IR	Pharmacy - Community ~ Independent	8
PHY	NR	Pharmacy - Nonresident	25
PHY	RC	Pharmacy - Community ~ Chain	5
Prefix Totals			40
PIC		Pharmacist-in-Charge (V)	15
Prefix Totals			15
PMP	CDS	PMP - CDS Credential	251
PMP	PST	PMP - Pharmacist	91
Prefix Totals			342
PNT		Pharmacy Intern	56
Prefix Totals			56
PST		Pharmacist	108
Prefix Totals			108
PTC		Pharmacy Technician Candidate	343
Prefix Totals			343
SWP		Special Work Permit	14
Prefix Totals			14
Grand Totals			1648



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



August 12, 2015

Agenda Item 10-L: Report of Executive Director

Section 2.C – Exceptions Report

1. PIC at Multiple Pharmacies

Board Policy I.A.4 permits the Executive Director to approve requests from pharmacists wishing to serve as the Pharmacist-in-Charge (PIC) of more than one pharmacy at the same time. The policy requires the concurrence of the President, as well as notice to the Board at its next meeting. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

- On June 11, 2015, Mr. Aron and Mr. Fontenot concurred to grant a request from Robin H. Braud (PST.013668) for dual PIC privileges at St. Vincent dePaul Tri Parish Community Pharmacy (PHY.004673-CH) and Medicine Shoppe of Bayou Vista (PHY.002662-IR).
- On June 15, 2015, Mr. Aron and Mr. Broussard concurred to grant a request from Anthony I. Laurent, Jr. (PST.011882) for dual PIC privileges at Interim LSU Hospital Pharmacy (PHY.006278) and the new University Medical Center at New Orleans (PHY-HOS permit still pending) for a limited period of time, to allow the new hospital to open and the current hospital to close, with the authority set to expire on August 31, 2015.
- On June 16, 2015, Mr. Aron and Mr. Fontenot concurred to grant a request from Robert A. Ray (PST.011612) for dual PIC privileges at Ray's Pharmacy (PHY.007049) in Alexandria and Ray's Pharmacy (PHY.001673) in Ball for a limited period of time with the authority set to expire on September 16, 2015.
- On July 8, 2015, Mr. Aron and Mr. Fontenot concurred to grant a request from Kristen M. Bradley (PST.019712) for dual PIC privileges at Genoa, a QoL Healthcare Company (PHY.006771-IR) in Marrero and Genoa, a QoL Healthcare Company (Permit Pending) in Metairie for a limited period of time with the authority set to expire on September 2, 2015.
- On July 28, 2015, Mr. Aron and Mr. Fontenot concurred to grant a request from Anne-Marie T. Karp (PST.014841) for dual PIC privileges at H & L Pharmacy (PHY.006251-IR) in New Orleans and CyberHealth Inc. d/b/a CH Pharmacy (Permit Pending) in New Orleans for a limited period of time with the authority set to expire 90 days from the date of issuance of the pharmacy permit to CH Pharmacy.

2. Special Work Permits for military-trained applicants and their spouses

LAC Title 46: LIII §904 authorizes the Board to provide preferential licensing procedures for military-trained applicants and their spouses. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

3. Special Work Permits

Board Policy I.A.7 permits the Executive Director to issue Special Work Permits to document the resurrection of expired non-renewable credentials and for other purposes as authorized by the Board. The policy requires the concurrence of the President, as well as notice to the Board at its next meeting. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

- On May 14, 2015, Mr. Aron and Mr. Broussard concurred to grant a request from Lindy Aultman. She had previously obtained PTC.020797 which will expire on June 17, 2016.

She will run out of time to complete the 600 hours. Should she pass PTCB by July 1, 2016, she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

- On May 14, 2015, Mr. Aron and Mr. Broussard concurred to grant a request from Brandie Book. She had previously obtained PTC.019183 which expired on February 24, 2014. She had gotten discouraged and given up, but has now changed her outlook. Should she pass PTCB by July 1, 2015, she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.
- On May 19, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Darya Mechelle Dugas. She had previously obtained PTC.020680 which expired on May 13, 2015. Should she pass PTCB by November 1, 2015, she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.
- On May 21, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Cyntiara Jamescia Loyell. She had previously obtained PTC.018712 which expired on October 9, 2013. Should she pass PTCB by November 1, 2015, she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.
- On May 22, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Ann Marie Eddie. She had previously obtained PTC.020029 which expired on November 14, 2014. She is PTCB-certified and was issued a Special Work Permit to earn the required hours.
- On May 29, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Kristin Nichelle Fairley. She had previously obtained PTC.019994 which expired on November 8, 2014. She is PTCB-certified and was issued a Special Work Permit to earn the required hours.
- On May 29, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Amanda Renee Walker. She had previously obtained PTC.017372 which expired on September 14, 2012. She is PTCB-certified and was issued a Special Work Permit to earn the required hours.
- On May 29, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Melinda Marie Turner. She had previously obtained PTC.018721 which expired on October 9, 2013. Should she pass PTCB by November 1, 2015, she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.
- On June 2, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Ingrid Enola Grant. She had previously obtained PTC.013864 which expired on October 17, 2009. Should she pass PTCB by December 1, 2015, she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.
- On June 8, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Erica Monique Mason. She had previously obtained PTC.020427 which expired on March 3, 2015. She is PTCB-certified and received a Special Work Permit valid until March 3, 2016 to earn her remaining hours of practical experience.
- On June 8, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Jennifer Noel Saunier. She had previously obtained PTC.016940 which expired on April 26, 2012. Should she pass PTCB by December 1, 2015, she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.
- On June 9, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Ariel Nicole Hollier. She had previously obtained PTC.020467 which expired on March 10, 2015. Should she pass PTCB by December 1, 2015, she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.
- On June 12, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Angelica Jasmine Cooper. She had previously obtained PTC.020422 which expired on February 28, 2015. She is PTCB-certified and received a Special Work Permit valid until June 12, 2016 to earn her remaining hours of practical experience.
- On June 15, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Crystal Deon Simmons. She had previously obtained PTC.020781 which expired on June 11, 2015. Should she pass PTCB by December 1, 2015, she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.
- On June 16, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Angel Ameia Johnson. She had previously obtained PTC.020041 which expired on November 15, 2014. Should she pass PTCB by December 1, 2015, she is authorized to receive a

- Special Work Permit for one year to earn 600 hours of practical experience.
- On June 18, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Tabitha Nicole Duhon. She had previously obtained PTC.020751 which expired on June 2, 2015. She is PTCB-certified and received a Special Work Permit valid until June 18, 2016 to earn her remaining hours of practical experience.
 - On June 23, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Kashena Lanell Blakes. She had previously obtained PTC.019372 which expired on April 24, 2014. Should she pass PTCB by December 1, 2015, she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.
 - On June 23, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Cherkeither LaShon Singleton. She had previously obtained PTC.020662 which expired on May 6, 2015. She is PTCB-certified and received a Special Work Permit valid until June 23, 2016 to earn her remaining hours of practical experience.
 - On June 24, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Bertha Alicia Guillen. She had previously obtained PTC.018625 which expired on May 11, 2012. Should she pass PTCB by December 1, 2015, she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.
 - On June 29, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from La'Sondra Sharnae Jackson. She had previously obtained PTC.018521 which expired on August 28, 2013. Should she pass PTCB by December 1, 2015, she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.
 - On July 7, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Kristen Nicole Meredith. She had previously obtained PTC.018645 which expired on September 27, 2013. Should she pass PTCB by January 1, 2016, she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.
 - On July 7, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Natalie Nicole Louviere. She had previously obtained PTC.015816 which expired on June 7, 2011. Should she pass PTCB by January 1, 2016, she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.
 - On July 7, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Angelica Denise James. She had previously obtained PTC.020424 which expired on March 3, 2015. Should she pass PTCB by January 1, 2016, she is authorized to receive a Special Work Permit for one year to earn her remaining hours of practical experience.
 - On July 8, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Crystal Craig. She had previously obtained PTC.013450 which expired on May 8, 2009. She is PTCB-certified and received a Special Work Permit valid until July 8, 2016 to earn 600 hours of practical experience.
 - On July 8, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Monica Morgan. She had previously obtained PTC.013608 which expired on June 27, 2009. Should she pass PTCB by January 1, 2016, she is authorized to receive a Special Work Permit for one year to earn her remaining hours of practical experience.
 - On July 9, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Dana Deserae Calhoun. She had previously obtained PTC.019147 which expired on February 15, 2014. Should she pass PTCB by January 1, 2016, she is authorized to receive a Special Work Permit for one year to earn her remaining hours of practical experience.
 - On July 10, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Chelsey Lynn Bonin. She had previously obtained PTC.019573 which expired on July 4, 2014. She is PTCB-certified and was issued a Special Work Permit for one year to earn her 600 hours of practical experience.
 - On July 10, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Gloria Inez Green. She had previously obtained PTC.020749 which expired on June 2, 2015. Should she pass PTCB by January 1, 2016, she is authorized to receive a Special Work Permit for one year to earn her remaining hours of practical experience.
 - On July 13, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Hina Nasir Khan. She had previously obtained PTC.017222 which expired on July 25, 2012. She is PTCB-certified and was issued a Special Work Permit for one year to earn her 600 hours of practical experience.
 - On July 13, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Monique

Lashown Davis. She had previously obtained PTC.017289 which expired on August 17, 2012. She is PTCB-certified and was issued a Special Work Permit for one year to earn her 600 hours of practical experience.

- On July 17, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Tawiania Lechelle Simpson. She had previously obtained PTC.015096 which expired on November 26, 2010. Should she pass PTCB by January 1, 2016, she is authorized to receive a Special Work Permit for one year to earn her remaining hours of practical experience.
- On July 17, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Chandelle Shante Hudson. She had previously obtained PTC.018960 which expired on December 14, 2013. Should she pass PTCB by January 1, 2016, she is authorized to receive a Special Work Permit for one year to earn her 600 hours of practical experience.
- On July 17, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Kimberly Shanise Broussard. She had previously obtained PTC.014531 which expired on May 5, 2010. Should she pass PTCB by January 1, 2016, she is authorized to receive a Special Work Permit for one year to earn her 600 hours of practical experience.
- On July 17, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Lacy Lynn Webre. She had previously obtained PTC.015867 which expired on December 23, 2009. Should she pass PTCB by January 1, 2016, she is authorized to receive a Special Work Permit for one year to earn her 600 hours of practical experience.
- On July 21, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Ronneshia Vonche' Bradford. She had previously obtained PTC.019216 which expired on March 7, 2014. Should she pass PTCB by January 1, 2016, she is authorized to receive a Special Work Permit for one year to earn her 600 hours of practical experience.
- On July 27, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Cornell Louise George. She had previously obtained PTC.015598 which expired on March 28, 2011. Should she pass PTCB by January 1, 2016, she is authorized to receive a Special Work Permit for one year to earn her 600 hours of practical experience.
- On July 27, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Elizabeth Monique Johnson. She had previously obtained PTC.014593 which expired on May 17, 2010. Should she pass PTCB by January 1, 2016, she is authorized to receive a Special Work Permit for one year to earn her 600 hours of practical experience.
- On July 28, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Angela Mashelle Thomas. She had previously obtained PTC.015956 which expired on July 25, 2011. Should she pass PTCB by January 1, 2016, she is authorized to receive a Special Work Permit for one year to earn her 600 hours of practical experience.
- On July 28, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from LaShawn Nicole Bonnet. She had previously obtained PTC.012909 which expired on December 10, 2008. Should she pass PTCB by January 1, 2016, she is authorized to receive a Special Work Permit for one year to earn her 600 hours of practical experience. This will be her last opportunity to do so as she was previously given the same opportunity and failed to follow through with those directives.
- On July 29, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Dinetria Mone'e Adams. She had previously obtained PTC.020426 which expired on March 3, 2015. Should she pass PTCB by January 1, 2016, she is authorized to receive a Special Work Permit for one year to earn her 600 hours of practical experience.
- On July 30, 2015, Mr. Aron and Mr. Finalet concurred to grant a request from Martha Isabel Williams. She had previously obtained PTC.010887 which expired on March 17, 2010. She is PTCB-certified and was issued a Special Work Permit for one year to earn her 600 hours of practical experience.

Louisiana Board of Pharmacy - Compliance Division
Statistical Summary for Fiscal Year 2014-2015

Individual Performance Data

	<i>Inspections</i>			<i>Investigations</i>		
	<u>CDS</u>	<u>Rx</u>	<u>Total</u>	<u>Cases Assigned</u>	<u>Audits Completed</u>	<u>Reports Submitted</u>
Aaron, Cary D.						
1st Qtr.	9	63	72	7	0	15
2nd Qtr.	17	44	61	6	1	3
3rd Qtr.	39	50	89	5	0	8
4th Qtr.	11	53	64	4	1	3
<i>Total</i>	<i>76/130</i>	<i>210/219</i>	<i>286/349</i>	<i>22</i>	<i>2</i>	<i>29</i>
Completion Rate:	58%	96%	82%			
Collins, Stephen L.						
1st Qtr	3	47	50	16	0	13
2nd Qtr	15	54	69	4	0	1
3rd Qtr	5	44	49	8	0	2
4th Qtr	2	102	104	6	0	0
<i>Total</i>	<i>25/126</i>	<i>247/332</i>	<i>272/458</i>	<i>34</i>	<i>0</i>	<i>16</i>
Completion Rate:	20%	75%	59%			
Savoie, Huey J.						
1st Qtr	7	50	57	6	0	33
2nd Qtr	26	96	122	3	0	7
3rd Qtr	32	100	132	4	0	2
4th Qtr	12	73	85	13	0	5
<i>Total</i>	<i>77/103</i>	<i>319/332</i>	<i>396/435</i>	<i>26</i>	<i>0</i>	<i>47</i>
Completion Rate:	75%	96%	91%			
Trisler, Rayland M.						
1st Qtr	19	20	39	4	0	10
2nd Qtr	23	19	42	7	0	4
3rd Qtr	20	50	70	3	0	3
4th Qtr	12	48	60	4	0	1
<i>Total</i>	<i>74/86</i>	<i>137/224</i>	<i>211/310</i>	<i>18</i>	<i>0</i>	<i>18</i>
Completion Rate:	86%	61%	68%			
Whaley, Benjamin S.						
1st Qtr	3	32	35	6	0	21
2nd Qtr	10	53	63	12	1	15
3rd Qtr	14	57	71	14	1	7
4th Qtr	13	41	54	9	0	16
<i>Total</i>	<i>40/161</i>	<i>183/378</i>	<i>223/539</i>	<i>41</i>	<i>2</i>	<i>59</i>
Completion Rate:	25%	48%	41%			
Fontenot, M. Joseph						
1st Qtr	0	0	0	11	0	11
2nd Qtr	0	0	0	7	0	3
3rd Qtr	0	0	0	3	0	5
4th Qtr	0	0	0	15	0	2
<i>Total</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>36</i>	<i>0</i>	<i>21</i>
Finalet, Carlos M.						
1st Qtr	0	0	0	34	0	19
2nd Qtr	0	0	0	45	0	38
3rd Qtr	0	0	0	159	0	44
4th Qtr	0	0	0	43	0	37
<i>Total</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>281</i>	<i>0</i>	<i>138</i>
Broussard, Malcolm J.						
1st Qtr	0	0	0	8	0	3
2nd Qtr	0	0	0	5	0	8
3rd Qtr	0	0	0	1	0	3
4th Qtr	0	0	0	8	0	7
<i>Total</i>	<i>0</i>	<i>0</i>	<i>0</i>	<i>22</i>	<i>0</i>	<i>21</i>
Agency Summary						
1st Qtr	41	212	253	92	0	125
2nd Qtr	91	266	357	89	2	79
3rd Qtr	110	301	411	197	1	74
4th Qtr	50	317	367	102	1	71
TOTAL	292/606	1096/1485	1388/2091	480	4	349
Completion Rate	48%	74%	66%			

Louisiana Board of Pharmacy - Compliance Division
 Statistical Summary for Fiscal Year 2014-2015

Summary of Investigations and Adjudications

Number of Cases Pending from Prior Fiscal Year(s)	252
Number of Complaints Received during Current Fiscal Year:	404
Number of Complaints Closed during Current Fiscal Year:	442
Number of Complaints Pending at End of Fiscal Year:	214

Disposition of Closed Complaints:

Withdrawn	18	
No violations found	83	
Administrative/Field corrections	113	
Referred to another agency	7	
Administrative sanction	21	
Termination of previously imposed probationary periods	15	
Referred to appropriate Board Committee	<u>185</u>	
	442	Total

Committee Action on Referrals:

31	Case dismissed or took no action
125	Voluntary Consent Agreement
28	Assessment
2	Denial / Refusal to Issue
5	Letter of Warning
14	Letter of Reprimand
15	Voluntary Surrender
16	Probation
2	Suspension
14	Revocation
29	Other decisions
<u>29</u>	Formal Hearing
185	
2	Denial / Refusal to Issue
1	Probation
23	Suspension
3	Revocation

Analysis of Adjudications by Type of Credential

	<u>PST</u>	<u>PNT</u>	<u>CPT</u>	<u>PTC</u>	<u>PHY</u>	<u>CDS</u>	<u>TOTAL</u>
Denial / Refusal to Issue	2	0	0	2	1	0	5
Reinstatement	15	0	8	0	0	1	24
Modification of Previous Orders	6	0	0	0	0	0	6
Assessment	0	0	4	0	26	0	30
Letter of Warning	0	0	0	0	4	0	4
Letter of Reprimand	9	0	0	0	1	0	10
Voluntary Surrender	7	0	7	0	0	2	16
Probation	3	0	3	0	3	0	9
Suspension	1	0	1	1	0	20	23
Revocation	0	0	9	4	4	0	17
TOTAL	43	0	32	7	39	23	144

Louisiana Board of Pharmacy - Compliance Division
Statistical Summary - Cumulative Data

	FY <u>02-03</u>	FY <u>03-04</u>	FY <u>04-05</u>	FY <u>05-06</u>	FY <u>06-07</u>	FY <u>07-08</u>	FY <u>08-09</u>	FY <u>09-10</u>	FY <u>10-11</u>	FY <u>11-12</u>
Summary of Complaint Investigations										
Complaints Pending from Prior Year(s)	46	96	132	124	98	82	112	140	127	197
Complaints Received During Year	355	315	273	250	239	280	519	356	432	349
Complaints Closed During Year	305	279	281	276	255	250	491	369	362	389
Complaints Pending at Year End	96	132	124	98	82	112	140	127	197	157
Disposition of Closed Complaints										
Withdrawn	20	11	7	4	10	3	23	16	26	23
No violations found	36	46	31	36	30	39	49	41	58	51
Field/administrative corrections	25	34	47	70	40	73	65	76	54	83
Referred to another agency	1	1	3	7	11	2	6	7	5	6
Administrative sanction	89	78	73	37	34	38	255	72	42	46
Termination of probationary period										
Referred for Board action	<u>134</u>	<u>109</u>	<u>120</u>	<u>122</u>	<u>130</u>	<u>95</u>	<u>93</u>	<u>157</u>	<u>177</u>	<u>180</u>
<i>Total</i>	305	279	281	276	255	250	491	369	362	389
Committee Action on Referrals										
Cases Dismissed	43	17	16	25	20	19	38	24	39	20
Voluntary Consent Agreements	79	80	91	90	97	67	47	124	132	150
Assessment only	11	11	7	2	4	38	25	18	10	12
Denial / Refusal to Issue								1	9	1
Letter of Warning	20	14	12	26	18	7	3	5	6	3
Letter of Reprimand	13	5	19	12	18	13	13	30	35	17
Voluntary Surrender	9	10	23	25	17	6	8	34	23	21
Probation	9	17	10	13	16	20	5	17	21	31
Suspension	6	10	4	1	5	10	5	2	2	10
Revocation	11	13	16	11	19	9	4	17	11	28
Other decisions									15	27
Formal Hearings	12	12	13	7	13	9	8	9	6	10
Assessment only	0	0	0	0	1	3	0	0	0	0
Denial / Refusal to Issue	0	0	0	0	0	0	0	0	0	0
Letter of Warning	0	2	0	0	0	0	0	0	0	0
Letter of Reprimand	0	0	1	0	0	0	0	0	0	0
Probation	0	1	0	2	2	0	0	0	1	0
Suspension	4	2	2	0	3	3	0	3	2	2
Revocation	8	7	10	5	7	4	8	6	3	8
Interlocutory Hearings	0	2	3	0	1	0	0	0	0	0
Summary Suspension	0	0	2	0	1	0	0	0	0	0

Louisiana Board of Pharmacy - Compliance Division
Statistical Summary - Cumulative Data

	FY <u>12-13</u>	FY <u>13-14</u>	FY <u>14-15</u>	<u>Totals</u>
Summary of Complaint Investigations				
Complaints Pending from Prior Year(s)	218	255	252	1879
Complaints Received During Year	392	479	404	4,643
Complaints Closed During Year	355	482	442	4,536
Complaints Pending at Year End	255	252	214	1,986
Disposition of Closed Complaints				
Withdrawn	25	13	18	199
No violations found	32	86	83	618
Field/administrative corrections	67	107	113	854
Referred to another agency	3	11	7	70
Administrative sanction	24	15	21	824
Termination of probationary period	24	27	15	39
Referred for Board action	<u>180</u>	<u>223</u>	<u>185</u>	<u>1905</u>
<i>Total</i>	<u>355</u>	<u>482</u>	<u>442</u>	<u>4,509</u>
Committee Action on Referrals				
Cases Dismissed	21	41	31	354
Voluntary Consent Agreements	157	155	125	1394
Assessment only	9	18	28	193
Denial / Refusal to Issue	5	5	2	23
Letter of Warning	3	13	5	135
Letter of Reprimand	19	7	14	215
Voluntary Surrender	21	25	15	237
Probation	29	31	16	235
Suspension	22	6	2	85
Revocation	19	5	14	177
Other decisions	30	46	29	147
Formal Hearings	2	27	29	157
Assessment only	0	0	0	4
Denial / Refusal to Issue	0	3	2	5
Letter of Warning	0	0	0	2
Letter of Reprimand	0	0	0	1
Probation	0	0	1	7
Suspension	1	20	23	65
Revocation	1	4	3	74
Interlocutory Hearings	0	0	0	6
Summary Suspension	0	0	0	3



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Annual Report

Fiscal Year 2014-2015

July 1, 2015

Mission

Created by the Louisiana Legislature in 1888, the mission of the Louisiana Board of Pharmacy remains unchanged over a century later: to regulate the practice of pharmacy in such a manner as to protect the public health, safety, and welfare of the citizens of Louisiana. Toward that goal, the Louisiana Pharmacy Practice Act specifically authorizes the Board to restrict the practice of pharmacy to qualified persons, as well as to control and regulate all persons and sites that sell drugs or devices or provide pharmacy care services to consumers in this state.

Membership

The Board is composed of seventeen members: two pharmacists from each of eight districts and one public member at large. The district representatives are nominated by pharmacists, appointed by the governor, confirmed by the state senate, and serve six year terms. The public member is selected by, and serves at the pleasure of, the governor. The current members of the Board are:

District 1	Diane G. Milano, Richard M. Indovina, Jr.
District 2	Jacqueline L. Hall, Deborah H. Simonson
District 3	Blake P. Pitre, Richard A. Soileau
District 4	Clovis S. Burch, Rhonny K. Valentine
District 5	Carl W. Aron, T. Morris Rabb
District 6	Ronald E. Moore, Pamela G. Reed
District 7	Ryan M. Dartez, Chris B. Melancon
District 8	Brian A. Bond, Marty R. McKay
Public	Don L. Resweber

Licensure

In order to facilitate the restriction of practice to qualified persons, the Board has established educational, experiential, and examination requirements for licensure. As authorized by the legislature, the Board has contracted its high-stakes examination procedures with professional testing services.

A. Examinations for Pharmacists

The North American Pharmacist Licensure Examination (NAPLEX) and the Multistate Pharmacy Jurisprudence Examination (MPJE) are administered by the National Association of Boards of Pharmacy (NABP). These computer adaptive tests are administered in continuous window opportunities at multiple sites throughout the state. A minimum scaled score of 75 is required on each test to qualify for pharmacist licensure. The results for all Louisiana-based NAPLEX and MPJE candidates from ULM School of Pharmacy and Xavier University – College of Pharmacy in Calendar Year 2014 are summarized below:

NAPLEX

	Jan – Apr		May – Aug		Sept – Dec	
	<u>ULM</u>	<u>XU</u>	<u>ULM</u>	<u>XU</u>	<u>ULM</u>	<u>XU</u>
Total No. of Candidates	1	18	68	138	11	27
Mean Scaled Score – School	101	71	95	96	82	80
Mean Scaled Score – State	74	74	96	96	81	81
Mean Scaled Score – National	80	80	102	102	89	89
School Pass Rate [%]	100	50	90	93	64	70
State Pass Rate	54	54	91	91	71	71
National Pass Rate	63	63	94	94	80	80

MPJE

	Jan – Apr		May – Aug		Sept – Dec	
	<u>ULM</u>	<u>XU</u>	<u>ULM</u>	<u>XU</u>	<u>ULM</u>	<u>XU</u>
Total No. of Candidates	5	12	62	82	6	43
Mean Scaled Score – School	79	76	81	78	79	77
Mean Scaled Score – State	80	80	80	80	80	80
Mean Scaled Score – National	81	81	83	83	81	81
School Pass Rate [%]	100	50	95	77	83	65
State Pass Rate	83	83	86	86	83	83
National Pass Rate	88	88	93	93	89	89

B. Examinations for Technicians

The Pharmacy Technician Certification Board (PTCB) administers a national certification examination; this computer adaptive test is administered in continuous window opportunities at multiple sites throughout the state. A minimum scaled score of 75 is required to successfully complete the examination. The Louisiana Board of Pharmacy accepts the PTCB examination score result as part of the licensure requirements for pharmacy technicians. The results for all Louisiana-based PTCB candidates for Calendar Year 2014 are summarized here:

No. of State Candidates	1,198
State Pass Rate [%]	46
No. of National Candidates	54,245
National Pass Rate [%]	76

C. Census Data

At the close of the fiscal year on June 30, 2015, a review of our records yielded the following census information:

	<u>2015</u>	<u>2014</u>	<u>2013</u>
• Pharmacy Program			
1. Pharmacists			
> Number of active licenses	8,108	7,841	7,758
> Number of licensees within the state	5,596	5,329	5,148
2. Pharmacy Interns			
> Number of active registrations	1,097	1,081	1,073

3.	Pharmacy technicians			
>	Number of active certificates	6,726	6,603	5,864
4.	Pharmacy technician candidates			
>	Number of active registrations	1,981	1,907	1,695
5	Pharmacies			
>	Number of active permits	1,954	1,872	1,784
	- Community – Independent	598	593	575
	- Community – Chain	649	619	597
	- Hospital	174	176	172
	- Institutional	21	23	25
	- Nuclear	14	15	15
	- Charitable	12	12	12
	- Penal	2	2	0
	- Nonresident	484	432	387
6.	Equipment Permits			
>	Emergency drug kit (EDK)	484	474	431
>	Automated medication systems (AMS)	812	451	638
>	Durable medical equipment (DME)	603	490	378
7.	Special Activity Credentials			
>	CDTM Registration	52	41	41
>	Med. Administration Registration	2,383	2,037	1,617
>	Special Work Permits	54	38	126
	<u>Subtotal of Credentials in Pharmacy Program</u>	<i>24,254</i>	<i>22,865</i>	<i>21,405</i>

2015 2014 2013

● CDS Program

1.	Animal Control Shelter	1	1	1
2.	Automated Medication System (AMS)	30	28	0
3.	Advanced Practice RN (APRN)	1,954	1,479	1,103
4.	Ambulatory Surgical Center (ASC)	87	89	85
5.	Correctional Center	4	6	5
6.	Dentist	2,133	2,123	1,902
7.	Drug Detection / Canine	12	12	10
8.	Distributor	327	324	273
9.	Podiatrist	142	133	118
10.	Veterinarian	1,045	1,002	852
11.	Dialysis Center	0	4	3
12.	Emergency Medical Center	26	22	17
13.	Emergency Medical Service	49	50	45
14.	Animal Euthanasia Technician	28	29	27
15.	Hospital	277	278	268
16.	Laboratory	13	13	12
17.	Physician	12,125	11,915	10,698
18.	Medical Clinic	81	89	82
19.	Manufacturer	42	42	45
20.	Miscellaneous	11	13	12
21.	Medical Psychologist	82	78	69

22.	Optometrist	316	309	279
23.	Pharmacies	1,403	1,387	1,370
24.	Physician Assistant	487	449	344
25.	Sales Representative	0	0	7
26.	Researcher	113	113	98
27.	Rural Health Clinic	11	12	11
28.	Substance Abuse Clinic	10	9	9
	<u>Subtotal of Credentials in CDS Program</u>	20,809	20,009	17,745
	<u>Total Credentials under Management</u>	45,063	42,874	39,150

D. *New Credentials*

During the past fiscal year, the Board issued 5,497 new credentials in the Pharmacy Program and 1,670 new credentials in the CDS Program. Of note within the Pharmacy Program, we issued 476 new pharmacist licenses, 300 new pharmacy intern registrations, and 565 new pharmacy technician certificates during the past fiscal year. Of note within the CDS Program, we issued new CDS licenses to 710 physicians, 516 advanced practice registered nurses, and 82 dentists.

E. *License Transfer (Reciprocity)*

Persons already licensed as a pharmacist by any other state (except California) who wish to obtain a license in Louisiana must successfully complete the MPJE as well as the application and criminal background check. Of the 476 new pharmacist licenses issued this past fiscal year, 269 were issued subsequent to successful completion of the reciprocity process.

Compliance

A. *Enforcement*

In order to control and regulate the practice of pharmacy in Louisiana, the Board employs five pharmacist compliance officers to perform routine inspections and special investigations throughout the year in all places under the Board's jurisdiction. Besides the routine inspections, site visits for permit changes, and other calls for assistance, the compliance officers completed 442 investigations during the last fiscal year: 18 of the original complaints were withdrawn, 15 resulted from termination of previously imposed probationary periods, 83 were determined to be without violation, 7 cases were referred to other agencies, 113 resulted in field/administrative corrections, 21 resulted in administrative sanctions, and 185 cases were referred to the Board's committees. The committees took no action in 31 of their cases, issued approvals for 29 non-disciplinary petitions, and recommended voluntary consent agreements for 125 cases. Of that number, all but 29 accepted the proposed discipline. The remaining 29 respondents did not, and they were referred for formal administrative hearings.

Compliance officers coordinate other investigative activities with a wide range of agencies, including local police departments, parish sheriff departments, other state regulatory and law enforcement agencies, and federal agencies such as the Drug Enforcement Administration, the Food and Drug Administration, and the Consumer Product Safety Commission. Though the compliance officers utilize the educational approach as the fundamental mechanism to achieve compliance, certain circumstances warrant formal board action.

B. Adjudications

During the past fiscal year, the Board conducted four administrative hearings and levied formal disciplinary action against several credentials. A summary of that activity is presented here:

<i>Sanction</i>	<u>Pharmacist</u>	<u>Intern</u>	<u>Technician</u>	<u>Candidate</u>	<u>Permit</u>	<u>CDS</u>
Assessment	0	0	4	0	26	0
Letter of Warning	0	0	0	0	4	0
Letter of Reprimand	9	0	0	0	1	0
Voluntary Surrender	7	0	7	0	0	2
Probation	3	0	3	0	3	0
Suspension	1	0	1	1	0	20
Revocation	0	0	9	4	4	0
Refused to Credential	2	0	0	2	1	0

C. Practitioner Recovery Program

The Board established its program in 1988 to assist practitioners obtain treatment for their impairment, maintain their recovery, and assist their re-entry into professional practice. As of July 1, 2015 there were 49 pharmacists and two pharmacy technicians actively engaged in the recovery program. They surrendered their credentials while in treatment; following treatment and upon favorable recommendation by board-certified addiction medicine specialists, they applied for the reinstatement of their credentials. The Board reinstated their credentials on probation, and the licensees practice under various restrictions designed to monitor their re-entry to professional practice. In addition, the credentials for 42 pharmacists, three interns, 15 technicians, and four technician candidates were still on active suspension for impairment reasons.

Board Activity

A. Regulatory

The Board's Regulation Revision Committee is tasked with the continuous review of the Board's rules and their revision as appropriate. The committee initiated and the Board completed several regulatory projects in the previous fiscal year.

- Pharmacy Records, amending LAC 46:LIII.Chapters 11 and 15;
- Pharmacy Compounding, amending LAC 46:LIII.Chapter 25;
- Prescriptions, amending LAC 46:LIII.Chapter 25;
- Special Event Pharmacy Permit, amending LAC 46:LIII.Chapter 24;
- Dispenser Reporting to Prescription Monitoring Program, amending LAC 46:LIII.Chapter 29; and
- Expiration Date of Schedule II Prescriptions, amending LAC 46:LIII.Chapter 27.

The Board has three additional regulatory projects not yet completed; the progress of these projects may be monitored at the Board's website:

- Electronic Product Verification, amending LAC 46:LIII.Chapters 12 and 15;
- Compounding for Office Use for Veterinarians, amending LAC 46:LIII.Chapter 25; and

- Electronic Signature on Fax Prescriptions; amending LAC 46:LIII.Chapter 25.

B. Legislative

During the 2015 regular session, the Board sponsored two bills, both of which were successful. Act 22 amended the prescription monitoring program law to harmonize the state's restriction on civil discovery of program information with other states' laws, to improve the ability of the Louisiana program to share information with other states. Act 189 amended the state list of controlled substances to add new prescription drugs added to the federal list of controlled substances since the last legislative session.

C. Operations

We have also completed four years of service with our website's content management system and its mass communication capabilities. We have increased the frequency of communications to our licensees through the use of targeted email, alerts, and bulletins. Through avoided postage and labor costs of mass snail mail notices, we have already recouped the cost of our investment and will continue our savings going forward. In response to requests from users of mobile communication devices, we have updated our website to be responsive to access requests from such mobile devices.

Finally, the Board continued its operation of Louisiana's Prescription Monitoring Program (PMP). The monthly average of the number of prescription transactions reported to the program's database, as well as the average number of queries per day, continue to increase. The contract for the program vendor reached the end of its five year life, and the contract was released for public bid. The new vendor is Optimum Technology, Inc. based in Columbus, OH, an experienced state PMP program operator. Since the program is required to file an annual report to the legislature, we have appended that report to this one to facilitate its separation.

D. Physical Plant

The Board moved to its current location in May 2011. We continue to make minor improvements to the building and grounds. The loan for the purchase of the building will be retired before the end of Calendar Year 2015.

Board Office

The Board currently employs 17 people on a full-time basis in a variety of professional, technical, and clerical roles; the Board also supports the local Cooperative Office Education (COE) program in Baton Rouge area high schools by hiring high school senior students on a temporary basis. The physical and mailing address of the board office is:

Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, LA 70809-1700
Telephone (225) 925-6496
Telecopier (225) 925-6499

The board's website address is www.pharmacy.la.gov and general email is received at info@pharmacy.la.gov.

Conclusion

The board has had an active year on several fronts, and all of these activities have contributed to the overall mission of the board. The officers and members of the board, as well as the entire office staff, are committed to achieving our goal of protecting the public's health, safety and welfare through appropriate regulation of the practice of pharmacy in this state. We understand that public service is a privilege, and we endeavor to render that service honorably.

Prepared by:
Malcolm J Broussard
Executive Director



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Prescription Monitoring Program Annual Report

Fiscal Year 2014-2015

July 1, 2015

Introduction

Act 676 of the 2006 Louisiana Legislature authorized the development, implementation, operation, and evaluation of an electronic system for the monitoring of controlled substances and other drugs of concern that are dispensed within the state or dispensed by a licensed pharmacy outside the state to an address within the state. The goal of the program is to improve the state's ability to identify and inhibit the diversion of controlled substances and drugs of concern in an efficient and cost-effective manner and in a manner that shall not impede the appropriate utilization of these drugs for legitimate medical purposes.

The Prescription Monitoring Program (PMP) was implemented in August 2008. We notified pharmacies of their requirement to report all eligible prescription transactions to the program, and further, required them to report all historical data retroactive to June 1, 2008 no later than December 31, 2008. In December 2008, the Board notified all prescribers and dispensers wishing to acquire direct access privileges of the requirement to complete the web-based orientation program prior to receiving their access privileges. The web portal to the program database was opened to queries on January 1, 2009, and the program remains fully functional.

Advisory Council

The enabling legislation created the PMP Advisory Council to assist the Board in the development and operation of the program. The Board shall seek, and the advisory council shall provide, information and advice regarding: (1) which controlled substances should be monitored, (2) which drugs of concern demonstrate a potential for abuse and should be monitored, (3) design and implementation of educational courses required by the PMP law, (4) methodology to be used for analysis and interpretation of prescription monitoring information, (5) design and implementation of a program evaluation component, and (6) identification of potential additional members to the advisory council. The original legislation specifically identified the 25 organizations named to the council and further, named the leader of the organization but permitted the leader to name a designee to function in the absence of the appointee. The organizations represented on the council include the licensing agencies for the prescribers and dispensers, the professional membership organizations for the prescribers and dispensers, organizations representing federal, state, and local law enforcement agencies, as well as representatives from the legislature. The advisory council has elected its own leadership, adopted policies and procedures for its operations, and meets on a quarterly basis.

Program Metrics

The data on the following page provides summary data for the operational aspects of the program – number of prescription transactions reported to the program database, number of prescribers and dispensers registered to access the program data, the number of queries performed by those authorized prescribers and dispensers as well as law enforcement agencies and regulatory agencies.

Louisiana Board of Pharmacy
Prescription Monitoring Program

Calendar Year:	<u>2008</u>	<u>2009</u>	<u>2010</u>	<u>2011</u>	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>6/30/2015</u>	<u>Total</u>
Prescription Database:									
Transactions Reported (in Millions)	6.015	11.144	12.117	12.775	12.990	13.032	13.020	6.093	87.186
Access to Program Data:									
New prescribers registered		1,526	721	548	574	640	1093	453	5,555
New prescriber-delegates registered							473	342	815
New pharmacists registered		728	483	361	494	509	466	170	3,211
New pharmacist-delegates registered							143	126	269
Searches Performed by Users:									
Solicited by prescribers		235,985	368,376	496,270	650,514	842,139	942,733	578,347	4,114,364
Solicited by prescriber-delegates							26,993	93,655	120,648
Solicited by pharmacists		74,277	111,075	153,783	212,754	382,204	456,568	470,536	1,861,197
Solicited by pharmacist-delegates							3,954	17,257	21,211
Solicited by law enforcement		680	889	1,230	845	1,150	1,224	556	6,574
Solicited by regulatory agencies		833	1,401	1,612	1,584	1,364	1,675	785	9,254
Average queries per day		854	1,319	1,788	2,372	3,361	3,926	6,362	2,585

Legislative Mandates

The 2014 Legislature adopted a number of measures which will serve to improve the program. Beginning August 1, 2014, pharmacies and other dispensers will be required to report their eligible prescription transactions to the program database no later than the next business day following the date of dispensing, instead of the previous seven day allowance. In addition, the Board has recently completed the rulemaking process authorized by the 2013 Legislature that will allow authorized prescribers and dispensers to appoint delegates for the purpose of retrieving data from the program's database.

The 2015 Legislature also adopted a measure that will require prescribers of certain controlled substances for the treatment of certain conditions to access the patient's history in the program database prior to initiating such treatment. The same measure will require pharmacists dispensing certain controlled substances to certain patients to access the patient's history in the program database prior to dispensing such medications.

Outlook for Next Fiscal Year

The program continues to enroll new authorized users, and the daily average number of queries continues to increase. With assistance from the licensing agencies encouraging use of the program by their licensees, we hope to improve on the current 30% registration rate, as well as the daily query rate of approximately 3,000.

Conclusion

The program has completed approximately seven years of operation. Based on feedback from authorized users, it appears to represent an efficient and cost-effective use of resources. Data from the program suggests we have made some early contributions to the reduction of diversion of controlled substances. Our interstate collaborations have yielded high marks for our program design and operation. We look forward to fully developing the potential of our program to identify and inhibit the diversion of controlled substances in Louisiana.

We acknowledge the contributions from Ms. Danielle Meadors, our Administrative Coordinator, and Mr. Joseph Fontenot, Program Manager, for their operation of the program and the development of this report.

Prepared by:
Malcolm J. Broussard
Executive Director



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Multistate Pharmacy Jurisprudence Examination (MPJE™)

January 1 – April 30, 2015

School Reports
Interpretation of Scores
Frequency Distribution of Scaled Scores
Cumulative Record (since January 2000)

August 12, 2015

Multistate Pharmacy Jurisprudence Examination (MPJE™)

This computer adaptive competency assessment is administered by the National Association of Boards of Pharmacy (NABP). The examination blueprint is designed to assess the applicant's competency in federal and state laws relative to pharmacy practice and is therefore specific for a given state. The examination is administered via an open window process; applicants may schedule the examination at a local testing center at any time following approval by the state board and receipt of an Authorization to Test (ATT) document from NABP. Individual scores are available to applicants via secure web posting approximately 7-10 days following the examination. Summary reports are provided to the state boards on a calendar trimester basis.

Table of Contents

Current Trimester Report for ULM School of Pharmacy	03
Cumulative Report (since January 2000) for ULM School of Pharmacy	09
Current Trimester Report for Xavier College of Pharmacy	13
Cumulative Report (since January 2000) for Xavier College of Pharmacy	20



**Multistate Pharmacy Jurisprudence Examination® (MPJE®)
School Summary Report**

Test Window: January 1, 2015 - April 30, 2015

School Name: University Louisiana Monroe

This MPJE score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution. Tables 1 and 2 contain school-specific as well as national pass rate information.

School 1: Examinees testing in same state as respective college

School 2: Examinees testing in different states than respective college

Table 1 First Time Candidates

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	11	72.73	76.91	8.61
School 2	27	92.59	82.04	5.43
State	122	83.61	80.63	6.27
National	3806	91.72	82.14	5.72

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 2 All Candidates

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	13	76.92	76.85	7.86
School 2	29	93.10	81.90	5.43
State	145	80.69	79.81	6.21
National	4703	88.20	81.32	5.93

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 3 Candidate Summary Report

Test Window: January 1, 2015 - April 30, 2015

	Pass/Fail	Total Scaled Score	Test Date	Graduation Date	First Attempt	State
1	Pass	76	02/07/2015	12/06/2014	Y	LA
2	Pass	87	04/23/2015	05/10/2014	Y	LA
3	Pass	84	04/15/2015	05/10/2014	Y	ID
4	Pass	95	04/02/2015	05/10/2014	Y	TX
5	Pass	78	04/01/2015	05/10/2014	Y	LA
6	Pass	79	03/21/2015	05/10/2014	Y	LA
7	Pass	81	02/26/2015	05/10/2014	Y	LA
8	Pass	80	02/10/2015	05/10/2014	Y	LA
9	Pass	77	03/13/2015	05/11/2013	Y	MI
10	Pass	89	02/16/2015	05/11/2013	Y	AL
11	Pass	76	04/25/2015	05/19/2012	Y	TX
12	Pass	77	02/16/2015	05/19/2012	N	LA
13	Fail	73	01/09/2015	05/19/2012	Y	LA
14	Pass	81	03/26/2015	05/21/2011	Y	TN
15	Pass	77	02/12/2015	12/18/2010	Y	TX
16	Pass	90	04/25/2015	05/22/2010	Y	LA
17	Pass	85	01/10/2015	05/22/2010	Y	TX
18	Pass	76	03/26/2015	05/16/2009	Y	MI
19	Pass	82	03/13/2015	05/19/2007	Y	MA
20	Pass	88	04/28/2015	05/01/2005	Y	MS
21	Pass	84	01/16/2015	12/01/2000	Y	MI
22	Pass	82	02/25/2015	12/01/1998	Y	WV
23	Pass	76	04/02/2015	12/01/1997	Y	LA
24	Pass	82	04/21/2015	12/15/1995	Y	MI
25	Fail	72	04/06/2015	08/14/1994	Y	TN
26	Pass	81	04/20/2015	12/19/1992	Y	KY
27	Pass	82	03/30/2015	12/19/1992	Y	MI
28	Pass	87	03/23/2015	12/19/1992	Y	OK
29	Pass	79	02/28/2015	12/19/1992	Y	MD
30	Pass	76	02/05/2015	08/15/1992	N	LA
31	Pass	84	01/15/2015	05/16/1992	Y	TN
32	Pass	75	03/02/2015	05/19/1985	Y	NC
33	Pass	84	01/15/2015	05/18/1984	Y	NE
34	Pass	87	02/13/2015	05/10/1983	Y	SC
35	Pass	80	04/16/2015	05/15/1982	Y	MI
36	Pass	88	01/07/2015	05/14/1982	Y	MI
37	Pass	75	04/11/2015	03/18/1982	N	FL
38	Pass	86	03/27/2015	12/21/1977	Y	TX
39	Pass	85	03/19/2015	12/01/1974	N	MD
40	Fail	72	02/03/2015	12/01/1974	Y	MD
41	Fail	67	03/07/2015	12/01/1973	Y	LA
42	Fail	59	04/20/2015	05/19/1971	Y	LA

National Statistics for All Candidates

Mean Scaled Score: 81.32
Standard Deviation: 5.93
Range: 49 - 100
Passing Rate (%): 88.20

National Statistics for First-Time Candidates

Mean Scaled Score: 82.14
Standard Deviation: 5.72
Range: 53 - 100
Passing Rate (%): 91.72

The following tables are scaled score frequency distributions for MPJE® candidates.
 Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

Table 4 National Frequency Distribution of Scaled Scores

Based on Total Tests Administered (N = 4703)

Test Window: January 1, 2015 - April 30, 2015

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	1	0.0%
50 - 54	1	0.0%
55 - 59	2	0.1%
60 - 64	10	0.3%
65 - 69	92	2.3%
70 - 74	444	11.7%
75 - 79	1200	37.2%
80 - 84	1592	71.1%
85 - 89	989	92.2%
90 - 94	298	98.5%
95 - 100	69	100.0%

Table 5 National Frequency Distribution of Scaled Scores

Based on First-Time Candidates from ACPE-Accredited Programs (N = 3806)

Test Window: January 1, 2015 - April 30, 2015

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	0	0.0%
50 - 54	1	0.0%
55 - 59	1	0.1%
60 - 64	6	0.2%
65 - 69	49	1.5%
70 - 74	254	8.2%
75 - 79	883	31.4%
80 - 84	1350	66.9%
85 - 89	914	91.0%
90 - 94	277	98.2%
95 - 100	67	100.0%

Multistate Pharmacy Jurisprudence Examination (MPJE)

University of Louisiana at Monroe

	2000		2001		2002		2003	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	125	82	100	57	59	123	77	119
School Average Score:	83.27	82.76	80.84	81.37	80.17	80.41	78.57	80.04
State Average Score:	81.64	80.49	80.64	80.32	80.34	79.41	77.32	78.87
National Average Score:	82.24	81.75	82.25	81.51	90.78	79.85	79.92	79.33
School Pass Rate:	94.40	91.46	90.00	91.23	88.14	88.62	77.92	88.24
State Pass Rate:	89.89	86.25	87.84	90.00	92.00	85.98	72.88	84.67
National Pass Rate:	91.37	90.50	91.22	90.54	90.78	84.93	84.52	82.61
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	117	78	92	51	55	111	59	110
School Average Score:	83.67	83.14	80.89	81.78	80.22	80.58	79.31	80.22
State Average Score:	82.14	80.97	80.67	80.51	80.30	79.41	77.69	79.23
National Average Score:	82.55	82.05	82.59	81.86	82.08	80.19	80.34	79.76
School Pass Rate:	96.58	93.59	90.22	90.20	89.09	88.29	81.36	88.18
State Pass Rate:	92.59	87.32	88.06	89.77	91.49	86.32	75.00	86.55
National Pass Rate:	92.57	91.37	92.45	91.75	92.15	86.45	86.58	84.67

Multistate Pharmacy Jurisprudence Examination (MPJE)

University of Louisiana at Monroe

	2004		2005		2006		2007	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	62	110	59	146	68	111	50	151
School Average Score:	79.39	80.79	79.25	80.50	80.43	81.92	80.20	81.62
State Average Score:	78.58	80.03	80.50	80.03	80.01	81.34	80.15	81.47
National Average Score:	80.10	79.83	80.39	80.04	80.68	80.42	81.26	81.14
School Pass Rate:	91.94	91.82	89.83	87.67	88.24	92.79	90.00	92.05
State Pass Rate:	86.90	92.55	90.55	87.03	91.09	92.39	87.18	90.39
National Pass Rate:	85.63	84.75	86.57	85.69	87.25	87.82	89.38	89.78
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	52	104	55	132	60	102	43	140
School Average Score:	79.73	80.96	79.33	80.66	80.80	82.14	81.05	81.83
State Average Score:	79.04	80.11	80.71	80.29	80.24	81.52	80.59	81.84
National Average Score:	80.58	80.25	80.80	80.44	81.09	80.80	81.72	81.51
School Pass Rate:	92.31	92.31	89.09	87.12	91.67	94.12	95.35	93.57
State Pass Rate:	90.14	92.53	91.38	88.69	92.31	93.53	91.18	92.49
National Pass Rate:	88.16	86.87	88.51	87.51	89.41	89.34	91.43	91.24

Multistate Pharmacy Jurisprudence Examination (MPJE)

University of Louisiana at Monroe

	2008		2009			2010			2011		
	<u>Jan - Jun</u>	<u>Jul - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP											
No. of Candidates	61	137	42	120	36	38	104	35	5	71	12
Mean Scaled Score - School	81.26	81.99	80.95	82.58	80.75	81.47	82.14	81.89	82.60	82.73	83.83
Mean Scaled Score - State	81.33	81.34	79.57	81.69	80.35	81.37	80.88	81.64		81.01	80.41
Mean Scaled Score - National	81.59	81.27	80.29	82.39	80.25	80.45	82.51	80.57	80.27	82.23	80.46
School Pass Rate:	96.72	91.97	88.10	95.00	86.11	94.74	90.38	91.43	100.00	97.18	100.00
State Pass Rate:	91.75	91.05	81.03	94.52	85.92	90.00	92.64	95.79		89.91	90.99
National Pass Rate:	90.31	89.92	86.23	93.74	87.04	89.09	94.83	89.35	86.43	92.17	86.24
FIRST-TIME CANDIDATE GROUP											
No. of Candidates	58	127	37	117	34	34	96	30	5	66	11
Mean Scaled Score - School	81.52	82.13	81.30	82.56	81.09	82.12	82.67	82.33	82.60	83.08	84.18
Mean Scaled Score - State	81.53	81.62	79.69	81.76	80.98	82.07	80.93	82.07		81.52	81.14
Mean Scaled Score - National	81.97	81.57	80.75	82.58	80.63	80.82	82.67	80.94	81.17	82.86	81.76
School Pass Rate:	96.55	91.34	89.19	94.87	88.24	97.06	93.75	93.33	100.00	100.00	100.00
State Pass Rate:	92.31	91.95	80.77	94.34	89.66	93.44	92.92	97.56		94.06	94.32
National Pass Rate:	91.82	91.16	88.45	94.30	88.68	90.64	95.50	90.79	92.24	96.05	94.00

Multistate Pharmacy Jurisprudence Examination (MPJE)

University of Louisiana at Monroe

	2012			2013			2014			2015		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	4	126	87	47	94	30	32	122	39	42		
<i>* testing in same/different state</i>		72 / 54	11 / 34	11 / 36	40 / 54	2 / 28	5 / 27	62 / 60	6 / 33	13 / 29		
Mean Scale Score - School *	82.25	82.44/82.70	80.09/79.85	81.45/84.03	82.50/82.59	80.50/82.79	79.40/81.41	81.44/83.32	78.50/81.42	76.85/81.90		
<i>* testing in same/different state</i>												
Mean Scaled Score - State	81.18	80.91	79.62	81.33	80.82	80.43	80.36	80.18	80.13	79.81		
Mean Scaled Score - National	80.41	82.43	80.55	80.92	82.50	80.52	81.04	82.52	81.08	81.32		
School Pass Rate: *	100.00	97.22/90.74	90.91/85.29	100/97.22	95.00/98.15	100 / 92.86	100 / 85.19	95.16/96.67	83.33/87.88	76.92/93.10		
<i>* testing in same/different state</i>												
State Pass Rate:	90.41	90.69	81.61	93.98	90.51	85.21	82.52	86.08	82.69	80.69		
National Pass Rate:	84.54	92.76	86.85	87.18	92.98	87.01	87.62	93.28	88.50	88.20		
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	4	124	70	44	93	28	29	119	33	38		
<i>* testing in same/different state</i>		72 / 52	10 / 29	10 / 34	39 / 54	1 / 27	5 / 24	62 / 57	3 / 30	11 / 27		
Mean Scaled Score - School *	82.25	82.44/83.02	80.62/79.90	81.80/84.26	82.77/82.59	82.00/83.19	79.40/82.29	81.44/83.58	78.00/81.97	76.91/82.04		
<i>* testing in same/different state</i>												
Mean Scaled Score - State	81.75	81.03	80.21	81.90	81.03	81.08	81.05	80.62	81.13	80.63		
Mean Scaled Score - National	81.44	82.75	81.26	81.78	82.76	81.22	81.82	82.80	81.79	82.14		
School Pass Rate: *	100.00	97.22/92.31	89.66/90.00	100.00/97.06	97.44/98.15	100 / 96.30	100 / 91.67	95.16/98.25	66.67/90.00	72.73/92.59		
<i>* testing in same/different state</i>												
State Pass Rate:	93.22	91.03	85.71	97.22	91.88	87.29	85.88	89.29	84.96	83.61		
National Pass Rate:	89.13	93.94	89.60	91.08	93.95	90.04	90.85	94.34	90.87	91.72		



**Multistate Pharmacy Jurisprudence Examination® (MPJE®)
School Summary Report**

Test Window: January 1, 2015 - April 30, 2015

School Name: Xavier University of Louisiana

This MPJE score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution. Tables 1 and 2 contain school-specific as well as national pass rate information.

School 1: Examinees testing in same state as respective college

School 2: Examinees testing in different states than respective college

Table 1 First Time Candidates

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	14	57.14	76.29	5.22
School 2	51	78.43	80.28	6.43
State	122	83.61	80.63	6.27
National	3806	91.72	82.14	5.72

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 2 All Candidates

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	26	50.00	75.27	4.58
School 2	55	72.73	79.70	6.72
State	145	80.69	79.81	6.21
National	4703	88.20	81.32	5.93

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 3 Candidate Summary Report

Test Window: January 1, 2015 - April 30, 2015

	Pass/Fail	Total Scaled Score	Test Date	Graduation Date	First Attempt	State
1	Pass	83	03/23/2015	12/31/2014	Y	TX
2	Fail	71	04/16/2015	12/12/2014	Y	LA
3	Pass	81	03/28/2015	12/12/2014	Y	MS
4	Fail	72	04/28/2015	06/28/2014	Y	LA
5	Pass	77	03/19/2015	06/28/2014	N	LA
6	Fail	73	02/09/2015	06/28/2014	Y	LA
7	Fail	69	01/23/2015	06/28/2014	Y	MS
8	Fail	71	04/30/2015	05/10/2014	N	LA
9	Pass	82	04/29/2015	05/10/2014	Y	LA
10	Pass	83	04/28/2015	05/10/2014	Y	LA
11	Pass	93	04/21/2015	05/10/2014	Y	TX
12	Pass	76	04/21/2015	05/10/2014	Y	AL
13	Pass	78	04/17/2015	05/10/2014	Y	MO
14	Pass	80	04/16/2015	05/10/2014	N	LA
15	Pass	76	04/08/2015	05/10/2014	Y	LA
16	Pass	76	04/08/2015	05/10/2014	Y	LA
17	Fail	71	04/07/2015	05/10/2014	Y	MS
18	Pass	80	03/31/2015	05/10/2014	Y	NV
19	Pass	81	03/30/2015	05/10/2014	Y	NE
20	Pass	79	03/26/2015	05/10/2014	Y	LA
21	Fail	73	03/26/2015	05/10/2014	Y	LA
22	Pass	78	03/26/2015	05/10/2014	Y	MS
23	Fail	74	03/16/2015	05/10/2014	Y	KY
24	Fail	74	02/20/2015	05/10/2014	N	LA
25	Fail	70	02/19/2015	05/10/2014	N	LA
26	Pass	87	01/30/2015	05/10/2014	Y	MO
27	Pass	86	01/29/2015	05/10/2014	Y	AL
28	Pass	76	01/22/2015	05/10/2014	N	LA
29	Fail	71	01/22/2015	05/10/2014	Y	AL
30	Fail	71	04/16/2015	12/13/2013	N	LA
31	Fail	68	03/12/2015	12/13/2013	N	LA
32	Fail	66	02/02/2015	12/13/2013	Y	LA
33	Pass	77	04/29/2015	05/11/2013	Y	LA
34	Pass	83	03/16/2015	05/11/2013	Y	LA
35	Fail	74	03/11/2015	05/11/2013	N	LA
36	Pass	90	03/05/2015	05/11/2013	Y	NY
37	Pass	83	02/03/2015	05/11/2013	Y	LA
38	Pass	85	01/13/2015	05/11/2013	Y	TX
39	Pass	82	04/02/2015	08/04/2012	Y	MS
40	Pass	77	04/29/2015	05/12/2012	Y	TX
41	Pass	82	02/05/2015	05/12/2012	Y	GA
42	Pass	75	01/30/2015	05/12/2012	Y	MS
43	Pass	86	01/29/2015	05/12/2012	Y	AL
44	Pass	86	03/26/2015	05/07/2011	Y	OR

Table 3 Candidate Summary Report

	Pass/Fail	Total Scaled Score	Test Date	Graduation Date	First Attempt	State
45	Pass	76	03/16/2015	05/07/2011	N	LA
46	Pass	80	02/24/2015	05/08/2010	Y	MD
47	Pass	81	01/08/2015	05/08/2010	Y	PA
48	Pass	82	02/03/2015	05/05/2010	Y	NE
49	Fail	74	01/26/2015	05/09/2009	N	LA
50	Pass	81	04/10/2015	05/20/2008	Y	NC
51	Fail	67	04/29/2015	05/10/2008	N	TX
52	Fail	74	04/29/2015	05/10/2008	Y	MS
53	Pass	78	03/31/2015	05/10/2008	Y	TX
54	Fail	71	02/12/2015	05/20/2006	Y	FL
55	Pass	90	01/08/2015	05/20/2006	Y	TX
56	Pass	79	04/01/2015	05/07/2005	Y	MI
57	Fail	67	04/29/2015	05/31/2004	Y	NJ
58	Pass	85	02/25/2015	05/08/2004	Y	AZ
59	Pass	78	01/05/2015	05/08/2004	Y	KY
60	Pass	89	03/05/2015	05/01/2003	Y	MS
61	Pass	75	01/05/2015	05/01/2003	Y	OK
62	Pass	78	04/04/2015	05/01/2002	N	LA
63	Fail	74	01/16/2015	05/01/2002	Y	LA
64	Fail	73	04/09/2015	05/01/2001	N	NY
65	Fail	72	01/23/2015	05/01/2001	Y	NY
66	Pass	78	01/16/2015	08/01/2000	Y	MD
67	Fail	70	03/25/2015	05/01/1999	N	TN
68	Fail	74	02/16/2015	05/01/1999	Y	TN
69	Pass	84	04/11/2015	05/01/1998	Y	TX
70	Pass	95	03/23/2015	05/12/1997	Y	WV
71	Pass	94	02/20/2015	05/12/1997	Y	OR
72	Pass	86	02/11/2015	05/12/1997	Y	MD
73	Pass	79	02/02/2015	05/12/1997	Y	AL
74	Pass	76	04/25/2015	05/10/1997	Y	PA
75	Fail	73	02/20/2015	05/10/1997	Y	FL
76	Pass	79	01/09/2015	05/10/1997	Y	TN
77	Fail		04/09/2015	05/01/1997	Y	AL
78	Pass	79	01/13/2015	05/13/1995	Y	OK
79	Pass	82	02/24/2015	05/01/1993	Y	MS
80	Pass	82	02/13/2015	05/18/1986	Y	AL
81	Fail		03/19/2015	05/21/1983	N	FL

National Statistics for All Candidates

Mean Scaled Score: 81.32
Standard Deviation: 5.93
Range: 49 - 100
Passing Rate (%): 88.20

National Statistics for First-Time Candidates

Mean Scaled Score: 82.14
Standard Deviation: 5.72
Range: 53 - 100
Passing Rate (%): 91.72

The following tables are scaled score frequency distributions for MPJE® candidates.
 Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

Table 4 National Frequency Distribution of Scaled Scores

Based on Total Tests Administered (N = 4703)

Test Window: January 1, 2015 - April 30, 2015

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	1	0.0%
50 - 54	1	0.0%
55 - 59	2	0.1%
60 - 64	10	0.3%
65 - 69	92	2.3%
70 - 74	444	11.7%
75 - 79	1200	37.2%
80 - 84	1592	71.1%
85 - 89	989	92.2%
90 - 94	298	98.5%
95 - 100	69	100.0%

Table 5 National Frequency Distribution of Scaled Scores

Based on First-Time Candidates from ACPE-Accredited Programs (N = 3806)

Test Window: January 1, 2015 - April 30, 2015

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	0	0.0%
50 - 54	1	0.0%
55 - 59	1	0.1%
60 - 64	6	0.2%
65 - 69	49	1.5%
70 - 74	254	8.2%
75 - 79	883	31.4%
80 - 84	1350	66.9%
85 - 89	914	91.0%
90 - 94	277	98.2%
95 - 100	67	100.0%

Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2000		2001		2002		2003	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	25	94	53	126	43	122	71	158
School Average Score:	78.92	78.90	77.43	79.86	79.12	78.18	76.75	77.99
State Average Score:	81.64	80.49	80.64	80.32	80.34	79.41	77.32	78.87
National Average Score:	82.24	81.75	82.25	81.51	81.72	79.85	79.92	79.33
School Pass Rate:	80.00	80.85	69.81	88.10	81.40	77.05	67.61	75.95
State Pass Rate:	89.89	86.25	87.84	90.00	92.00	85.98	72.88	84.67
National Pass Rate:	91.37	90.50	91.22	90.54	90.78	84.93	84.52	82.61
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	23	86	38	107	38	102	53	122
School Average Score:	79.04	79.01	77.58	79.92	79.58	78.18	77.04	78.48
State Average Score:	82.14	80.97	80.67	80.51	80.30	79.41	77.69	79.23
National Average Score:	82.55	82.05	82.59	81.86	82.08	80.19	80.34	79.76
School Pass Rate:	78.26	80.23	71.05	86.92	86.84	78.43	71.70	78.69
State Pass Rate:	92.59	87.32	88.06	89.77	91.49	86.32	75.00	86.55
National Pass Rate:	92.57	91.37	92.45	91.75	92.15	86.45	86.58	84.67

Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2004		2005		2006		2007	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	66	123	82	135	139	181	77	169
School Average Score:	77.36	78.64	78.06	78.96	79.04	79.82	78.47	79.76
State Average Score:	78.58	80.03	80.50	80.03	80.01	81.34	80.15	81.47
National Average Score:	80.10	79.83	80.39	80.04	80.68	80.42	81.26	81.14
School Pass Rate:	78.79	80.49	76.83	82.22	87.77	86.19	77.92	87.57
State Pass Rate:	86.90	92.55	90.55	87.03	91.09	92.39	87.18	90.39
National Pass Rate:	85.63	84.75	86.57	85.69	87.25	87.82	89.38	89.78
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	56	101	63	121	121	156	62	154
School Average Score:	77.73	79.19	78.57	79.36	79.14	80.27	79.47	80.03
State Average Score:	79.04	80.11	80.71	80.29	80.24	81.52	80.59	81.84
National Average Score:	80.58	80.25	80.80	80.44	81.09	80.80	81.72	81.51
School Pass Rate:	80.36	84.16	79.37	85.12	87.60	89.10	85.48	88.96
State Pass Rate:	90.14	92.53	91.38	88.69	92.31	93.53	91.18	92.49
National Pass Rate:	88.16	86.87	88.51	87.51	89.41	89.34	91.43	91.24

Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2008		2009			2010			2011		
	<u>Jan - Jun</u>	<u>Jul - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP											
No. of Candidates	55	208	63	162	68	42	160	83	10	77	44
Mean Scaled Score - School	78.25	79.49	78.03	80.20	78.10	78.93	79.89	78.17	76.50	79.32	78.93
Mean Scaled Score - State	81.33	81.34	79.57	81.69	80.35	81.37	80.88	81.64		81.01	80.41
Mean Scaled Score - National	81.59	81.27	80.29	82.39	80.25	80.45	82.51	80.57	80.27	82.23	80.46
School Pass Rate:	80	83.17	74.60	88.27	77.94	80.95	88.75	78.31	70.00	81.82	81.82
State Pass Rate:	91.75	91.05	81.03	94.52	85.92	90.00	92.64	95.79		89.91	90.99
National Pass Rate:	90.31	89.92	86.23	93.74	87.04	89.08	94.83	89.35	86.43	92.17	86.24
FIRST-TIME CANDIDATE GROUP											
No. of Candidates	45	181	44	150	47	32	157	61	7	67	29
Mean Scaled Score - School	79.02	79.71	78.55	80.35	78.79	79.66	79.95	78.48	78.14	79.84	80.14
Mean Scaled Score - State	81.53	81.62	79.69	81.76	80.98	82.07	80.93	82.07		81.52	81.14
Mean Scaled Score - National	81.97	81.57	80.75	82.58	80.63	80.82	82.67	80.94	81.17	82.86	81.76
School Pass Rate:	88.89	85.64	79.55	88.67	82.98	84.38	89.17	78.69	85.71	86.57	89.66
State Pass Rate:	92.31	91.95	80.77	94.34	89.66	93.44	92.92	97.56		94.06	94.32
National Pass Rate:	91.82	91.16	88.45	94.30	88.68	90.64	95.50	90.89	92.24	96.05	94.00

Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2012			2013			2014			2015		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	13	181	87	53	188	115	52	193	128	81		
<i>* testing in same/different state</i>		94 / 87	23 / 65	6 / 47	95 / 93	46 / 69	12 / 40	82 / 111	43 / 85	26 / 55		
Mean Scaled Score - School *	79.69	79.27/78.48	76.96/79.95	78.17/79.09	79.46/79.55	77.33/78.72	76 / 79.28	78.35/79.98	77.05/80.62	75.27/79.70		
<i>* testing in same/different state</i>												
Mean Scaled Score - State	81.18	80.91	79.62	81.33	80.82	80.43	80.36	80.18	80.13	79.81		
Mean Scaled Score - National	80.41	82.43	80.55	80.92	82.50	80.52	81.04	82.52	81.08	81.32		
School Pass Rate: *	84.62	84.04/81.61	60.87/86.15	83.33/76.60	85.26/81.72	71.74/76.81	50 / 82.50	76.83/90.09	65.12/90.59	50.00/72.73		
<i>* testing in same/different state</i>												
State Pass Rate:	90.41	90.69	81.61	93.98	90.51	85.21	82.52	86.08	82.69	80.69		
National Pass Rate:	84.54	92.76	86.85	87.18	92.98	87.01	87.62	93.28	88.50	88.20		
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	9	163	70	43	171	86	43	176	98	65		
<i>* testing in same/different state</i>		87 / 76	11 / 54	3 / 40	89 / 82	31 / 55	8 / 35	76 / 100	24 / 74	14 / 51		
Mean Scaled Score - School *	79.78	79.34/78.70	77.55/80.57	81.33/79.38	79.66/79.94	77.03/78.85	76.63/79.31	78.83/80.23	77.33/80.86	76.29/80.28		
<i>* testing in same/different state</i>												
Mean Scaled Score - State	81.75	81.03	80.21	81.90	81.03	81.08	81.05	80.62	81.13	80.63		
Mean Scaled Score - National	81.44	82.75	81.26	81.78	82.76	81.22	81.82	82.80	81.79	82.14		
School Pass Rate: *	88.89	83.91/84.24	63.64/87.04	100 / 77.50	87.64/82.93	67.74/74.55	50 / 80	80.26/90.00	62.5 / 91.89	57.14/78.43		
<i>* testing in same/different state</i>												
State Pass Rate:	93.22	91.03	85.71	97.22	91.88	87.29	85.88	89.29	84.96	83.61		
National Pass Rate:	89.13	93.94	89.60	91.08	93.95	90.04	90.85	94.34	90.87	91.72		



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



North American Pharmacist Licensure Examination (NAPLEX™)

January 1 – April 30, 2015

School Reports
Interpretation of Scores
Frequency Distribution of Scaled Scores
Cumulative Record (since January 2000)


August 12, 2015

North American Pharmacist Licensure Examination (NAPLEX™)

This computer adaptive competency assessment is administered by the National Association of Boards of Pharmacy (NABP). The examination blueprint is designed to assess the applicant's competency in basic pharmacy practice and is recognized by pharmacy regulatory authorities in all of the states and territories within the USA. The examination is administered via an open window process; applicants may schedule the examination at a local testing center at any time following approval by the state board and receipt of an Authorization to Test (ATT) document from NABP. Individual scores are available to applicants via secure web posting approximately 7-10 days following the examination. Summary reports are provided to the state boards on a calendar trimester basis.

Table of Contents

Current Trimester Report for ULM College of Pharmacy	03
Cumulative Report (since January 2000) for ULM College of Pharmacy	10
Current Trimester Report for Xavier College of Pharmacy	14
Cumulative Report (since January 2000) for Xavier College of Pharmacy	21



**North American Pharmacist Licensure Examination® (NAPLEX) ®
School Summary Report**

Test Window: January 1, 2015 - April 30, 2015

School Name: University Louisiana Monroe

This NAPLEX score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution.

Tables 1 and 2 contain school-specific as well as national pass rate information and mean area scores for each of the three main NAPLEX competency areas:

- Area 1 - Assess Pharmacotherapy to Assure Safe and Effective Therapeutic Outcomes (56%),
- Area 2 - Assess Safe and Accurate Preparation and Dispensing of Medications (33%), and
- Area 3 - Assess, Recommend and Provide Health Care Information that Promotes Public Health (11%).

Table 1 First-Time Candidates, ACPE-Accredited Programs Only

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation
School	1	0.00	74.00		10.00		11.00		11.00	
State	3	33.33	77.00	7.00	10.67	0.58	11.00	1.00	10.67	0.58
National	266	84.96	94.01	18.23	11.98	1.26	11.95	1.39	11.92	1.95

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 2 All Candidates

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation
School	4	50.00	82.00	14.24	10.75	0.96	11.50	1.00	11.50	1.29
State	13	69.23	82.15	13.83	11.15	0.80	11.08	0.95	11.38	1.66
National	853	67.06	83.84	21.78	11.40	1.38	11.37	1.50	11.36	1.97

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Interpretation and Uses of Candidate Scores

At the candidate level, two sets of scores are produced: an overall, composite scaled score and individual area scores. Only overall scores are used to make pass/fail decisions. Area scores are intended to provide insight into areas of strength and weakness and can be used as a tool for self-assessment and subsequent remediation.

Area scores are numerical performance indicators for each of the three main competency areas of the NAPLEX. There are a total of three area scores, one per main competency area. Area scores are always reported on a scale of [6, 18], where a score of 6 is the lowest possible score and a score of 18 is the highest possible score. This reporting scale does not have a number-correct interpretation. In other words, a score of 6 does not mean that the candidate answered 6 questions correctly. Instead, area scores are computed from ability estimates that are created for sets of items that map to each of the three content areas.

Reference Tables 3 and 4 contain summative data for all first-time test takers from ACPE-accredited programs (2014). In table 3, scaled scores were ordered and divided into four equi-sized bins for the computation of quartile values. The column labeled "Top (1st) Quartile" applies to the highest scoring group of examinees. The column labeled "Bottom (4th) Quartile" applies to the lowest scoring group. Table 4 contains similar information but is based on pass/fail status of examinees.

**Reference Table 3 NAPLEX
Mean Area Score Summary (2014) by Quartiles**

	Top (1st) Quartile	2nd Quartile	3rd Quartile	Bottom (4th) Quartile
Mean Area 1 Scaled Score	13.75	12.67	11.89	10.76
Mean Area 2 Scaled Score	13.80	12.74	11.97	10.80
Mean Area 3 Scaled Score	13.89	12.92	12.20	11.12
Mean Overall Scaled Score	118.80	106.64	95.26	74.28
Scaled Score Range	[138, 112]	[112, 101]	[101, 88]	[88, 5]
# Examinees per bin	3,968	3,968	3,968	3,968

In the quartile table (above), the mean overall scaled score for the bottom quartile is 74.28 which is greater than the NAPLEX passing threshold of 75. Because the set of overall scaled scores is not normally distributed, the scores and subsequent interpretations should be evaluated carefully.

**Reference Table 4 NAPLEX
Mean Area Score Summary (2014) by Pass/Fail Status**

	Pass	Fail
Mean Area 1 Scaled Score	12.49	10.13
Mean Area 2 Scaled Score	12.55	10.19
Mean Area 3 Scaled Score	12.75	10.48
Mean Overall Scaled Score	102.71	61.55
Scaled Score Range	[138, 75]	[74, 5]
# Examinees per bin	14,343	1,529

Table 5 Candidate Summary Report

Test Window: January 1, 2015 - April 30, 2015

Candidate	Pass/Fail	Total Scaled Score	Area 1 Scaled Score	Area 2 Scaled Score	Area 3 Scaled Score	Test Date	Graduation Date	First Attempt
1	Fail	74	10	11	11	02/24/2015	12/06/2014	Y
2	Fail	70	10	11	12	04/09/2015	05/10/2014	N
3	Pass	82	11	11	10	02/07/2015	05/10/2014	N
4	Pass	102	12	13	13	02/03/2015	05/10/2014	N

National Statistics for All NAPLEX Candidates

Mean Scaled Score: 83.84
Standard Deviation: 21.78
Range: 10 - 130
Passing Rate (%): 67.06

National Statistics for First-Time NAPLEX Candidates

Mean Scaled Score: 94.01
Standard Deviation: 18.23
Range: 33 - 130
Passing Rate (%): 84.96

The following tables are scaled score frequency distributions for NAPLEX candidates.
 Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

Table 6 National Frequency Distribution of Scaled Scores

Based on Total Tests Administered (N = 853)

Test Window: January 1, 2015 - April 30, 2015

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	3	0.4%
15 - 19	2	0.6%
20 - 24	2	0.8%
25 - 29	6	1.5%
30 - 34	7	2.4%
35 - 39	13	3.9%
40 - 44	10	5.1%
45 - 49	13	6.6%
50 - 54	24	9.4%
55 - 59	32	13.2%
60 - 64	39	17.8%
65 - 69	51	23.8%
70 - 74	74	32.5%
75 - 79	67	40.4%
80 - 84	69	48.6%
85 - 89	76	57.5%
90 - 94	77	66.6%
95 - 99	54	73.0%
100 - 104	71	81.4%
105 - 109	55	87.9%
110 - 114	49	93.6%
115 - 119	36	97.9%
120 - 124	10	99.1%
125 - 129	7	99.9%
130 - 134	1	100.0%
135 - 139	0	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

Table 7 National Frequency Distribution of Scaled Scores

Based on First-Time Candidates from ACPE-Accredited Programs (N = 266)

Test Window: January 1, 2015 - April 30, 2015

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	1	0.4%
35 - 39	3	1.5%
40 - 44	1	1.9%
45 - 49	2	2.7%
50 - 54	2	3.4%
55 - 59	3	4.5%
60 - 64	6	6.8%
65 - 69	6	9.1%
70 - 74	14	14.4%
75 - 79	21	22.3%
80 - 84	15	28.0%
85 - 89	16	34.1%
90 - 94	31	45.8%
95 - 99	25	55.3%
100 - 104	31	67.0%
105 - 109	33	79.5%
110 - 114	27	89.8%
115 - 119	19	97.0%
120 - 124	4	98.5%
125 - 129	3	99.6%
130 - 134	1	100.0%
135 - 139	0	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

North American Pharmacist Licensure Examination (NAPLEX)

University of Louisiana at Monroe

	2000			2001			2002			2003		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	76	47	18	40	30	10	13	62	27	10	70	24
School Average Score:	96.51	91.62	88.61	88.93	87.30	87.00	82.85	100.24	89.56	78.40	101.44	92.50
State Average Score:	96.75	88.52	86.05	84.66	93.82	82.05	75.50	101.46	87.48	77.50	99.40	87.33
National Average Score:	91.78	99.86	91.21	90.25	101.70	90.50	90.81	101.21	90.02	91.50	101.40	89.40
School Pass Rate:	96.05	82.98	88.89	85.00	90.00	90.00	84.62	85.48	77.78	60.00	95.71	87.50
State Pass Rate:	92.50	78.57	77.27	75.86	89.29	70.00	50.00	85.90	70.37	62.50	94.90	80.00
National Pass Rate:	82.95	92.05	83.04	81.07	94.38	83.69	81.52	93.76	81.73	82.77	93.84	79.55
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	71	33	9	37	20	6	13	61	20	2	64	16
School Average Score:	97.13	96.00	94.00	88.32	86.90	90.67	82.85	100.44	92.80	73.50	102.69	98.56
State Average Score:	97.49	93.61	87.77	88.78	95.92	85.93	81.89	103.71	91.15	74.00	100.41	92.38
National Average Score:	96.51	101.85	96.48	94.54	103.35	94.22	95.13	103.00	94.62	97.39	103.38	95.88
School Pass Rate:	95.77	96.97	100.00	83.78	85.00	100.00	84.62	85.25	75.00	50.00	96.88	100.00
State Pass Rate:	94.59	93.18	84.62	83.33	91.84	73.33	77.78	90.28	70.00	66.67	95.65	90.48
National Pass Rate:	91.44	95.44	91.39	87.91	96.75	90.10	89.27	96.74	88.52	91.47	96.54	89.64

North American Pharmacist Licensure Examination (NAPLEX)

University of Louisiana at Monroe

	2004			2005			2006			2007		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	3	64	18	9	72	17	2	60	10	3	90	23
School Average Score:	85.67	105.30	94.83	82.67	104.17	101.65	98.00	113.17	95.80	107.67	117.27	101.57
State Average Score:	81.33	103.47	96.71	95.00	101.77	92.50	86.67	111.87	96.07	88.00	117.29	94.73
National Average Score:	92.13	102.16	91.70	91.32	104.85	87.72	86.89	107.02	93.18	89.95	113.33	94.18
School Pass Rate:	100.00	96.88	94.44	88.89	90.28	94.12	100.00	93.33	80.00	100.00	95.56	78.26
State Pass Rate:	83.33	96.12	100.00	100.00	87.83	78.57	77.78	89.17	79.31	63.64	95.52	74.51
National Pass Rate:	83.22	95.11	84.79	82.88	89.15	71.73	68.82	90.52	77.07	71.38	94.47	78.76
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	2	58	17	5	70	11	2	58	4	3	89	19
School Average Score:	87.00	107.34	93.47	81.40	105.09	110.09	98.00	114.59	125.00	107.67	117.66	103.05
State Average Score:	84.00	105.61	99.73	101.50	103.64	98.94	93.33	112.95	95.41	103.40	118.18	95.00
National Average Score:	100.14	104.14	96.60	98.84	107.67	95.89	97.18	110.34	99.96	102.16	116.00	102.19
School Pass Rate:	100.00	100.00	94.12	80.00	91.43	100.00	100.00	94.83	100.00	100.00	95.51	78.95
State Pass Rate:	100.00	100.00	100.00	100.00	90.09	88.89	100.00	90.38	70.59	100.00	96.69	76.74
National Pass Rate:	95.07	97.38	92.22	91.31	92.86	82.12	81.12	94.49	84.74	84.09	97.23	88.12

North American Pharmacist Licensure Examination (NAPLEX)


University of Louisiana at Monroe

	2008			2009			2010			2011		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	11	98	12	6	91	8	3	67	6	2	91	9
Mean Scaled Score - School	94.73	106.39	93.83	97.83	113.84	77.25	98.00	99.97	93.17	67.50	97.40	87.22
Mean Scaled Score - State	93.70	103.31	95.41	94.80	108.26	84.32	83.15	94.22	80.13		99.66	85.27
Mean Scaled Score - National	96.76	112.08	96.61	93.72	112.51	93.62	84.75	101.11	84.90	83.97	103.27	88.08
School Pass Rate:	90.91	92.86	83.33	83.33	95.60	50.00	100.00	95.52	100.00	0.00	89.01	77.78
State Pass Rate:	90.00	90.34	82.76	80.00	92.64	63.16	61.54	83.24	65.00		90.81	73.17
National Pass Rate:	83.11	95.48	81.96	76.40	95.03	78.20	65.07	92.39	72.20	67.85	94.16	76.57
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	3	97	5	3	88	3	0	67	2	1	87	3
Mean Scaled Score - School	110.33	106.76	95.80	93.00	115.34	78.33	0.00	99.97	97.00	62.00	99.39	84.67
Mean Scaled Score - State	96.00	104.42	95.82	86.00	108.80	84.10	92.00	94.46	90.75		100.88	83.70
Mean Scaled Score - National	106.63	114.11	103.62	106.27	114.65	102.87	100.12	103.06	94.26	96.99	105.03	96.71
School Pass Rate:	100.00	93.81	80.00	66.67	96.59	33.33	0.00	95.52	100.00	0.00	93.10	66.67
State Pass Rate:	83.33	92.35	82.35	57.14	93.04	60.00	66.67	84.15	83.33		93.18	74.07
National Pass Rate:	92.24	97.44	90.66	90.76	97.50	89.51	88.38	95.31	86.71	87.50	96.57	89.24

North American Pharmacist Licensure Examination (NAPLEX)

University of Louisiana at Monroe

	2012			2013			2014			2015		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	6	80	17	3	40	7	1	68	11		4	
Mean Scaled Score - School	75.33	97.14	85.41	92.00	100.45	88.43	101.00	95.10	82.27		82.00	
Mean Scaled Score - State	81.25	98.42	86.95	77.25	98.66	86.88	73.85	96.45	80.88		82.15	
Mean Scaled Score - National	83.15	102.81	88.15	80.17	102.78	87.03	80.22	101.71	89.22		83.84	
School Pass Rate:	83.33	92.50	82.35	100.00	90.00	100.00	100.00	89.71	63.64		50.00	
State Pass Rate:	68.75	93.82	76.19	55.56	92.95	81.82	53.85	90.75	70.59		69.23	
National Pass Rate:	68.33	95.21	77.86	61.07	94.65	75.91	63.24	93.86	79.77		67.06	
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	2	80	9	3	38	4	1	68	3		1	
Mean Scaled Score - School	49.50	97.14	87.11	92.00	101.68	92.00	101.00	95.10	92.00		74.00	
Mean Scaled Score - State	84.00	99.47	91.00	80.75	99.30	88.33	85.00	96.96	83.34		77.00	
Mean Scaled Score - National	94.87	104.13	95.75	92.48	104.02	92.69	90.89	102.80	93.94		94.01	
School Pass Rate:	50.00	92.50	77.78	100.00	92.11	100.00	100.00	89.71	66.67		0.00	
State Pass Rate:	75.00	95.35	72.73	75.00	94.08	83.33	100.00	92.12	73.68		33.33	
National Pass Rate:	87.69	97.19	90.14	85.14	96.57	84.46	83.15	95.61	85.36		84.96	



**North American Pharmacist Licensure Examination® (NAPLEX) ®
School Summary Report**

Test Window: January 1, 2015 - April 30, 2015

School Name: Xavier University of Louisiana

This NAPLEX score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution.

Tables 1 and 2 contain school-specific as well as national pass rate information and mean area scores for each of the three main NAPLEX competency areas:

- Area 1 - Assess Pharmacotherapy to Assure Safe and Effective Therapeutic Outcomes (56%),
- Area 2 - Assess Safe and Accurate Preparation and Dispensing of Medications (33%), and
- Area 3 - Assess, Recommend and Provide Health Care Information that Promotes Public Health (11%).

Table 1 First-Time Candidates, ACPE-Accredited Programs Only

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation
School	4	75.00	84.75	16.21	11.50	0.58	11.25	1.50	9.50	1.29
State	3	33.33	77.00	7.00	10.67	0.58	11.00	1.00	10.67	0.58
National	266	84.96	94.01	18.23	11.98	1.26	11.95	1.39	11.92	1.95

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 2 All Candidates

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation
School	15	53.33	72.13	20.41	10.73	1.03	10.53	1.36	10.73	2.02
State	13	69.23	82.15	13.83	11.15	0.80	11.08	0.95	11.38	1.66
National	853	67.06	83.84	21.78	11.40	1.38	11.37	1.50	11.36	1.97

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Interpretation and Uses of Candidate Scores

At the candidate level, two sets of scores are produced: an overall, composite scaled score and individual area scores. Only overall scores are used to make pass/fail decisions. Area scores are intended to provide insight into areas of strength and weakness and can be used as a tool for self-assessment and subsequent remediation.

Area scores are numerical performance indicators for each of the three main competency areas of the NAPLEX. There are a total of three area scores, one per main competency area. Area scores are always reported on a scale of [6, 18], where a score of 6 is the lowest possible score and a score of 18 is the highest possible score. This reporting scale does not have a number-correct interpretation. In other words, a score of 6 does not mean that the candidate answered 6 questions correctly. Instead, area scores are computed from ability estimates that are created for sets of items that map to each of the three content areas.

Reference Tables 3 and 4 contain summative data for all first-time test takers from ACPE-accredited programs (2014). In table 3, scaled scores were ordered and divided into four equi-sized bins for the computation of quartile values. The column labeled "Top (1st) Quartile" applies to the highest scoring group of examinees. The column labeled "Bottom (4th) Quartile" applies to the lowest scoring group. Table 4 contains similar information but is based on pass/fail status of examinees.

**Reference Table 3 NAPLEX
Mean Area Score Summary (2014) by Quartiles**

	Top (1st) Quartile	2nd Quartile	3rd Quartile	Bottom (4th) Quartile
Mean Area 1 Scaled Score	13.75	12.67	11.89	10.76
Mean Area 2 Scaled Score	13.80	12.74	11.97	10.80
Mean Area 3 Scaled Score	13.89	12.92	12.20	11.12
Mean Overall Scaled Score	118.80	106.64	95.26	74.28
Scaled Score Range	[138, 112]	[112, 101]	[101, 88]	[88, 5]
# Examinees per bin	3,968	3,968	3,968	3,968

In the quartile table (above), the mean overall scaled score for the bottom quartile is 74.28 which is greater than the NAPLEX passing threshold of 75. Because the set of overall scaled scores is not normally distributed, the scores and subsequent interpretations should be evaluated carefully.

**Reference Table 4 NAPLEX
Mean Area Score Summary (2014) by Pass/Fail Status**

	Pass	Fail
Mean Area 1 Scaled Score	12.49	10.13
Mean Area 2 Scaled Score	12.55	10.19
Mean Area 3 Scaled Score	12.75	10.48
Mean Overall Scaled Score	102.71	61.55
Scaled Score Range	[138, 75]	[74, 5]
# Examinees per bin	14,343	1,529

Table 5 Candidate Summary Report

Test Window: January 1, 2015 - April 30, 2015

Candidate	Pass/Fail	Total Scaled Score	Area 1 Scaled Score	Area 2 Scaled Score	Area 3 Scaled Score	Test Date	Graduation Date	First Attempt
1	Pass	93	12	12	11	03/17/2015	12/31/2014	Y
2	Pass	85	11	12	10	04/06/2015	12/12/2014	Y
3	Pass	99	12	12	8	03/23/2015	12/12/2014	Y
4	Pass	85	12	10	13	04/14/2015	06/28/2014	N
5	Pass	79	10	12	12	03/16/2015	06/28/2014	N
6	Fail	50	10	10	8	03/12/2015	05/10/2014	N
7	Fail	62	11	9	9	02/25/2015	05/10/2014	Y
8	Fail	71	11	10	10	02/05/2015	05/10/2014	N
9	Pass	79	11	11	10	01/22/2015	12/13/2013	N
10	Fail	53	10	9	13	03/21/2015	05/11/2013	N
11	Pass	101	12	12	14	03/16/2015	05/11/2013	N
12	Fail	52	10	9	10	04/06/2015	05/07/2011	N
13	Fail	38	9	9	8	03/28/2015	05/10/2008	N
14	Fail	47	9	9	12	02/19/2015	05/08/2008	N
15	Pass	88	11	12	13	02/11/2015	05/31/2004	N

National Statistics for All NAPLEX Candidates

Mean Scaled Score: 83.84
Standard Deviation: 21.78
Range: 10 - 130
Passing Rate (%): 67.06

National Statistics for First-Time NAPLEX Candidates

Mean Scaled Score: 94.01
Standard Deviation: 18.23
Range: 33 - 130
Passing Rate (%): 84.96

The following tables are scaled score frequency distributions for NAPLEX candidates.
 Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

Table 6 National Frequency Distribution of Scaled Scores

Based on Total Tests Administered (N = 853)

Test Window: January 1, 2015 - April 30, 2015

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	3	0.4%
15 - 19	2	0.6%
20 - 24	2	0.8%
25 - 29	6	1.5%
30 - 34	7	2.4%
35 - 39	13	3.9%
40 - 44	10	5.1%
45 - 49	13	6.6%
50 - 54	24	9.4%
55 - 59	32	13.2%
60 - 64	39	17.8%
65 - 69	51	23.8%
70 - 74	74	32.5%
75 - 79	67	40.4%
80 - 84	69	48.6%
85 - 89	76	57.5%
90 - 94	77	66.6%
95 - 99	54	73.0%
100 - 104	71	81.4%
105 - 109	55	87.9%
110 - 114	49	93.6%
115 - 119	36	97.9%
120 - 124	10	99.1%
125 - 129	7	99.9%
130 - 134	1	100.0%
135 - 139	0	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

Table 7 National Frequency Distribution of Scaled Scores

Based on First-Time Candidates from ACPE-Accredited Programs (N = 266)

Test Window: January 1, 2015 - April 30, 2015

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	1	0.4%
35 - 39	3	1.5%
40 - 44	1	1.9%
45 - 49	2	2.7%
50 - 54	2	3.4%
55 - 59	3	4.5%
60 - 64	6	6.8%
65 - 69	6	9.1%
70 - 74	14	14.4%
75 - 79	21	22.3%
80 - 84	15	28.0%
85 - 89	16	34.1%
90 - 94	31	45.8%
95 - 99	25	55.3%
100 - 104	31	67.0%
105 - 109	33	79.5%
110 - 114	27	89.8%
115 - 119	19	97.0%
120 - 124	4	98.5%
125 - 129	3	99.6%
130 - 134	1	100.0%
135 - 139	0	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2000			2001			2002			2003		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	10	80	43	28	85	40	22	69	48	19	90	40
School Average Score:	77.60	87.99	81.67	76.50	93.14	85.15	76.00	93.23	86.98	79.42	94.46	84.33
State Average Score:	96.75	88.52	86.05	84.66	93.82	82.05	75.50	101.46	87.48	77.50	99.40	87.33
National Average Score:	91.78	99.86	91.21	90.25	101.70	83.69	90.81	101.21	90.02	91.50	101.40	89.40
School Pass Rate:	60.00	77.50	62.79	57.14	85.88	82.50	54.55	79.71	85.42	68.42	90.00	75.00
State Pass Rate:	92.50	78.57	77.27	75.86	89.29	70.00	50.00	85.90	70.37	62.50	94.90	80.00
National Pass Rate:	82.95	92.05	83.04	81.07	94.38	83.69	81.52	93.76	81.73	82.77	93.84	79.55
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	1	77	23	10	74	29	8	63	40	8	83	26
School Average Score:	95.00	88.19	82.13	74.80	95.92	86.48	80.63	95.00	88.60	87.75	95.34	88.04
State Average Score:	97.49	93.61	87.77	88.78	95.92	85.93	81.89	103.71	91.15	74.00	100.41	92.38
National Average Score:	96.51	101.85	96.48	94.54	103.35	94.22	95.13	103.00	94.62	97.39	103.38	95.88
School Pass Rate:	100.00	77.92	65.22	50.00	90.54	82.76	75.00	84.13	90.00	87.50	90.36	80.77
State Pass Rate:	94.59	93.18	84.62	83.33	91.84	73.33	77.78	90.28	70.00	66.67	95.65	90.48
National Pass Rate:	91.44	95.44	91.39	87.91	96.75	90.10	89.27	96.74	88.52	91.47	96.54	89.64

North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2004			2005			2006			2007		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	10	82	19	6	95	30	20	94	48	17	81	56
School Average Score:	76.40	98.99	91.68	83.00	98.92	73.07	72.15	106.20	92.81	74.18	109.07	86.77
State Average Score:	81.33	103.47	96.71	95.00	101.77	92.50	86.67	111.87	96.07	88.00	117.29	94.73
National Average Score:	92.13	102.16	91.70	91.32	104.85	87.72	86.89	107.02	93.18	89.95	113.33	94.18
School Pass Rate:	70.00	96.34	84.21	83.33	86.32	56.67	50.00	82.98	77.08	52.94	83.95	64.29
State Pass Rate:	83.33	96.12	100.00	100.00	87.83	78.57	77.78	89.17	79.31	63.64	95.52	74.51
National Pass Rate:	83.22	95.11	84.79	82.88	89.15	71.73	68.82	90.52	77.07	71.38	94.47	78.76
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	2	79	10	3	90	19	5	87	31	3	68	46
School Average Score:	72.50	100.06	98.80	85.00	101.34	79.79	69.40	109.32	93.10	94.67	114.60	90.50
State Average Score:	84.00	105.61	99.73	101.50	103.64	98.94	93.33	112.95	95.41	103.40	118.18	95.00
National Average Score:	100.14	104.14	96.60	98.84	107.67	95.89	97.18	110.34	99.96	102.16	116.00	102.19
School Pass Rate:	50.00	98.73	100.00	66.67	88.89	68.42	40.00	86.21	77.42	100.00	92.65	71.74
State Pass Rate:	100.00	100.00	100.00	100.00	90.09	88.89	100.00	90.38	70.59	100.00	96.69	76.74
National Pass Rate:	95.07	97.38	92.22	91.31	92.86	82.12	81.12	94.49	84.74	84.09	97.23	88.12

North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2008			2009			2010			2011		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	22	138	55	18	138	28	19	148	52	25	124	45
Mean Scaled Score - School	81.36	96.77	89.82	80.33	97.59	86.96	73.63	89.73	77.15	76.00	99.13	85.04
Mean Scaled Score - State	93.70	103.31	95.41	94.80	108.26	84.32	83.15	94.22	80.13		99.66	85.27
Mean Scaled Score - National	96.76	112.08	96.61	93.72	112.51	93.62	84.75	101.11	84.90	83.97	103.27	88.08
School Pass Rate:	68.18	81.88	76.36	61.11	83.33	71.43	42.11	75.00	59.62	64.00	87.10	75.56
State Pass Rate:	90.00	90.34	82.76	80.00	92.64	63.16	61.54	83.24	65.00		90.81	73.17
National Pass Rate:	83.11	95.48	81.96	76.40	95.03	78.20	65.07	92.39	72.20	67.85	94.16	76.57
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	5	124	36	6	127	12	6	143	16	6	115	33
Mean Scaled Score - School	85.40	98.77	92.47	81.00	99.77	83.33	79.83	90.78	84.00	61.00	101.95	85.45
Mean Scaled Score - State	96.00	104.42	95.82	86.00	108.80	84.10	92.00	94.46	90.75		100.88	83.70
Mean Scaled Score - National	106.63	114.11	103.62	106.27	114.65	102.87	100.12	103.06	94.26	96.99	105.03	96.71
School Pass Rate:	80.00	84.68	80.56	50.00	86.61	66.67	50.00	76.92	75.00	16.67	92.17	81.82
State Pass Rate:	83.33	92.35	82.35	57.14	93.04	60.00	66.67	84.15	83.33		93.18	74.07
National Pass Rate:	92.24	97.44	90.66	90.76	97.50	89.51	88.38	95.31	86.71	87.50	96.57	89.24

North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2012			2013			2014			2015		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	13	120	21	10	136	43	18	138	27	15		
Mean Scaled Score - School	76.69	95.13	83.24	68.67	95.13	81.47	70.72	96.29	80.41	72.13		
Mean Scaled Score - State	81.25	98.42	86.95	77.25	98.66	86.88	73.85	96.45	80.88	82.15		
Mean Scaled Score - National	83.15	102.81	88.15	80.17	102.78	87.03	80.22	101.71	89.22	83.84		
School Pass Rate:	46.15	90.00	61.90	40.00	86.03	65.12	50.00	92.75	70.37	53.33		
State Pass Rate:	68.75	93.82	76.19	55.56	92.95	81.82	53.85	90.75	70.59	69.23		
National Pass Rate:	68.33	95.21	77.86	61.07	94.65	75.91	63.24	93.86	79.77	67.06		
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	3	111	12	1	131	29	3	131	18	4		
Mean Scaled Score - School	84.67	97.71	95.58	47.00	96.65	82.76	61.00	97.15	82.33	84.75		
Mean Scaled Score - State	84.00	99.47	91.00	80.75	99.30	88.33	85.00	96.96	83.84	77.00		
Mean Scaled Score - National	94.87	104.13	95.75	92.48	104.02	92.69	90.89	102.80	93.94	94.01		
School Pass Rate:	66.67	93.69	91.67	0.00	89.31	68.97	66.67	93.89	72.22	75.00		
State Pass Rate:	75.00	95.35	72.73	75.00	94.08	83.33	100.00	92.12	73.68	33.33		
National Pass Rate:	87.69	97.19	90.14	85.14	96.57	84.46	83.15	95.61	85.36	84.96		

Louisiana Board of Pharmacy

Pharmacy Technician Certification Board (PTCB) Examination

	1995-1999									
<u>National Data</u>	<u>Data</u>	<u>3/25/2000</u>	<u>7/22/2000</u>	<u>11/18/2000</u>	<u>3/10/2001</u>	<u>7/14/2001</u>	<u>11/10/2001</u>	<u>3/16/2002</u>	<u>7/27/2002</u>	<u>11/16/2002</u>
No. of Candidates Attempting	58,382	8,101	12,317	12,941	8,442	12,057	10,608	8,874	13,399	11,521
No. of Candidates Passing	47,973	6,206	10,006	9,520	6,116	9,799	8,354	7,072	10,681	9,164
Passing Score										
Average Score										
Pass Rate	82%	77%	81%	74%	72%	81%	79%	80%	80%	80%
Louisiana Data										
No. of Candidates Attempting	514	141	346	327	187	310	324	269	383	308
No. of Candidates Passing	390	92	271	221	125	227	228	184	269	213
Average Score										
Pass Rate	76%	65%	78%	68%	67%	73%	70%	68%	70%	69%
<hr/>										
	2000-2002									
<u>National Data</u>	<u>Data</u>	<u>3/29/2003</u>	<u>7/26/2003</u>	<u>11/15/2003</u>	<u>3/20/2004</u>	<u>7/17/2004</u>	<u>11/13/2004</u>	<u>3/19/2005</u>	<u>7/23/2005</u>	<u>11/19/2005</u>
No. of Candidates Attempting	98,260	12,147	14,162	13,401	11,508	15,942	13,795	13,673	18,250	14,068
No. of Candidates Passing	76,918	9,506	11,720	11,006	9,100	12,196	10,818	11,009	14,246	10,583
Passing Score										650
Average Score										702
Pass Rate	78%	78%	83%	82%	79%	77%	78%	81%	78%	75%
Louisiana Data										
No. of Candidates Attempting	2,595	385	384	351	285	382	290	337	488	216
No. of Candidates Passing	1,830	294	286	271	211	281	214	274	351	167
Average Score										688
Pass Rate	71%	76%	74%	77%	74%	74%	74%	81%	72%	77%

Louisiana Board of Pharmacy

Pharmacy Technician Certification Board (PTCB) Examination

	2000-2005 Data	3/11/2006	7/22/2006	9/9/2006	11/18/2006	2000-2006 Data	2/5/2007 3/9/2007	4/24/2007 5/25/2007	8/27/2007 9/28/2007	11/26/2007 12/31/2007
National Data										
No. of Candidates Attempting	225,206	12,383	18,992	3,029	15,285	274,895	8,768	10,730	14,666	10,881
No. of Candidates Passing	177,102	8,559	12,609	2,006	9,145	209,421	6,034	7,487	10,497	7,472
Passing Score		650	650	650	650	650	650	650	650	650
Average Score		688	683	683	668					
Pass Rate	79%	69%	66%	66%	60%	76%	69%	70%	72%	69%
Louisiana Data										
No. of Candidates Attempting	5,713	288	420	59	312	6,792	216	306	266	207
No. of Candidates Passing	4,179	181	239	37	137	4,773	133	196	177	121
Average Score		673	664	685	641					
Pass Rate	73%	63%	57%	63%	44%	70%	62%	64%	67%	58%
<hr/>										
	2000-2007 Data	2/4/2008 3/14/2008	4/28/2008 6/20/2008	8/18/2008 10/10/2008	11/10/2008 12/19/2008	2000-2008 Data	1/1/2009 3/31/2009	4/1/2009 6/30/2009	7/1/2009 9/30/2009	10/1/2009 12/31/2009
National Data										
No. of Candidates Attempting	319,940	7,547	14,291	16,385	11,792	369,955	13,087	8,424	13,735	10,674
No. of Candidates Passing	240,911	5,165	10,155	11,781	7,770	275,782	9,141	6,363	10,067	7,682
Passing Score	650	650	650	650	650	650	650	650	650	650
Average Score										
Pass Rate	75%	68%	72%	72%	66%	75%	70%	76%	73%	72%
Louisiana Data										
No. of Candidates Attempting	7,787	128	392	304	215	8,826	301	260	238	218
No. of Candidates Passing	5,400	72	233	182	118	6,005	184	196	166	137
Average Score										
Pass Rate	69%	56%	59%	60%	55%	68%	61%	75%	70%	63%

Louisiana Board of Pharmacy

Pharmacy Technician Certification Board (PTCB) Examination

	2000-2009 Data	1/1/2010 3/31/2010	4/1/2010 6/30/2010	7/1/2010 9/30/2010	10/1/2010 12/31/2010	2000-2010 Data	1/1/2011 3/31/2011	4/1/2011 6/30/2011	7/1/2011 9/30/2011	10/1/2011 12/31/2011
National Data										
No. of Candidates Attempting	415,875	11,611	15,033	16,025	12,774	471,318	11,219	14,026	12,356	14,031
No. of Candidates Passing	309,035	8,521	11,216	12,349	9,275	350,396	8,366	10,472	9,565	10,826
Passing Score	650	650	650	650	650	650	650	650	650	650
Average Score										
Pass Rate	74%	73%	75%	77%	73%	74%	75%	75%	77%	77%
Louisiana Data										
No. of Candidates Attempting	9,843	217	421	320	268	11,069	247	437	268	257
No. of Candidates Passing	6,688	121	287	219	166	7,481	161	306	182	168
Average Score										
Pass Rate	68%	56%	68%	68%	62%	68%	65%	70%	68%	65%
<hr/>										
	2000-2011 Data	1/1/2012 3/31/2012	4/1/2012 6/30/2012	7/1/2012 9/30/2012	10/1/2012 12/31/2012	2000-2012 Data	Changed to semi-annual reports 1/1/2013 to 6/30/2013		7/1/2013 to 12/31/2013	
National Data										
No. of Candidates Attempting	522,950	11,851	14,356	14,375	11,180	574,712	25,448		28,797	
No. of Candidates Passing	389,625	9,232	11,044	10,982	8,471	429,354	19,581		21,745	
Passing Score	650	650	650	650	650	650	650		650	
Average Score										
Pass Rate	75%	78%	77%	76%	76%	75%	77%		76%	
Louisiana Data										
No. of Candidates Attempting	12,278	246	368	329	239	13,460	622		537	
No. of Candidates Passing	8,298	158	269	226	168	9,119	412		351	
Average Score										
Pass Rate	68%	64%	73%	69%	70%	68%	66%		65%	

Louisiana Board of Pharmacy

Pharmacy Technician Certification Board (PTCB) Examination

	2000-2013 Data	<u>1/1/2014 to 6/30/2014</u>	<u>7/1/2014 to 12/31/2014</u>	2000-2014 Data	<u>1/1/2015 to 6/30/2015</u>	<u>7/1/2015 to 12/31/2015</u>
National Data						
No. of Candidates Attempting	628,957	26,423				
No. of Candidates Passing	470,680	15,233				
Passing Score	650	650				
Average Score						
Pass Rate	75%	58%				
Louisiana Data						
No. of Candidates Attempting	11,002	630	568			
No. of Candidates Passing	7,451	287	265			
Average Score						
Pass Rate	68%	46%	47%			
<hr/>						
	2000-2015 Data	<u>1/1/2016 to 6/30/2016</u>	<u>7/1/2016 to 12/31/2016</u>	2000-2016 Data	<u>1/1/2017 to 6/30/2017</u>	<u>7/1/2017 to 12/31/2017</u>
National Data						
No. of Candidates Attempting						
No. of Candidates Passing						
Passing Score						
Average Score						
Pass Rate						
Louisiana Data						
No. of Candidates Attempting						
No. of Candidates Passing						
Average Score						
Pass Rate						



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Final Legislative Report

2015-0611 @ 1800

Regular Session of the 2015 Louisiana Legislature
Convened 2015-0413 @ 1200 – Adjourned 2015-0611 @ 1800

Last Items Reviewed						
HB 847	HR 229	HCR 232	HSR 5	HCSR 1		
SB 285	SR 229	SCR 140	SSR 1	SCSR 3	Acts 473	
Total = 1,972				Items on Watch List = 42		

House of Representatives

Bills

HB 6 Honore Health & Welfare
Authorizes the use of medical marijuana in Louisiana.
02-06-2015 Prefiled and referred to committee.

This measure closely resembles last year's bill that was unsuccessful. It seeks to amend the controlled substance law to enable the prescribing and dispensing of medical marijuana for a short list of valid indications. Since we include the controlled substance law in the pharmacy law book, passage of this bill will require an update of the law book.

HB 72 Mack Administration of Criminal Justice
Adds additional substances to Schedule I of the Uniform Controlled Dangerous Substances Law.

03-09-2015	Prefiled and referred to committee.
04-21-2015	Reported favorably (12-0).
04-22-2015	Engrossed; passed to debate calendar.
04-27-2015	Passed House (97-0).
04-28-2015	Received in Senate; lies over for referral.
04-29-2015	Referred to Senate Committee on Judiciary-C.
05-19-2015	Amended, then reported favorably.
05-20-2015	Re-committed to Senate Committee on Finance.
05-29-2015	Reported favorably.
06-02-2015	Referred to Legislative Bureau.
06-03-2015	Reported without action; passed to debate calendar
06-04-2015	Passed Senate (37-0); returned to House.
06-05-2015	Pending House concurrence with Senate amendments.
06-09-2015	House concurred with Senate amendments (95-0).
06-10-2015	Enrolled; signed by House Speaker & Senate President.
06-11-2015	Sent to the Governor.
07-01-2015	Signed by Governor; Act 373 effective 07-01-2015.

This measure seeks to add additional substances to the hallucinogenic, stimulant, and synthetic cannabinoids sections within Schedule I. Since we include the controlled substances law in the pharmacy law book, passage of this bill will require an update of the law book.

HB 149 Badon Administration of Criminal Justice
Amends certain criminal penalties for possession of marijuana and prohibits the applicability of the Habitual Offender Law relative to possession of marijuana.

03-25-2015	Prefiled and referred to committee.
05-06-2015	Amended, then reported favorably (10-4).
05-07-2015	Engrossed; passed to debate calendar.
05-13-2015	Passed House (53-36); sent to Senate; lies over for referral.
05-14-2015	Referred to Senate Committee on Judiciary-C.
05-26-2015	Amended, then reported favorably.
05-27-2015	Referred to Legislative Bureau; reported without action; passed to debate calendar
06-03-2015	Passed Senate (24-13); returned to House.
06-05-2015	Pending House concurrence with Senate amendments.
06-08-2015	House concurred with Senate amendments (74-19).
06-09-2015	Enrolled; signed by House Speaker & Senate President.
06-10-2015	Sent to the Governor.
06-29-2015	Signed by Governor; Act 295 effective 06-29-2015.

This measure seeks to reduce the criminal penalties for possession of marijuana. Since we include the controlled substances law in the pharmacy law book, passage of this will require an update of the law book.

HB 159 Hoffman Health & Welfare
Adds a fee at license renewal for pharmacists and pharmacies and dedicates proceeds to certain pharmacy education programs.

03-25-2015	Prefiled and referred to committee.
04-21-2015	Amended, then reported favorably (16-0).
04-22-2015	Engrossed; passed to debate calendar.
04-27-2015	Returned to the calendar; notice given.
04-29-2015	Amended, then passed House (93-0); Having received required two-thirds vote, sent to Senate.
04-30-2015	Received in the Senate; lies over for referral.
05-04-2015	Referred to Senate Committee on Health & Welfare.
05-20-2015	Reported favorably.
05-21-2015	Re-committed to Senate Committee on Revenue & Fiscal Affairs.
06-01-2015	Reported favorably.
06-02-2015	Referred to Legislative Bureau.
06-03-2015	Reported without action; passed to debate calendar.
06-04-2015	Passed Senate (37-2); returned to the House.
06-07-2015	Enrolled; signed by House Speaker.
06-08-2015	Signed by Senate President.
06-09-2015	Sent to the Governor.
06-29-2015	Signed by Governor; Act 298 effective 08-01-2015.

This measure seeks to amend the fee section of the Pharmacy Practice Act to require the Board to assess each pharmacist license and pharmacy permit a \$100 pharmacy education support fee, in addition to the regular renewal fee, at the time of license renewal, and further, to remit those proceeds to ULM College of Pharmacy on or before April 1 of each year. The law also requires the Board to provide an option for each pharmacist and pharmacy to elect not to pay the pharmacy education support fee. The amendments added in the House committee were technical in nature, not substantive.

HB 174 LeBas Administration of Criminal Justice
Provides for the scheduling of controlled dangerous substances.

03-26-2015	Prefiled and referred to committee.
04-21-2015	Amended, then reported favorably (12-0).

04-22-2015	Engrossed; passed to debate calendar.
04-27-2015	Amended, then passed House (93-0).
04-28-2015	Received in the Senate; lies over for referral.
04-29-2015	Referred to Senate Committee on Judiciary-C.
05-12-2015	Amended, then reported favorably.
05-13-2015	Referred to Legislative Bureau.
05-14-2015	Reported without action; passed to debate calendar
05-19-2015	Amended, then passed Senate (38-0); returned to House.
05-20-2015	Received from Senate with amendments.
05-21-2015	Pending House concurrence with Senate amendments.
06-01-2015	House concurred with Senate amendments (90-0).
06-02-2015	Enrolled; signed by House Speaker.
06-04-2015	Signed by Senate President.
06-05-2015	Sent to the Governor.
06-23-2015	Signed by Governor; Act 189 effective 06-23-2015.

This measure, which is sponsored by the Board, seeks to amend the state list of controlled substances to re-schedule hydrocodone from Schedule III to Schedule II, and to place tramadol and suvorexant in Schedule IV. The bill was amended in the House committee to place mitragynine and a related substance in Schedule I and fixed the penalties for those substances equivalent to those for marijuana and synthetic cannabinoids. Prior to the House floor vote, the members voted to strip off the mitragynine amendment added in committee. The Senate added an amendment to reduce the dispensing limitations on opioid prescriptions written by practitioners in other states that was enacted into law in 2014. The House voted to concur with that amendment, so those limitations will not be applicable in states where the PMP information is available for inquiry by the dispensing pharmacist.

HB 210	Moreno	Health & Welfare
Authorizes the prescribing and dispensing of naloxone to third parties.		
03-30-2015		Prefiled and referred to committee.
04-21-2015		Amended, then reported favorably (16-0).
04-22-2015		Engrossed; passed to debate calendar.
04-27-2015		Passed House (97-0).
04-28-2015		Received in the Senate; lies over for referral.
04-29-2015		Referred to Senate Committee on Health & Welfare.
05-13-2015		Amended, then reported favorably.
05-14-2015		Referred to Legislative Bureau.
05-18-2015		Reported without action; passed to debate calendar.
05-26-2015		Passed Senate (35-0); returned to House.
05-27-2015		Received in House with Senate amendments; pending House concurrence with Senate amendments.
06-02-2015		House concurred with Senate amendments (99-0).
06-03-2015		Enrolled; signed by House Speaker.
06-04-2015		Signed by Senate President.
06-05-2015		Sent to the Governor.
06-23-2015		Signed by Governor; Act 192 effective 08-01-2015.

This measure seeks to authorize a medical practitioner to prescribe naloxone (intra-nasal route only) or another opioid antagonist to a third party without a prior examination of the patient when deemed appropriate for treatment of opioid-related drug overdose. Further, the measure will require the pharmacist to dispense such prescriptions. The House committee amendments were technical in nature and not substantive.

HB 247	Huval	Health & Welfare
Provides relative to the disciplinary proceedings of the Louisiana Physical Therapy Board.		
03-31-2015		Prefiled and referred to committee.
04-22-2015		Reported favorably (15-0).
04-28-2015		Engrossed; passed to debate calendar.
05-04-2015		Passed House (92-0); received in Senate; lies over for referral.
05-05-2015		Referred to Senate Committee on Health & Welfare.

05-27-2015	Reported favorably.
05-28-2015	Referred to Legislative Bureau.
06-01-2015	Reported without action; passed to debate calendar.
06-03-2015	Passed Senate (39-0); returned to the House.
06-04-2015	Enrolled; signed by House Speaker and Senate President.
06-05-2015	Sent to the Governor.
06-23-2015	Signed by Governor; Act 195 effective 08-01-2015.

This measure seeks to add the Physical Therapy Board to the list of agencies which have an exemption to the provision of law limiting the time by which disciplinary proceedings must be instituted. We will monitor this bill to ensure the Board of Pharmacy is not removed from that list of agencies with exemptions.

HB 304 **Hall** **Health & Welfare**
 Provides relative to sharing of prescription monitoring program information with equivalent programs of other states.

03-31-2015	Prefiled and referred to committee.
04-21-2015	Reported favorably (14-0).
04-27-2015	Engrossed; passed to debate calendar.
05-04-2015	Passed House (95-0); received in Senate; lies over for referral.
05-05-2015	Referred to Senate Committee on Health & Welfare.
05-13-2015	Reported favorably.
05-14-2015	Referred to Legislative Bureau.
05-18-2015	Reported without action; passed to debate calendar.
05-19-2015	Passed Senate (38-0); returned to House.
05-20-2015	Received from Senate without amendment; Enrolled; signed by House Speaker.
05-21-2015	Signed by Senate President; sent to the Governor.
05-29-2015	Signed by Governor; Act 22 effective 08-01-2015.

This measure, which is sponsored by the Board, seeks to amend the PMP Law to update the protection from civil discovery clause in a manner that will allow the Board to share such information with more states than currently allowed.

HB 319 **Simon** **Health & Welfare**
 Provides relative to the dispensing of interchangeable biological products.

04-01-2015	Prefiled and referred to committee.
05-06-2015	Amended, then reported favorably (16-0).
05-07-2015	Engrossed; passed to debate calendar.
05-14-2015	Returned to the calendar; notice given.
05-20-2015	Passed House (84-6); sent to Senate.
05-21-2015	Received in Senate; lies over for referral.
05-25-2015	Referred to Senate Committee on Health & Welfare.
06-02-2015	Amended, then reported favorably.
06-03-2015	Referred to Legislative Bureau.
06-04-2015	Reported without action; passed to debate calendar.
06-05-2015	Passed Senate (38-0); returned to the House.
06-06-2015	Pending House concurrence with Senate amendments.
06-09-2015	House concurred with Senate amendments (91-0).
06-10-2015	Enrolled; signed by House Speaker & Senate President.
06-11-2015	Sent to the Governor.
07-01-2015	Signed by Governor; Act 391 effective 08-01-2015.

This measure seeks to amend the Pharmacy Practice Act, more specifically the provision relative to generic interchange, to insert an additional provision relative to biological product interchange. The additional provision will require the dispensing pharmacist to notify the prescriber when dispensing an interchangeable biological product. Further, the bill requires the board to maintain certain information on it website, specifically a link to the list of interchangeable biological products as determined by the FDA. The Senate added amendments simplifying the communication process and removing the website

requirement.

HB 351	LeBas	Insurance
Provides relative to pharmacy services.		
	04-02-2015	Prefiled and referred to committee.
	04-22-2015	Recalled from Committee on Insurance; Recommitted to Committee on Appropriations.
	05-04-2015	On agenda – not considered.

This measure seeks to extend the current requirement on employers not to restrict their employees to obtaining their prescription services from a mail order pharmacy to state employees.

HB 397	Pope	Health & Welfare
Provides relative to prescription refills.		
	04-02-2015	Prefiled and referred to committee.
	04-21-2015	Amended, then reported favorably (16-0).
	04-22-2015	Engrossed; passed to debate calendar.
	04-28-2015	Passed House (96-0); Received in Senate; lies over for referral.
	04-29-2015	Referred to Senate Committee on Health & Welfare.
	05-27-2015	Voluntarily deferred for an indefinite period of time.

This measure seeks to amend the Pharmacy Practice Act to authorize a pharmacist to dispense early refills of topical ophthalmic prescriptions. The House committee amendments were technical in nature, and not substantive.

HB 416	Barrow	Health & Welfare
Provides relative to advanced practice registered nurses.		
	04-02-2015	Prefiled and referred to committee.
	05-06-2015	On agenda – not considered.
	05-13-2015	Voluntarily deferred for an indefinite period of time.

This measure seeks to provide an exemption to the collaborative practice agreement requirement for certain APRNs.

HB 436	Johnson, R.	Health & Welfare
Provides for insurance reimbursement of certain provider fees paid by pharmacies.		
	04-02-2015	Prefiled and referred to committee.
	05-13-2015	Amended, then reported favorably (10-0).
	05-14-2015	Engrossed; passed to debate calendar.
	05-20-2015	Amended, then passed House (91-0); sent to Senate.
	05-21-2015	Received in Senate; lies over for referral.
	05-25-2015	Referred to Senate Committee on Health & Welfare.
	06-02-2015	Reported favorably.
	06-03-2015	Referred to Legislative Bureau.
	06-04-2015	Reported without action; passed to debate calendar.
	06-05-2015	Amended, then passed Senate (39-0); returned to House.
	06-06-2015	Pending House concurrence with Senate amendments.
	06-09-2015	House concurred with Senate amendments (98-0).
	06-10-2015	Enrolled; signed by House Speaker & Senate President.
	06-11-2015	Sent to the Governor.
	07-01-2015	Signed by governor; Act 399 effective 08-01-2015.

This measure has three initiatives: (1) changes the current 10 cent prescription fee for Medicaid to 20 cents, (2) requires payors to reimburse pharmacies for this fee when the pharmacy requests reimbursement for that fee, and (3) requires all payors licensed by the Board of Pharmacy to pay those fees directly to DHH.

HB 440	LeBas	Insurance
Prohibits certain fees relative to the adjudication of pharmacy benefit claims.		
	04-02-2015	Prefiled and referred to committee.
	04-29-2015	Reported without action (13-0); Recommended dual referral to Cmte. on Appropriations.
	04-30-2015	Referred to House Committee on Appropriations.

This measure seeks to prohibit an insurer or PBM from charging any fees related to the adjudication of pharmacy benefit claims such as claim transmission fees.

HB 451	Schexnayder	House & Governmental Affairs
Provides relative to boards, commissions, authorities, districts, and like entities.		
	04-02-2015	Prefiled and referred to committee.
	04-29-2015	Amended, then reported favorably (7-0).
	04-30-2015	Engrossed; passed to debate calendar.
	05-06-2015	Amended, then passed House (96-0); sent to Senate.
	05-07-2015	Received in Senate; lies over for referral.
	05-11-2015	Referred to Senate & Governmental Affairs Committee.
	05-20-2015	Amended, then reported favorably.
	05-21-2015	Referred to Legislative Bureau.
	05-25-2015	Reported with amendments; passed to debate calendar.
	05-26-2015	Passed Senate (36-0); returned to House.
	05-27-2015	Received in House with Senate amendments; Pending House concurrence with Senate amendments.
	06-02-2015	House rejected Senate amendments; pending in Conference Committee.
	06-03-2015	House conferees appointed.
	06-05-2015	Senate conferees appointed.
	06-10-2015	House adopted Conference Committee report (91-0).
	06-11-2015	Senate adopted Conference Committee report (34-0).
	06-12-2015	Enrolled; signed by House Speaker & Senate President; Sent to Governor.
	07-01-2015	Signed by Governor; Act 401 effective 08-01-2015.

This measure seeks to abolish certain and specifically named inactive boards and commissions. We will monitor this bill to ensure the Board of Pharmacy is not added at a later date.

HB 461	Simon	Health & Welfare
Provides relative to the regulation of telemedicine and telehealth services.		
	04-03-2015	Prefiled and referred to committee.

This measure seeks to amend the Medical Practice Act to specify requirements for physicians intending to practice telemedicine for the benefit of a Louisiana resident.

HB 486	Johnson, R.	Health & Welfare
Provides relative to collaborative practice agreements between advanced practice registered nurses and physicians.		
	04-03-2015	Prefiled and referred to committee.
	04-21-2015	Reported favorably (12-4).
	04-22-2015	Engrossed; passed to debate calendar.
	04-28-2015	Passed House (73-24) Received in Senate; lies over for referral.
	04-29-2015	Referred to Senate Committee on Health & Welfare.
	05-13-2015	Voluntarily deferred for one week.
	05-20-2015	Voluntarily deferred for one week.
	05-27-2015	Voluntarily deferred for an indefinite period of time.

This measure seeks to prohibit the Board of Medical Examiners from limiting APRNs and MDs in their ability to enter into collaborative practice agreements.

HB 491	Willmott	Health & Welfare
Amends the requirements for dental license applicants.		
	04-03-2015	Prefiled and referred to committee.
	04-21-2015	Reported favorably (13-0).
	04-22-2015	Engrossed; passed to debate calendar.
	04-28-2015	Passed House (97-0); Received in Senate; lies over for referral.
	04-29-2015	Referred to Senate Committee on Health & Welfare.
	05-13-2015	Reported favorably.
	05-14-2015	Referred to Legislative Bureau.
	05-18-2015	Reported without action; passed to debate calendar.
	05-19-2015	Passed Senate (38-0); returned to House; received from Senate.
	05-20-2015	Enrolled; signed by House Speaker.
	05-20-2015	Signed by Senate President; sent to the Governor.
	05-22-2015	Signed by the Governor; Act 7 effective 05-22-2015.

This measure seeks to amend the Dental Practice Act to change the current requirement of either citizenship or permanent residency to legal authority to reside and work in the U.S.

HB 552	Thierry	Health & Welfare
Provides relative to the scope of practice of chiropractic.		
	04-03-2015	Prefiled and referred to committee.
	04-29-2015	Removed from agenda prior to meeting.
	05-06-2015	On agenda – not considered.

This measure, similar to SB 56, expands the scope of practice for chiropractic, and in addition, changes the title from chiropractic to chiropractic physician.

HB 568	Thierry	Health & Welfare
Provides relative to the licensing and regulation of pharmacists.		
	04-03-2015	Prefiled and referred to committee.
	05-06-2015	Amended, then reported favorably (11-0).
	05-07-2015	Engrossed; passed to debate calendar.
	05-14-2015	Amended, then passed House (94-0); sent to Senate.
	05-18-2015	Received in Senate; lies over for referral.
	05-19-2015	Referred to Senate Committee on Health & Welfare.
	05-27-2015	Voluntarily deferred for one week.
	06-02-2015	Amended, then reported favorably.
	06-03-2015	Referred to Legislative Bureau.
	06-04-2015	Reported without action; passed to debate calendar.
	06-06-2015	Amended, then passed Senate (38-0); returned to the House.
	06-07-2015	Pending House concurrence with Senate amendments.
	06-09-2015	House concurred with Senate amendments (94-0).
	06-10-2015	Enrolled; signed by House Speaker & Senate President.
	06-11-2015	Sent to the Governor.
	07-01-2015	Signed by Governor; Act 409 effective 08-01-2015.

This measure seeks to amend the Pharmacy Practice Act, more specifically the section on discipline, to establish additional activities for which the board may sanction a licensee, including the use of an independent contractor to market any practitioner where the compensation of the contractor is based on the volume or value of prescriptions generated by the practitioner, as well as the dispensing of prescriptions generated by a practitioner where the practitioner has a direct or indirect financial relationship with the pharmacy, with the exception of those transaction meeting certain federal rules.

HB 573	Hazel	Health & Welfare
Provides for the investigation and adjudication of violations by the Louisiana State Board of Medical Examiners.		
	04-03-2015	Prefiled and referred to committee.
	05-13-2015	Reported favorably, by substitute (10-0).

05-14-2015 Became HB 843. [See that entry for further action.]

This measure seeks to amend the Medical Practice Act, to re-define the definition of a quorum, to prohibit certain expenditures, and to re-vamp their investigative and adjudicatory activities.

HB 600 Geymann House & Governmental Affairs
Provides relative to the Administrative Procedure Act.
04-03-2015 Prefiled and referred to committee.
05-13-2015 Voluntarily deferred.

This measure seeks to amend the act to require strict compliance with the provisions of rule-making and to veto rules that fail to meet that standard, and in addition, prohibits the issuance of successive identical or similar emergency rules.

HB 638 Ivey Appropriations
Provides for the collection of fees associated with payments to state agencies by credit cards, debit cards, or other forms of electronic payment.

04-03-2015 Prefiled and referred to committee.
05-19-2015 Amended, then reported favorably (14-0).
05-20-2015 Engrossed; passed to debate calendar.
05-27-2015 Amended, then passed House (97-1); sent to Senate.
05-28-2015 Received in Senate; lies over for referral.
06-01-2015 Referred to Senate Committee on Finance.
06-05-2015 Amended, then reported favorably.
06-06-2015 Referred to Legislative Bureau;
Returned without action; passed to debate calendar.
06-08-2015 Amended, then passed Senate (34-2); returned to the House.
06-09-2015 House rejected the Senate amendments (95-0);
Senate conferees appointed.
06-10-2015 House conferees appointed.
06-11-2015 Senate adopted Conference Committee report (38-1);
House adopted Conference Committee (100-0).
06-15-2015 Enrolled; signed by House Speaker & Senate President;
Sent to Governor.
07-01-2015 Signed by Governor: **Act 414 effective 08-01-2015.**

This measure amends an existing law that permits certain state departments to receive payments by credit cards, debit cards, or other forms of electronic payments and requires those departments to levy a convenience fee calculated in a certain manner. The amendment would allow any state department to receive payments in that fashion and would allow the imposition of a convenience fee to be permissive as opposed to mandatory, and would allow the convenience fee to be a flat fee or percentage of the fee.

HB 643 Pearson Appropriations
Creates the State Employer Health Insurance Fund for state agencies to use to pay their portion of employee health insurance costs for retired employees.
04-03-2015 Prefiled and referred to committee.
04-27-2015 On agenda – not considered.
04-28-2015 Voluntarily deferred for an indefinite period of time.

This measure creates a special fund with the state's general fund, to receive legislative appropriations for state agencies to pay their portion of employee health insurance costs for their retired employees.

HB 843 Hazel
Provides for the investigation and adjudication of violations by the Louisiana State Board of Medical Examiners.
05-14-2015 Reported as substitute for HB 573.
05-18-2015 Engrossed; passed to debate calendar.
05-26-2015 Amended, then passed House (87-8); sent to Senate.

05-27-2015	Received in Senate; lies over for referral.
05-28-2015	Referred to Senate Committee on Commerce.
06-03-2015	Amended, then reported favorably.
06-04-2015	Re-committed to Senate Committee on Finance.
06-05-2015	Reported favorably.
06-06-2015	Referred to Legislative Bureau; Reported without action; passed to debate calendar.
06-08-2015	Amended, then passed Senate (33-5); returned to the House.
06-09-2015	House concurred with Senate amendments.
06-10-2015	Enrolled; signed by House Speaker.
06-11-2015	Signed by Senate President; sent to the Governor.
07-01-2015	Signed by Governor; Act 441 effective 07-01-2015.

Resolutions

HR 185 Thibault
Requests state-approved non-public schools to consider keeping epinephrine on the school premises for emergency situations.

06-08-2015	Filed; lies over.
06-09-2015	Passed to debate calendar.
06-10-2015	Passed House (97-0).
06-11-2015	Enrolled; signed by House Speaker; delivered to Secretary of State

HR 196 James
Authorizes the Dept. of Agriculture & Forestry to establish the Medical Marijuana Patient Access Review Committee.

06-09-2015	Filed; lies over.
06-10-2015	Read by title; returned to the calendar.

Concurrent Resolutions

HCR 4 Simon Health & Welfare
Expresses the intent of the legislature regarding the standard of care prescribed by law for the practice of telemedicine.

03-27-2015	Prefiled and referred to committee.
04-21-2015	Amended, then reported favorably (13-3).
04-22-2015	Engrossed; passed to debate calendar.
05-06-2015	Passed House (96-0); received in Senate; lies over for referral.
05-07-2015	Referred to Senate Committee on Health & Welfare.
05-13-2015	Reported favorably.
05-19-2015	Passed Senate (39-0); returned to House.
05-20-2015	Enrolled; signed by House Speaker.
05-21-2015	Signed by Senate President; delivered to Secretary of State.

This measure seeks to express the intent of the legislature relative to the standard of care for the prescribing of controlled substances telemedicine identified in the Telehealth Access Act of 2014, in response to a proposed telemedicine rule on that topic from the Board of Medical Examiners. The House committee amendment specified the Board of Medical Examiners lacks the authority to specify which actions constitute an appropriate standard of care.

HCR 10 Burford Health & Welfare
Suspends rules of the Louisiana Board of Pharmacy that invalidate prescriptions with computer generated electronic signatures.

04-03-2015	Prefiled and referred to committee.
04-21-2015	Removed from agenda prior to meeting.

This measure will suspend a portion of the rule recently promulgated by the Board, more specifically, LAC 46:LIII.2511.C.4, for a period of time until 60 days following the conclusion of the 2016 Regular Session of the Legislature.

HCR 44	Foil	House & Governmental Affairs
Requests all state agencies in the executive branch of state government to provide for a crisis leave pool and requests the Dept. of State Civil Service to report progress to the state legislature.		
	04-14-2015	Filed.
	04-15-2015	Referred to committee.
	04-29-2015	Reported favorably (9-0).
	04-30-2015	Engrossed; passed to debate calendar.
	05-06-2015	Passed House (95-0); received in Senate; lies over for referral.
	05-07-2015	Referred to Senate Committee on Health & Welfare.
	05-13-2015	Reported favorably.
	05-19-2015	Passed Senate (39-0); returned to House.
	05-20-2015	Enrolled; signed House Speaker.
	05-21-2015	Signed by Senate President; delivered to Secretary of State.

This measure urges and requests all state agencies in the executive branch to develop a policy for a crisis leave pool, where employees may donate a portion of their previously-earned leave to a crisis pool which may be utilized by a fellow employee in a time of need where they have exhausted their own leave balance. The Board of Pharmacy has already adopted such a policy for its employees; we will monitor this item to see if any additional requirements will be added.

HCR 84	Simon	Health & Welfare
Directs the La. Law Institute to reorganize and recodify the Miscellaneous Health Provisions chapter of Title 40 of the Louisiana Revised Statutes.		
	04-27-2015	Filed.
	04-28-2015	Referred to committee.
	05-06-2015	Reported favorably (16-0).
	05-07-2015	Engrossed; passed to debate calendar.
	05-13-2015	Amended, then passed House (98-0); sent to Senate.
	05-14-2015	Received in Senate; lies over for referral.
	05-18-2015	Referred to Senate Committee on Health & Welfare.
	05-27-2015	Reported favorably.
	05-28-2015	Passed Senate (36-0); returned to House.
	06-01-2015	Enrolled; signed by House Speaker.
	06-02-2015	Signed by Senate President.
	06-04-2015	Delivered to Secretary of State.

This measure seeks to reorganize a very disorganized section of health-related law. Since some of those laws are included in the pharmacy law book, we will monitor this resolution.

HCR 188	Thibault	
Requests state-approved nonpublic schools to consider keeping epinephrine on the school premises for emergency situations.		
	05-26-2015	Filed; passed House.
	05-27-2015	Received in Senate; lies over for referral.
	05-28-2015	Referred to Senate Committee on Health & Welfare.
	06-02-2015	Amended, then reported favorably.
	06-03-2015	Passed Senate (38-0); returned to the House.
	06-04-2015	Pending House concurrence with Senate amendments.
	06-09-2015	Read by title; returned to the calendar.

Study Resolutions

Concurrent Study Resolutions

Senate

Bills

SB 39	Mills	Health & Welfare
Provides for the Louisiana Board of Drug and Device Distributors.		
	03-23-2015	Prefiled and referred to committee.
	04-21-2015	Amended, then reported favorably (8-0).
	04-27-2015	Engrossed; passed to debate calendar.
	04-28-2015	Amended, then passed Senate (35-0); Ordered re-engrossed, then sent to House.
	04-29-2015	Received in House; lies over for referral.
	04-30-2015	Referred to House Committee on Health & Welfare.
	05-27-2015	Amended, then reported favorably (11-0); Referred to Legislative Bureau.
	05-28-2015	Reported without action.
	06-01-2015	Passed to debate calendar.
	06-04-2015	Amended, then passed House (93-0); returned to Senate.
	06-05-2015	Pending Senate concurrence with House amendments.
	06-08-2015	Senate rejected House amendments (38-0); Pending in Conference Committee.
	06-09-2015	Senate conferees appointed.
	06-10-2015	House conferees appointed; Senate adopted Conference Committee report (39-0).
	06-11-2015	House adopted Conference Committee report (95-0).
	06-12-2015	Enrolled; signed by Senate President & House Speaker; Sent to Governor.
	07-01-2015	Signed by Governor; Act 443 effective 07-01-2015.

This measure seeks to amend the law relative to drug and device distribution. Among other changes, the name of the current Board of Wholesale Drug Distributors is changed to the Board of Drug and Device Distributors. It also makes significant changes to that law in order to harmonize the state law with the recently-enacted federal Drug Supply Chain Security Act. The Senate committee amendment was technical in nature, and not substantive.

SB 56	Dorsey-Colomb	Commerce, Consumer Protection, International Affairs
Provides for the practice of chiropractic.		
	03-30-2015	Prefiled and referred to committee.
	04-13-2015	Recalled from Committee on Commerce; Recommitted to Committee on Health & Welfare.
	05-06-2015	Amended, then reported favorably (9-0).
	05-07-2015	Engrossed; passed to debate calendar.
	05-11-2015	Returned to calendar; subject to call; notice given.
	05-13-2015	Amended, then passed Senate (23-16); Re-engrossed; sent to House.
	05-14-2015	Received in House; lies over for referral.
	05-18-2015	Referred to House Committee on Health & Welfare.
	05-27-2015	Voluntarily deferred for an indefinite period of time.

This measure expands the scope of practice for chiropractors, authorizing to order and interpret a range of diagnostic examinations, including X-rays. We will monitor this bill to see if prescriptive authority is added.

SB 83	White	Commerce, Consumer Protection, International Affairs
Provides relative to the exception from the issuance of provisional licenses to ex-offenders to work in certain fields.		
	03-31-2015	Prefiled and referred to committee.
	04-21-2015	Reported favorably (9-0).
	04-22-2015	Engrossed; passed to debate calendar.

04-28-2015	Passed Senate (29-5); received in House; lies over for referral.
04-29-2015	Referred to House Committee on Commerce.
05-19-2015	Reported favorably (15-0); referred to Legislative Bureau.
05-20-2015	Reported without action; passed to debate calendar.
06-01-2015	Passed House (86-0); returned to Senate.
06-02-2015	Enrolled; signed by Senate President and House Speaker.
06-04-2015	Sent to the Governor.
06-23-2015	Signed by Governor; Act 157 effective 08-01-2015.

This measure seeks to add the Real Estate Commission to the list of licensing agencies which are exempted from the law requiring the issuance of provisional licenses to certain ex-offenders. We will monitor this bill to ensure the Board of Pharmacy is not removed from that list.

SB 115	Mills	Health & Welfare
Provides with respect to the practice of physician assistants.		
	04-01-2015	Prefiled and referred to committee.
	04-29-2015	Amended, then reported favorably (8-0).
	04-30-2015	Engrossed; passed to debate calendar.
	05-04-2015	Proposed amendment failed (7-27); passed Senate (36-0).
	05-05-2015	Received in House; lies over for referral.
	05-06-2015	Referred to House Committee on Health & Welfare.
	05-27-2015	Amended, then reported favorably (16-1); Referred to Legislative Bureau.
	05-28-2015	Reported with amendments
	06-01-2015	Passed to debate calendar.
	06-04-2015	Amended, then passed House (94-3); returned to the Senate.
	06-05-2015	Pending Senate concurrence with House amendments.
	06-08-2015	Senate concurred with House amendments (38-0).
	06-10-2015	Enrolled; signed by Senate President & House Speaker.
	06-11-2015	Sent to the Governor.
	07-01-2015	Signed by Governor; Act 453 effective 07-01-2015.

This measure amends the medical practice act and primarily addresses the supervisory relationship requirements between physicians and physician assistants. The bill also revises the scope of practice for physician assistants, including a revision of their prescriptive authority that adds Schedule II to the list of controlled substances they may prescribe. One of the unexpected amendments added in the Senate Committee added Schedule II authority for optometrists. The proposed amendment that failed on the Senate floor would have stripped off the optometrist amendment added in the Senate committee.

SB 143	Mills	Health & Welfare
Provides relative to prescribed marijuana for therapeutic uses and the development of rules and regulations by the Louisiana Board of Pharmacy and the Louisiana State Board of Medical Examiners.		
	04-02-2015	Prefiled and referred to committee.
	04-29-2015	Amended, then reported favorably (7-0).
	04-30-2015	Engrossed; passed to debate calendar.
	05-04-2015	Amended, then passed Senate (22-13); Ordered re-engrossed, then sent to House.
	05-05-2015	Received in House; lies over for referral.
	05-06-2015	Referred to House Committee on Health & Welfare.
	05-27-2015	Amended, then reported favorably (16-0); Referred to Legislative Bureau.
	05-28-2015	Reported without action.
	06-01-2015	Passed to debate calendar.
	06-04-2015	Amended, then passed House (70-29); returned to the Senate.
	06-05-2015	Pending Senate concurrence with House amendments.
	06-08-2015	Senate concurred with House amendments (30-6).
	06-10-2015	Enrolled; signed by Senate President & House Speaker.
	06-11-2015	Sent to the Governor.
	06-29-2015	Signed by Governor; Act 261 effective 06-29-2015.

This measure seeks to amend the controlled substances law to expand the authorized medical conditions eligible for the prescribing of marijuana, and further, directs the Board of Pharmacy to develop rules relative to the production and dispensing of marijuana. One of the amendments added in the Senate Committee charged the Dept. of Agriculture with regulation of the production process, and left the dispensing regulation to the Board of Pharmacy.

SB 163	Mills	Health & Welfare
Provides relative to Medicaid managed care.		
	04-02-2015	Prefiled and referred to committee.
	05-06-2015	Amended, then reported favorably (9-0).
	05-07-2015	Engrossed; re-committed to Senate Committee on Finance.
	05-29-2015	Amended, then reported favorably.
	06-02-2015	Ordered re-engrossed; passed to debate calendar.
	06-03-2015	Amended, then passed Senate (38-0); Ordered re-engrossed; sent to the House.
	06-04-2015	Referred to House Committee on Health & Welfare.

This measure seeks to allow managed care organizations to negotiate an ingredient cost reimbursement with certain pharmacies.

SB 170	Kostelka	Health & Welfare
Provides relative to Medicaid managed care.		
	04-02-2015	Prefiled and referred to committee.
	04-21-2015	Voluntarily deferred for an indefinite period of time.

This measure seeks to prohibit any limitation on the number of prescriptions available for reimbursement for patients in long-term facilities, and further, seeks to base the dispensing fees on certain cost data. At the outset of the hearing, the sponsor indicated DHH was working on a potential remedy of the problem (limit on number of prescriptions in long-term care) to be cured by the bill, so the sponsor voluntarily deferred his bill for an indefinite period of time.

SB 241	Morrell	Judiciary-C
Provides relative to criminal penalties for marijuana possession.		
	04-03-2015	Prefiled and referred to committee.
	05-19-2015	Amended, then reported favorably.
	05-20-2015	Engrossed; passed to debate calendar.
	05-25-2015	Amended, then passed Senate (27-12); Ordered re-engrossed; sent to the House.
	05-26-2015	Received in House; lies over for referral.
	05-27-2015	Referred to House Committee on Criminal Justice.

This measure seeks to amend the controlled substance law to reduce the criminal penalties for possession of marijuana.

SB 256	Martiny	Health & Welfare
Provides relative to a closed pharmacy formulary.		
	04-03-2015	Prefiled and referred to committee.
	05-06-2015	Voluntarily deferred for an indefinite period of time.

This measure seeks to establish a closed pharmacy formulary for the Louisiana Workman Compensation Program, and further, establishes the Closed Pharmacy Formulary Oversight Panel and names the five members to that panel.

Resolutions

SR 177	Mills	
Creates a task force to study and recommend revisions of regulations related to the distribution of medical devices in Louisiana.		
	06-03-2015	Filed.

06-04-2015

Passed Senate without objection.

Concurrent Resolutions

Study Resolutions

Concurrent Study Resolutions



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Request for Interpretation of Board Rules LAC 46:LIII.2745.C.2 and 2747.B.4.b

(Fred's Pharmacies)

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.

From: [info](#)
To: [Malcolm J. Broussard](#)
Subject: FW: Chapter 27 Question
Date: Thursday, May 28, 2015 2:09:43 PM

Felicia Smith
Secretary
Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, LA 70809
Email: info@pharmacy.la.gov
Website: www.pharmacy.la.gov

From: Fred Pharmacy [mailto:lapharmacydistrict7@gmail.com]
Sent: Thursday, May 28, 2015 2:09 PM
To: info
Subject: Chapter 27 Question

I have heard conflicting opinions from members of the board, compliance officers, and practicing pharmacists. Please respond as to how these sections are interpreted by the LABP.

Question Regarding:

2745 Prescriptions, Section C., #2 and 2747 Dispensing Requirements, Section B., #4 (b) page 33 & 37 of CDS chap 27:

Does the pharmacist need to physically write the patient's address on the hardcopy of CDS when presented or is backtag (containing the patient's address typed) adhered to the back of the Rx sufficient to meet this requirement....

If the patients address appears on the RX, typed on the Rx backtag, not handwritten by the doctor or pharmacist, are these subsections of the law fulfilled?

Thank you

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII: Pharmacists

Chapter 27. Controlled Dangerous Substances

...

§2745. Prescriptions

...

C. Manner of Issuance

1. ...
2. All prescriptions for controlled substances shall contain the following information:
 - a. full name and address of the patient;
 - b. drug name, strength and dosage form;
 - c. quantity of drug prescribed;
 - d. directions for use; and
 - e. name, address, telephone number and DEA registration number of the prescriber.

...

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:972.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 34:2149 (October 2008).

§2747. Dispensing Requirements

...

B. Prescriptions for Controlled Substances Listed in Schedule II

...

4. Completion of Prescription Form

In the event a pharmacist receives a prescription for a controlled substance listed in Schedule II lacking certain required information, the pharmacist may consult with the prescriber (but not the prescriber's agent) to clarify the prescriber's intent. Following a consultation with the prescriber and the appropriate documentation thereof on the prescription form:

- a. A pharmacist may record changes to the following data elements on the prescription form:
 - i. patient's address;
 - ii. drug strength;
 - iii. quantity prescribed; or
 - iv. directions for use.
- b. A pharmacist may add the following data elements on the prescription form:
 - i. patient's address;
 - ii. drug dosage form; or
 - iii. prescriber's DEA registration number; however,
- c. A pharmacist shall never make changes to or add the following data elements on the prescription form:
 - i. patient's name;
 - ii. date of issue;
 - iii. drug name (except for generic interchange as permitted by law); or
 - iv. prescriber signature.

...

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:972.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 34:2157 (October 2008).



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Announcements

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



August 12, 2015

Agenda Item 12: Announcements

- | | |
|-------------------|---|
| Aug. 18 | La Pharmacy Law Update for 2015 – New Orleans |
| Aug. 19 | P-1 Orientation at Xavier College of Pharmacy |
| Aug. 20 | La Pharmacy Law Update for 2015 – Monroe |
| Aug. 21 | P-1 Orientation at ULM School of Pharmacy |
| Aug. 26 | Public Hearing |
| Sept. 2-3 | Violations Committee Informal Conference |
| Sept. 7 | Labor Day – <i>Board office closed</i> |
| Sept. 14-17 | NABP-AACP Districts 6-7-8 Meeting – Lake Tahoe, NV |
| Sept. 26 | 10 th Annual DEA Prescription Drug Take Back Day |
| Sept. 28 – Oct. 3 | FIP World Congress – Dusseldorf, DE |
| Oct. 2-3 | LSHP MidYear Meeting – Shreveport |
| Oct. 6-7 | Tri-Regulator Collaborative Symposium – Arlington, VA |
| Oct. 10-14 | NCPA Annual Meeting – Washington, DC |
| Oct. 14 | La. Pharmacy Congress
Prescription Monitoring Program (PMP) Advisory Council |
| Oct. 20-23 | NASCSA Annual Meeting – Scottsdale, AZ |
| Oct. 25-28 | MALTAGON Conference – Louisville, KY |
| Nov. 11 | Veterans' Day – <i>Board office closed</i> |
| Nov. 17 | Reinstatement, Impairment, Finance, & Executive Committees |
| Nov. 18 | Board Meeting |
| Nov. 19 | Administrative Hearing |
| Nov. 26 | Thanksgiving Day – <i>Board office closed</i> |
| Nov. 27 | Acadian Day – <i>Board office closed</i> |